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Abstract 
This thesis aims to demonstrate how understanding of the nature of MSCs in vivo 
can be used to guide bone disease therapy development. It first address the 
unpredictable MSC content of bone marrow (BM) aspirates used for therapy; then 
examines MSC enrichment using clinical grade immunomagnetic cell selection. 
Induction of osteogenesis was subsequently explored; by examining an induced 
membrane (IM) used for bone regeneration. Finally the potential of a janus kinase 
(JAK) inhibitor to block osteogenesis was assessed, by studying its effect on MSCs in 
vitro. 
Flow cytometry was used to enumerate cells expressing a CD45-/low CD271+ 
phenotype in BM aspirate and this was compared to colony forming unit fibroblast 
(CFU-F) content. MSCs were enriched from BM, enzymatically treated femoral 
heads (FH) and intramedullary canal aspirates and enumerated. The composition 
morphology, MSC content and differentiation potential of IM was compared to 
periosteum. The potential effects of JAK inhibition on MSC colony formation, 
expansion and differentiation potential were examined. 
The concentration of cells expressing a CD45-/low CD271+ phenotype strongly 
correlated with CFU-F concentration (R=0.812, p<0.001). Immunomagnetic cell 
selection resulted in an increase in the proportion of MSCs in BM, FH and 
intramedullary canal aspirates by 204, 14.1 and 291-fold respectively. The 
regenerative potential of periosteum and IM were comparable. JAK inhibition did 
not affect MSC growth, osteogenesis or chondrogenesis but caused an increase in 
adipogenesis at concentrations ≥100nM compared to controls (1.38 fold, p=0.041).  
Flow cytometry may be used to rapidly and accurately predict the MSC content of 
BM. Clinical grade immunomagnetic selection can substantially increase the purity 
of MSCs from bone cavities. The similarity, in terms of regenerative potential, of 
periosteum and IM gives insight into its use for bone regeneration. JAK inhibition 
did not affect in vitro osteogenesis but has potential to affect in vivo osteogenesis 
through stimulation of adipogenesis. 
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1. General introduction 
1.1. Regenerative medicine 
Regenerative medicine is a field of research that aims to replace or repair diseased 
or damaged tissue and organs. Regenerative medicine strategies rely on the 
activation, stimulation or correction of endogenous repair mechanisms (Horwitz et 
al. 1999; Lee et al. 2010; Homma et al. 2014) or mechanisms involved in natural 
developmental processes, in order to restore function (Jopling et al. 2011).  
Cellular therapeutics is a branch of regenerative medicine that seeks to utilise cells 
as therapeutic agents. These may be autologous, originating from the patient’s own 
tissue or allogeneic, originating from donor tissue (Galipeau 2013; Homma et al. 
2014). They may be administered alone or combined with natural or synthetic 
scaffolds (Hernigou et al. 2005b; Hattori et al. 2006; Homma et al. 2014). They may 
also be subject to in vitro culture expansion or have undergone genetic 
manipulation (Okita et al. 2007; Galipeau 2013). 
Research into stem cell biology plays a central role in regenerative medicine. 
Understanding of the nature and behaviour of stem cells in vivo is critical for the 
development of effective treatments. 
 
1.2. Stem cells 
The concept of a cell type that is self-renewing as well as capable of giving rise to 
multiple specialised cell types was first suggested in the 19th century (Ramalho-
Santos et al. 2007; Bianco et al. 2008). Stem cells were postulated to account for 
the observation that certain tissues, such as the blood or skin, were comprised of 
short-lived cells, yet had the capacity to self-renew for the lifetime of the organism. 
Alexander Maximow is often credited with coining the term “stem cell”, used to 
describe the common precursor of the blood system in 1909, although uses of the 
term can be found as early as 1896 (Ramalho-Santos et al. 2007).  The eventual 
identification of stem cells required the development of methods to isolate, as well 
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as to test the potency of prospective stem cell candidates following in vivo 
transplantation (Bianco et al. 2008). . 
 
1.3. Mesenchymal stromal cells 
Mesenchymal stromal cells (MSCs), also referred to as mesenchymal stem cells and 
multipotential stromal cells were first described by Friedenstein et al as a rare 
population of adherent, highly proliferative, colony forming cells present in the 
bone marrow (BM) (Friedenstein et al. 1970; Friedenstein et al. 1992). Since then, 
MSCs have been reported to be resident in numerous tissues including BM 
(Pittenger et al. 1999; Noth et al. 2002; Quirici et al. 2002; Tormin et al. 2011), 
umbilical cord (Kouroupis et al. 2013; Kang et al. 2014), periosteum (Arnsdorf et al. 
2009; Radtke et al. 2013), adipose tissue (Gronthos et al. 2001; Guilak et al. 2004; 
Hattori et al. 2004), synovium (Fickert et al. 2003; Jo et al. 2007; Karystinou et al. 
2009; Jones et al. 2010a), placenta (in't Anker et al. 2004; Chang et al. 2006; Miao 
et al. 2006) and endometrium (Schwab et al. 2007; Gargett et al. 2009).  
The term mesenchymal stem cell was first coined and described by Arnold Caplan. 
He theorised the existence of a single cell type capable of differentiating into cells 
comprising bone, cartilage, tendon, ligament, marrow stroma, adipocyte, dermis, 
muscle and connective tissue (Caplan 1991). Caplan envisioned a future where a 
patient’s own MSCs could be taken, expanded in vitro and reintroduced, in a 
manner that guaranteed that they would differentiate into a specific tissue.  
The potential therapeutic properties of MSCs continue to draw interest. More 
recent discoveries have further highlighted their therapeutic potential. For 
example, MSCs have been shown to release potentially regenerative trophic factors 
(Ponte et al. 2007; Sato et al. 2011), as well as be able to act as immunosuppressive 
agents (Ren et al. 2009; Galipeau 2013). Table 1 shows current open trials that seek 
to utilise the therapeutic properties of MSCs. 
Many of the properties of MSCs are potentially useful for therapeutic approaches 
that seek to regenerate damaged bone. However, in some cases bone formation 
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may not only be undesirable, but actively drive the progression of degenerative 
diseases. Inappropriate bone formation is seen in some spondioarthropathies and 
in osteoarthritis (Braem et al. 2012; Zhen et al. 2013).  
 
Table 1: Current open clinical trials using MSCs 
Search term: Mesenchymal 
stem cell AND: 
Open 
studies 
Actively 
recruiting 
Mode of action 
Osteoarthritis 12 11 Differentiation 
Non union 9 4 Differentiation 
Graft versus host disease 21 11 Immunosuppression 
Ischemia 28 22 Release of trophic factors 
Multiple sclerosis 14 10 Immunosuppression 
Rheumatoid arthritis 5 4 Immunosuppression 
Ankylosing spondylitis 2 1 Immunosuppression 
Osteoporosis 1 1 Differentiation 
Acute respiratory distress 4 4 Immunosuppression 
Systemic Lupus Erythematosus 1 1 Immunosuppression 
Data supplied by Clinical trials.gov (http://Clinical trials.gov, accessed on 
11/06/2014) 
 
1.4. Differentiation capacity of MSCs 
Early in vitro and animal implantation studies indicated that BM contained 
mesenchymal progenitor cells able to contribute to the formation of adipose, 
cartilage and bone (Gimble et al. 1990; Gundle et al. 1995; Kadiyala et al. 1997; 
Kuznetsov et al. 1997). However, these studies were not able to discern if tissue 
progenitors were present as a mixed population of cells or rather as a single cell 
type capable of multilineage differentiation. Pittenger et al expanded an individual 
colony from BM and demonstrated that these expanded cells could be induced in 
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vitro to differentiate into the adipocytic, chondrocytic or osteocytic lineages 
(Pittenger et al. 1999).   
Although this was undoubtedly a significant step in the search for MSCs, Pittenger 
failed to identify a single cell phenotype responsible for the formation of colonies.  
This is important because rates of proliferation, cell morphology and differentiation 
potential differ widely between individual colonies (Castro-Malaspina et al. 1980; 
Kuznetsov et al. 1997; Pittenger et al. 1999).  Similarly, expression of various 
adipogenic, chondrogenic and osteogenic markers differ both between individual 
colonies and as a function of time in culture (Kuznetsov et al. 1997; Wagner et al. 
2008). The capacity of BM derived MSCs to consistently form lineages beyond bone, 
cartilage and fat remains controversial and has never been supported by direct and 
reproducible experimental evidence (Bianco et al. 2010; Bianco et al. 2013b). 
 
1.5. MSCs and osteogenesis 
1.5.1. Bone development 
Growth and maintenance of the skeleton occurs by distinct two processes known as 
endochondral and intramembranous ossification. Endochondral ossification is the 
process responsible for the replacement of the embryonic cartilaginous skeleton 
and the growth of long bones until adult height is achieved (Maes et al. 2010; 
Mackie et al. 2011; Dirckx et al. 2013).  This type of bone formation is driven in 
developing bone initially by chondrocyte proliferation (Maes et al. 2010; Mackie et 
al. 2011; Dirckx et al. 2013).  Proliferating chondrocytes secrete extracellular matrix 
(ECM) and eventually hypertrophic chondrocytes in the mid shaft are invaded by 
blood vessels (Maes et al. 2010; Mackie et al. 2011; Dirckx et al. 2013). Blood vessel 
infiltration begins from the bone collar, which is formed in the perichondrium, and 
is accompanied by osteoclast and osteoblast precursor migration (Maes et al. 2010; 
Mackie et al. 2011; Dirckx et al. 2013).  
Osteoclasts then remove the cartilage ECM and osteoblasts deposit bone, as a 
result the cartilage is progressively eroded and replaced by trabecular bone (Maes 
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et al. 2010; Mackie et al. 2011; Dirckx et al. 2013). Trabecular bone is synthesised 
by mature osteoblasts that deposit mineralised ECM, a process that is largely 
mediated by TGF-β superfamily signalling molecules (Maeda et al. 2004; Tsuji et al. 
2006; Chen et al. 2012). After birth, the remaining cartilage at the epiphysis also 
becomes invaded by blood vessels leading to the formation of a growth plate. 
Further chondrocyte proliferation, at the growth plate, followed by angiogenesis 
and osteoclast invasion drives longitudinal bone growth (Mackie et al. 2011; Dirckx 
et al. 2013).  
In terms of foetal bone development intramembranous ossification occurs in a 
relatively small number of bones, those comprising the flat bones of the skull 
(Mackie et al. 2011; Dirckx et al. 2013; Percival et al. 2013). Here, bone formation 
occurs directly from pre-osteogenic condensations of mesenchymal progenitors, 
from which presumptive bone cells rapidly proliferate outward (Percival et al. 
2013). Following the initial expansion and mineralisation, bone growth is driven by 
proliferation and differentiation of pre-osteogenic MSCs at the osteogenic fronts 
along fibrous sutures (Rice et al. 2003; Percival et al. 2013).  
Once formed, mature bone is not static but continually undergoes remodelling 
(Kular et al. 2012). This is an essential process for the repair of the micro-damage 
that is a normal consequence of the stress placed on bone during everyday life 
(Kular et al. 2012). Frost was the first to describe what he termed the basic 
multicellular unit of bone remodelling comprising osteoclasts, osteoblasts and 
osteocytes (Frost et al. 1969). Bone is constantly broken down by bone degrading 
osteoclasts and replaced by bone forming osteoblasts which may then become 
surrounded by mineralised bone to form osteocytes (Crockett et al. 2011).  It has 
since become clear that bone lining cells also play an important role in the bone 
remodelling cycle and the complex interaction between all these cell types 
regulates the balance of bone formation and resorption (Crockett et al. 2011).  
The osteoclast is a unique exocrine cell that is capable of dissolving bone as well as 
degrading ECM (Teitelbaum 2007). It is a large multinucleated cell that forms 
through fusion of mononuclear precursor cells of the monocyte/macrophage 
26 
 
lineage (Teitelbaum 2007; Crockett et al. 2011). Differentiation is controlled by 
interactions between stromal cells, osteoblasts and pre-osteoclasts (Teitelbaum 
2007). Two important mediators of this are macrophage colony stimulating factor 
(M-CSF) and receptor activator of nuclear factor-κB ligand (RANKL). RANKL acts as 
the key osteoclastogenic cytokine (Teitelbaum 2007; Crockett et al. 2011). 
Osteoblasts and their precursors are the principle expressers of RANKL which is 
expressed on their cell surface as a response to parathyroid hormone and the active 
dihydroxy form of vitamin D3 (Leibbrandt et al. 2008; Nakashima et al. 2011). 
Signalling through RANK, the receptor for RANKL, is an important driver of 
osteoclast differentiation (Teitelbaum 2007; Crockett et al. 2011).  Mutations 
causing the loss of function in either RANKL or RANK result in the development of 
osteopetrosis, a disease characterised by brittle bones and high bone mass 
(Sobacchi et al. 2007; Guerrini et al. 2008). 
Osteoprotegerin (OPG) is a negative regulator of RANKL activity, OPG competes 
with RANK as a soluble decoy receptor and is also produced by osteoblast lineage 
cells (Lacey et al. 1998; Teitelbaum 2007). The balance between RANKL and OPG is 
critical in controlling osteoclast differentiation. Thus, osteoblasts play an integral 
role in regulating osteoclast differentiation and this is a pivotal interaction which 
governs the balance between bone formation and resorption. 
 
1.5.2. Fracture repair 
Following fracture, endochondral and intramembranous ossification are 
recapitulated in a multi-step process with many similarities to foetal skeletal 
development. Both endochondral and/or intramembranous ossification may occur 
depending on the type of fracture and the degree of stability (Thompson et al. 
2002; Marsell et al. 2011). The most common process by which bone is repaired is 
conventionally partitioned into four stages, each characterised by a distinct set of 
cellular and molecular events. These stages are: acute inflammation, soft callus 
formation, hard callus formation and remodelling (Schindeler et al. 2008; Marsell et 
al. 2011).  
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In mice the acute inflammation stage peaks within the first 24 hours after injury 
(Cho et al. 2002) and involves the secretion of a range of pro-inflammatory 
cytokines including tumour necrosis factor-α (TNF-α). Bleeding into the fracture site 
leads to the formation of a haematoma between and around the fracture ends.  
Degranulating platelets, macrophages and other inflammatory cells infiltrate the 
haematoma and secrete cytokines and growth factors (Schindeler et al. 2008; 
Marsell et al. 2011), leading to the recruitment of various cell types into the 
fracture site including MSCs (Cho et al. 2002; Gerstenfeld et al. 2003; Marsell et al. 
2011). Stromal derived factor 1 (SDF-1) signalling via its receptor CXCR4 had been 
shown to be a critical mediator of MSC migration into fracture sites. Kitaori et al  
showed that SDF-1 increases MSC chemotaxis in a dose dependent manner, it is 
highly expressed in periosteum and that disruption of SDF-1/CXCR4 signalling 
resulted in impaired bone formation in a mouse model (Kitaori et al. 2009).  
Following the formation of the primary haematoma, MSC differentiate into 
chondrocytes and their subsequent expansion is responsible for the formation of a 
soft callus. This typically forms 7-9 days following injury and serves to provide 
mechanical support as well as a template for the bony callus that will supersede it 
(Schindeler et al. 2008; Marsell et al. 2011).  A hard bony callus is then formed, 
composed of woven bone (Schindeler et al. 2008; Marsell et al. 2011). This then 
undergoes remodelling to form laminar bone. 
Sometimes fracture healing fails. The US Federal Drug Administration (FDA) council, 
defines a fracture non-union as a fracture which has not achieved bone union after 
nine months since the initial injury, and for which a minimum of three months has 
elapsed with no sign of healing (Fayaz et al. 2011). Several factors are known to be 
associated with possibility of a fracture progressing to non-union including loss of 
bone at the fracture site (bone defect), inadequate mechanical stability, extensive 
soft tissue damage, open fractures, the administration of non-steroidal anti-
inflammatory drugs and smoking  (Giannoudis et al. 2000). Recently, single 
nucleotide polymorphisms in noggin, an inhibitor of bone morphogenic proteins 
(BMP) signalling and SMAD-6, have been shown contribute a genetic component to 
the development non-union (Dimitriou et al. 2011a).  
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Radiological observation is commonly used to classify aseptic non-unions into two 
distinct types. These are hypertrophic, characterised by hyper-vascularisation of the 
fracture site or atrophic, characterised by poor vascularisation of the fracture site 
(Megas 2005). The former is often associated with inadequate stabilisation of the 
fracture site and can be addressed by revision surgery to improve stability  (Megas 
2005). Whereas the latter is associated with an inadequate healing response 
(Megas 2005) and is therefore more difficult to treat.  
 
1.5.2.1. MSC therapy for fracture repair 
Healey et al used percutaneous injection of autologous BM aspirates into the site of 
failed healing in eight patients treated for primary sarcomas by en bloc resection. 
Union was achieved in five patients, although new bone formation was observed in 
seven (Healey et al. 1990). These encouraging results were attributed to the 
presence of “osteoprogenitor” cells (a term used in lieu of MSCs reflecting the 
uncertainty surrounding MSC identity at the time) within the BM. However, a direct 
link between the presence of MSCs in BM aspirates and the efficacy of this method 
of treatment was not proven.  
This question was addressed by Hernigou et al who demonstrated that the absolute 
number and concentration of MSCs in a concentrated and injected BM aspirate had 
a direct impact on the probability of achieving union (Hernigou et al. 2005a). 
Patients receiving concentrated BM containing 2835±1160 (mean±SD) MSCs/ml or 
a total of 54962±17431 (mean±SD) MSCs following percutaneous injection into 
atrophic non-unions went on to achieve union, whereas patients receiving lower 
doses of MSCs did not.  
It must be noted however, that Hernigou et al could not rule out the possibility that 
other cell types concentrated alongside MSCs were responsible for this effect, nor 
could the engraftment of injected MSCs into the fracture site be demonstrated. 
Indeed, it has been established that MSCs are potent inducers of vascularisation 
(Sato et al. 2011) and that this can be independent of engraftment to the site of 
action (Preda et al. 2014). Nevertheless this was an important study since it 
29 
 
demonstrated the efficacy of minimally manipulated MSC for fracture repair in the 
clinical setting. Moreover, it led to the development of several BM concentrator 
devices that are now actively used in clinical orthopaedics, for treatment of a range 
of conditions including fracture non-union (Giannoudis et al. 2013), avascular 
necrosis (Aarvold et al. 2013), chondral defects (Gigante et al. 2012) and critical 
limb ischemia (Murphy et al. 2011).  
One important limitation to the use of BM concentration for fracture repair is the 
lack of prospective evaluation of the MSC dose delivered to patients. Hernigou et al 
relied on ex vivo expansion of individual colonies to determine MSC content, 
therefore only retrospective analysis was possible (Hernigou et al. 2005a). This 
meant that the quality of aspirates at the point of use was unknown leading to a 
proportion of patients receiving far fewer MSCs and failing to achieve union. 
Methods such as volumetric flow cytometry may offer a means of rapidly evaluating 
MSC content in BM aspirate. To be a realistic option for use as an intraoperative 
quality control, it should take no longer than 1 hour to return a result. 
 
1.5.2.2. BMP therapy for fracture repair  
BMP-2 is a powerful inducer of bone formation and has been shown to irreversibly 
induce in vivo bone formation after only transient short term expression (Noel et al. 
2004). Several clinical studies have demonstrated the efficacy of BMP therapy in 
accelerating fracture healing and bone regeneration (Govender et al. 2002; McKay 
et al. 2007; Ristiniemi et al. 2007; Kanakaris et al. 2008). rhBMP-2 was approved by 
the FDA in 2004 (McKay et al. 2007), this followed a successful clinical trial by 
Govender et al  who evaluated the effects of BMP-2 for the treatment of open tibial 
fracture in 450 patients (Govender et al. 2002). Implantation of 1.5mg of BMP-2 
resulted in a 44% reduction in need for secondary intervention due to delayed 
union and a significantly faster average healing time compared to the standard of 
care treatment (Govender et al. 2002). BMP-7 has been evaluated for tibial fracture 
repair with significantly shorter mean time to union reported (Ristiniemi et al. 2007) 
and BMP-7 therapy with revision of tibial non-union in 67 patients had a reported 
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success rate of 89.7% (Kanakaris et al. 2008). This rate of success is comparable to 
the gold standard of care (autologous bone graft) but avoids the associated 
complications such as donor site morbidity (Kanakaris et al. 2008).  
However, while BMP therapy has emerged as a promising addition or alternative to 
autologous bone grafting, the doses used clinically are significantly higher than 
physiological concentrations of BMPs (Gautschi et al. 2007). Additionally, several 
adverse effects associated with BMP therapy have been reported including implant 
displacement, ectopic bone formation and neurological effects (Carragee et al. 
2011). There is also growing concern that BMP-2 therapy may be associated with an 
increased risk of cancer, although studies have so far have returned inconclusive or 
conflicting results (Cooper et al. 2013; Fu et al. 2013; Simmonds et al. 2013) This 
has led several groups to develop novel delivery systems for BMP delivery aimed at 
providing a more localised, sustained and physiological dose of BMP for bone 
regeneration (Ben-David et al. 2013; Fan et al. 2014; Shekaran et al. 2014). 
In the most severe cases a combination of therapies may be required. The diamond 
concept of fracture healing, a term coined by Giannoudis et al, sets out the four 
elements that are essential for maximum osteogenic effect (Giannoudis et al. 2007). 
This approach combines the utilisation of optimal mechanical stability, 
osteoconductive scaffolds, growth factors such as BMPs and MSCs. (Giannoudis et 
al. 2007). However, if the MSC element of the diamond takes the form of BM 
aspirate it is subject to all the before mentioned issues pertaining to unknown and 
uncontrolled MSC dose. The Diamond concept of fracture healing would be 
similarly improved by prospective MSC enumeration. 
 
1.5.3. Regulatory networks and osteogenesis 
1.5.3.1. The WNT signalling pathway  
The WNT family proteins are highly conserved secreted glycoproteins that play 
essential and diverse roles in development and homeostasis (Baron et al. 2013; 
Fakhry et al. 2013). Loss of function mutations in the gene encoding for the WNT 
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co-receptor low density lipoprotein-related protein-5 (LRP5), were found in patients 
with low bone mass and osteoporosis-pseudoglioma syndrome (Gong et al. 2001). 
Mutations in the same gene, resulting in gain of function, cause abnormally high 
bone mass in otherwise healthy patients (Boyden et al. 2002; Little et al. 2002). 
These finding generated a great deal of interest in WNT signalling and its 
involvement in bone development and homeostasis. 
It has since become clear that the canonical or β-catenin WNT pathway plays a 
major role in skeletal biology (Baron et al. 2013). Β-catenin is the key molecule 
involved in signal transduction. In the absence of signal, cytoplasmic β-catenin is 
bound by the multi-protein destruction complex, facilitating proteasomal 
destruction of β-catenin via sequential phosphorylation and ubiqitination (Clevers 
2006; Cadigan et al. 2009; Baron et al. 2013). WNT molecules initiate signalling by 
binding to a duel receptor complex comprised of the frizzled protein, a seven-pass 
transmembrane receptor, and either LRP5 or LRP6. This triggers phosphorylation of 
the cytoplasmic tail of LRP5/6 and binding to Axin, a key constituent protein of the 
destruction complex (Clevers 2006; Cadigan et al. 2009; Baron et al. 2013). This has 
the effect of inactivating the destruction complex leading to accumulation of β-
catenin and its translocation to the nucleus, where it activates WNT target gene 
expression (Clevers 2006; Cadigan et al. 2009; Baron et al. 2013). 
In general, canonical WNT signalling enhances MSC osteoblastic differentiation (Day 
et al. 2005; Hu et al. 2005; Bennett et al. 2007) and promotes chondrocyte 
hypertrophy (Day et al. 2005), whilst inhibiting adipogenesis (Kennell et al. 2005; 
Kawai et al. 2007; Laudes 2011). Sclerostin and dickkopf-1 (DKK1) are soluble 
inhibitors of WNT signal transduction, (Bafico et al. 2001; Poole et al. 2005) both 
inhibit WNT signalling by binding to the LRP5/6 receptor and promoting 
internalisation (Bafico et al. 2001; Moester et al. 2010). Mutations resulting in a lack 
of sclerostin were shown to be responsible for the high bone mass observed in Van 
Buchem disease and sclerosteosis (Balemans et al. 2001; Brunkow et al. 2001). 
Whereas changes in DKK1 expression have been implicated in the development of 
fracture non-union (Bajada et al. 2009) and ankylosing spondylitis (Uderhardt et al. 
2010).  
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1.5.3.2. The TGF-β/BMP signalling pathway 
The transforming growth factor-beta (TGF-β) superfamily is a diverse group of 
signalling molecules which control a plethora of cellular responses. TGF-β family 
cytokines are comprised of over forty members including TGF-βs, Activin and BMPs 
(Shi et al. 2003). In the canonical signalling pathway, TGF-β cytokines bind to 
specific type I and type II serine/threonine kinase receptors resulting in the 
formation of heteromeric complexes of type I and type II receptors and 
phosphorylation of R-SMAD proteins (Shi et al. 2003; Chen et al. 2012). 
Phosphorylated R-SMADs form a complex with co-SMADs and SMAD4 which then 
translocates to the nucleus and brings about expression of target genes (Shi et al. 
2003; Chen et al. 2012). TGF-β signalling may also occur through alternative or non-
canonical pathway that involves complex interactions between TGF-β receptors and 
the mitogen activated protein kinase (MAPK), and the phosphoinositide 3-kinase 
(PI3K) signalling cascades (Moustakas et al. 2009; Massague 2012). 
TGF-β1 increases bone formation by stimulating the proliferation and chemotaxis of 
osteoblast progenitors and stimulating the production of bone matrix (Janssens et 
al. 2005). However, TGF-β1 has been shown to block the late phases of osteoblast 
differentiation and inhibits mineralisation (Maeda et al. 2004). These later phases 
are regulated by BMPs. Mice which lack the capacity to produce BPM-2 in their limb 
bones spontaneously develop fractures that do not heal with time (Tsuji et al. 
2006), indicating that BMP-2 is a necessary component of the signalling cascade 
that governs fracture repair, although BMP-4, 5,6 and 7 all have the ability to 
induce osteogenesis (Chen et al. 2012). 
 
1.5.3.3. The JAK/STAT signalling pathway 
The Janus kinase/signal transducers and activators of transcription (JAK/STAT) 
signalling pathway is responsible for mediating responses to cytokines and growth 
factors and is involved in a wide variety of cellular responses (Harrison 2012; Kiu et 
al. 2012; Stark et al. 2012). Binding of extracellular ligand to the cognate 
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transmembrane receptors activates JAKs via auto or trans-phosphorylation, leading 
to phosphorylation of cytoplasmic STAT tyrosine residues (Harrison 2012; Kiu et al. 
2012). STAT phosphorylation leads to dimerization followed by translocation to the 
nucleus, where STATs bind specific sequences and initiate transcription of target 
genes (Kiu et al. 2012). 
In mammals there are a total of four JAKs, JAK1-3 and TYK2 and 7 STATs, STAT1-4 
STAT5A, STAT5B and STAT6 (Kiu et al. 2012; Stark et al. 2012). Rodig et al showed 
that JAK1 is required for signalling by cytokines that utilise class II cytokine 
receptors and those which utilise cytokine receptors that depend on either the 
common gamma (c) or gp130 subunits (Rodig et al. 1998).  Therefore, JAK1 has an 
indispensable role in mediating biologic responses to interferon (IFN) α/β, IFN 
Interleukin (IL) 10 (type II receptors), IL-2, IL-4, IL-7, IL-9, IL-15, IL-21 (c subunit), IL-
6, IL11, Leukaemia inhibitory factor, Oncostatin M, ciliary neurotrophic factor and 
cardiotrophin-1 (gp130 subunit) (Rodig et al. 1998; Habib et al. 2002). JAK2 deletion 
is embryonically lethal due to the absence of definitive erythropoiesis and analysis 
of JAK2 deficient cells showed that JAK2 has a critical, non-redundant role in 
mediating responses to IFN, thrombopoietin, IL-3, IL-5 and 
granulocyte/macrophage stimulating factor (Parganas et al. 1998). Signalling via the 
c subunit is also dependent on JAK3, in humans mutations in the c result in X-
linked severe combined immunodeficiency syndrome (Suzuki et al. 2000; Habib et 
al. 2002). Tyk2 plays a restricted role in IFNα signalling and is required in mediating 
IL-12 dependent biological response (Shimoda et al. 2000).   
The effect of JAK/STAT signalling on MSCs and their differentiated progeny is not 
well understood. There is substantial evidence for JAK/STAT involvement in 
adipogenesis (Rosen et al. 2006b; Zhang et al. 2011; Shi et al. 2014); by comparison 
little is known regarding JAK/STAT activity in MSC proliferation or differentiation 
into bone and cartilage. However, it has been shown that IL-6 type cytokines, those 
signalling through the gp130 subunit, are able to stimulate alkaline phosphatase 
(ALP) and osteocalcin, and promote osteoblast differentiation (Bellido et al. 1997). 
Additionally, gp-130 null mice died at or before birth with multiple skeletal 
abnormalities and the number of osteoblasts present in bone was significantly 
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reduced (Shin et al. 2004). In humans STAT3 mutation is responsible for hyper-
immunoglobulin E syndrome, a rare immunodeficiency disorder also known as Job 
syndrome (Holland et al. 2007; Minegishi et al. 2007). Patients commonly suffer 
from recurrent fractures, hyper extendable joints and scoliosis (Grimbacher et al. 
1999; Grimbacher et al. 2005). Growth hormone (GH) has a well-recognised 
influence on bone growth, and relies on JAK/STAT signalling for many of its 
downstream effects (Wang et al. 2004; Hadjidakis et al. 2006; DiGirolamo et al. 
2007; Giustina et al. 2008). In BM GH inhibits MSC adipogenesis in favour of 
osteogenesis and chondrogenesis (Gevers et al. 2002) and also inhibits osteoblast 
apoptosis (DiGirolamo et al. 2007). Collectively, this suggests an important role for 
JAK/STAT signalling in osteogenesis, therefore inhibition of this pathway could 
potentially lead to reduced osteogenesis and/or chondrogenesis. 
 
1.5.3.4. Nuclear receptor signalling 
The nuclear receptor superfamily of ligand dependent transcription factors regulate 
diverse aspects of development and homeostasis, by both positive and negative 
regulation of gene expression (Glass et al. 2010). Classical steroid hormone 
receptors comprise the most well characterised subfamily of nuclear receptors and 
mediate most of the biological effects of mineralocorticoids, oestrogens, progestins 
and androgens (Glass et al. 2010). They also mediate the effects of glucocorticoids, 
retinoic acid and vitamin D (Glass et al. 2010). 
Glucocorticoid signalling, mediated by the glucocorticoid receptor is of particular 
importance in osteogenesis (Eijken et al. 2006). The artificial glucocorticoid 
derivative dexamethasone (DEX) is a common component in in vitro MSC 
differentiation assays (Pittenger et al. 1999; Jones et al. 2010b; Kouroupis et al. 
2013). Glucocorticoid signalling stimulates the expression of genes involved in bone 
formation including Runt-related transcription factor 2 (RUNX2), ALP and 
osteopontin whilst inhibiting the expression of genes that negatively regulate bone 
formation (Eijken et al. 2006). Glucocorticoid signalling has also been shown to 
stimulate osteogenesis by modulating the phosphorylation state of a regulatory 
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serine residue on RUNX2, in rat primary fibroblasts (Phillips et al. 2006). However, 
long term and/or high dose glucocorticoid administration, usually for the treatment 
of oncological disorders, is associated with a range of negative side effect including 
osteoporosis (Yao et al. 2008; Biddie et al. 2012). This effect was addressed by Yao 
et al, who showed that in mice glucocorticoid excess drove increased 
osteoclastogenesis and adipogenesis (Yao et al. 2008).  
1,25-dihydroxyvitamin D3 (1,25(OH)2D3) the biologically active metabolite of vitamin 
D, has been claimed to influence osteogenesis both directly and indirectly. In the 
intestine vitamin D acts as an essential mediator of calcium homeostasis by 
stimulating calcium and phosphate absorption  (Holick et al. 2011). Additionally, 
1,25(OH)2D3 has been reported to stimulate osteogenic differentiation in vitro and 
synergise DEX driven osteogenesis, by stimulating expression of genes involved in 
differentiation and cell cycle regulation (Piek et al. 2010). However, these findings 
are not supported in animal studies, Tanaka et al transplanted bone from vitamin D 
receptor knockout mice into a wild type mouse, this led to excessive bone 
formation and mineralisation in the knockout tissue (Tanaka et al. 2004), suggesting 
that vitamin D is a negative regulator of bone formation in vivo. Additionally  
1,25(OH)2D3 is a powerful inducer of RANKL and strongly promotes osteoclast 
formation (Suda et al. 2012). Nevertheless 1,25(OH)2D3 has been used as a 
therapeutic agent for the treatment of osteoporosis since 1983 and has been 
shown to increase bone mineral density and reduce the incidence of bone fracture 
in vivo. (Suda et al. 2012).  
Retinoic acid is a small lipophilic molecule derived from retinoids, of which retinol 
(vitamin A) is the main circulating form in mammals (Rochette-Egly et al. 2009; 
Rhinn et al. 2012). Retinoid acid signalling is involved in a diverse range of biological 
processes including limb patterning, brain development and differentiation (Rhinn 
et al. 2012). Retinoids and retinoic acid can act as powerful teratogens and 
exposure has been associated with numerous craniofacial defects (Morriss-Kay 
1993; Vieux-Rochas et al. 2007). Compound null mutations of the genes encoding 
retinoid acid receptors (RARs) α and γ in mice resulted in severe craniofacial and 
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skeletal abnormalities (Lohnes et al. 1994), highlighting the importance of retinoic 
acid signalling in skeletal development. 
The role of retinoic acid in regulating MSC differentiation is not well understood. 
Early experiments showed that treatment of a mouse mesenchymal cell line with 
retinoic acid induced expression of ALP and modulated expression TGF-β family 
proteins (Gazit et al. 1993). Later James et al showed that retinoic acid enhanced 
osteogenesis in mouse cranial suture derived MSCs (James et al. 2010), suggesting 
one potential mechanism driving retinoic acid induced craniofacial malformation. 
Additionally, several studies have suggested a possible synergy between retinoic 
acid and BMP signalling in potentiating osteogenesis (Cowan et al. 2005; Wan et al. 
2006; Zhang et al. 2010), although the precise mechanism underlying this effect 
remains to be elucidated. Nevertheless this potential synergy has led some to 
suggest combined retinoic acid and BMP therapy for the treatment of large bone 
defects (Cowan et al. 2005; Zhang et al. 2010). It must be noted however, that 
other studies have reported inhibitory effects of retinoic acid on osteogenic 
induction (Hoffman et al. 2006; Wang et al. 2008). Moreover, in a mouse model of 
heterotopic bone formation, treatment with a RAR agonist almost totally blocked 
bone formation (Shimono et al. 2011). However, in this model bone is formed by 
endochondral ossification and it is likely that inhibition of the preceding 
chondrogenesis rather than inhibition of osteoblast differentiation or activity is the 
primary mode of action (Kaplan et al. 2011). 
 
1.5.3.5. Transcriptional regulation of bone formation 
BMP-2 and TGF-β1 both stimulate the expression of RUNX2 in a pluripotent 
mesenchymal precursor cell line (Lee et al. 2000). Targeted disruption of RUNX2 in 
mice results in total blockage of intramembranous and endochondral ossification 
owing to arrest of osteoblast maturation (Komori et al. 1997). RUNX2 controls the 
expression of genes expressed specifically in osteoblasts such as osteocalcin, 
collagen type I alpha 1, bone sialoprotein and osteopontin through direct binding to 
the osteoblast-specific cis-acting elements (Ducy et al. 1997). Overexpression of 
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RUNX2 by adenoviral transfection of adipose derived MSCs resulted in rapid 
osteoblast differentiation, mineral deposition and inhibition of adipogenesis in vitro 
(Zhang et al. 2006).  
Osterix (OSX), also known as Sp7, is a mediator of osteogenesis which acts 
downstream of RUNX2. OSX null mice develop a cartilage matrix but do not develop 
bone despite the expression of RUNX2 in pre-osteoblasts (Nakashima et al. 2002). 
In these mice neither endochondral nor intramembranous ossification occurs 
despite the invasion of blood vessels into the zone of hypertrophic chondrocytes, 
suggesting the OSX expression is required for the final stages of osteoblast 
differentiation.   
 
1.6. The capacity of MSCs to stimulate endogenous bone repair 
mechanisms 
1.6.1. Stimulation of vascularisation  
A growing body of evidence suggests that MSCs are able to exert regenerative 
effects that are independent of differentiation. Recently animal studies have 
demonstrated that MSCs are able to stimulate angiogenesis (Zhou et al. 2010; 
Martinez et al. 2013; Kai et al. 2014; Kang et al. 2014). Because of this, MSCs have 
been investigated as therapeutic agents for the treatment of ischemic heart injury, 
Hare et al, demonstrated that following acute myocardial infarction, patients 
administered with expanded MSCs showed an improvement in heart function (Hare 
et al. 2009). Further studies in a porcine model suggested that the favourable 
effects of MSC infusion are achieved by enhanced neovascularisation as a result of 
secretion of angiogenic factors such as vascular endothelial growth factor (VEGF) 
(Sato et al. 2011). Moreover, subcutaneous transplantation of adipose derived 
MSCs can protect against ischemic injury without any extensive migration from the 
injection site (Preda et al. 2014). 
Several groups are now experimenting with technologies aimed at retaining MSCs 
at the site of ischemic injury. MSCs seeded onto a variety of materials and applied 
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as a cardiac patch have shown impressive efficacy in animal models (Zhou et al. 
2010; Martinez et al. 2013; Kai et al. 2014; Kang et al. 2014). This suggests that 
prolonged retention of MSCs, close to the site of injury, augments MSC mediated 
cardiac repair by increasing the local concentration of angiogenic factors. 
The ability of MSCs to stimulate angiogenesis is also of interest in bone disease 
therapy. Neovascularisation is well recognised as a crucial component to successful 
fracture healing (Megas 2005). Therefore, in this setting MSCs may provide a duel 
benefit by stimulating vascularisation and contributing to new bone formation. 
 
1.6.2. Recruitment of cells to sites of tissue damage 
The repair of cartilage defects are another area to which MSC therapy is seen to 
hold promise. In 2002 Wakitani et al administered BM derived MSCs to cartilage 
defects in patients with knee osteoarthritis. Although no significant clinical 
improvement was observed the authors reported an improvement in arthroscopic 
and histological grading score (Wakitani et al. 2002). More recently studies in rabbit 
(Dashtdar et al. 2011) and pig (Nakamura et al. 2012) models have shown 
significant but incomplete cartilage regeneration upon administration of expanded 
MSCs. Interestingly, a proof of concept study showed that after excision of proximal 
humeral condyles in rabbits, implantation of a TGF-β3 infused scaffold was able to 
almost totally recapitulate the mechanical properties of native cartilage at the 
articular surface (Lee et al. 2010).  This was done without the addition of any 
cellular component (Lee et al. 2010). The impressive level of bone and cartilage 
regeneration seen suggests that stimulating endogenous cells, rather than cell 
delivery, may be a more successful strategy in treating cartilage defects. A similar 
strategy is employed with the use of osteoconductive scaffold for the treatment of 
bone defects (Guda et al. 2013), although in both these cases the exact mechanisms 
governing MSC recruitment remain unknown. 
MSCs are able to stimulate the migration of other MSCs as well as non-MSC cell 
types (Ponte et al. 2007; Miller et al. 2008). The chemokine SDF-1 has been 
identified as an important mediator of this property (Ponte et al. 2007; Miller et al. 
39 
 
2008). It is secreted in large amounts by immature osteoblasts and MSCs as well as 
other cell types including endothelial cells (Ponomaryov et al. 2000; Ma et al. 2011) 
and expression was found to be increased in the tissue surrounding damaged bone 
in a murine fracture model (Liu et al. 2013). Human MSCs were also shown to 
migrate towards an SDF-1 gradient in a dose dependent manner in vitro (Ryu et al. 
2010). This suggests that SDF-1 release and SDF-1 driven MSC migration plays an 
important role in recruitment of additional MSCs to the site of healing.  
 
1.6.3. Osteogenesis imperfecta 
Perhaps one unintended demonstration of the capacity of MSCs to exert 
regenerative effects that are independent of differentiation may be seen by 
attempts to use MSCs for the treatment of osteogenesis imperfecta. Osteogenesis 
imperfecta (OI) is a genetic disorder most commonly caused by mutations in one of 
two genes encoding collagen type 1 (Rauch et al. 2004). It is characterised by 
increased bone fragility, low bone mass and other connective tissue manifestations 
(Rauch et al. 2004). Horwitz et al proposed MSC therapy as a potential treatment 
for OI. It was hoped that donor MSCs would engraft, expand and differentiate to 
form normal bone. Horwitz treated six children with severe OI with culture 
expanded BM derived allogeneic MSCs. Five patients showed accelerated growth 
velocity during the first six months post infusion but only one patient showed a 
substantial increase in total body mineral content (Horwitz et al. 2002). However, 
the observed accelerated growth was not sustained long term leading to the 
realisation that donor cells had limited regenerative capacity following 
transplantation (Dominici et al. 2008). Later experiments in murine models of OI 
suggested that transplanted MSCs do not substantially engraft in bone but rather 
exert their positive effects via soluble mediators that indirectly stimulate growth 
(Otsuru et al. 2012). 
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1.7. Immunomodulation 
The immunosuppressive effects of MSCs have been well documented, they have 
been shown to be capable of suppressing T and B cell proliferation in a dose 
dependent manner, this is largely mediated by indoleamine 2,3-dioxgenase (Ren et 
al. 2009; Galipeau 2013). At the same time they do not express major 
histocompatibility (MHC) class II antigens (Le Blanc et al. 2003). Allogeneic MSCs 
escape recognition by alloreactive T cells and natural killer cells and do not 
stimulate a T-cell mediated response (Di Nicola et al. 2002; Sotiropoulou et al. 
2006). These properties of MSCs are important, as they allow allogeneic MSCs to be 
safely administered to patients with intact immune systems (Raynaud et al. 2013). 
The immunomodulatory effects of MSCs have led to interest in their use for a range 
of immunological conditions including graft versus host disease, multiple sclerosis 
and rheumatoid arthritis (Table 1). This property of MSCs may also prove useful in 
bone disease therapy development, particularly when considered in the light of 
their ability to stimulate endogenous repair mechanisms. Allogeneic MSCs may be 
implanted without eliciting an immune response and contribute to new bone 
formation by releasing chemokines and pro-angiogenic factors. 
 
1.8. MSC as causative agents of bone disease 
1.8.1. Osteoarthritis 
The causes of primary osteoarthritis (OA) are unknown, but it rarely occurs in 
people below 40 years old. It is characterised by hyaline cartilage fibrillation and 
loss, synovial inflammation, muscle weakness, ligament laxity, increased density of 
the subchondral bone and the development of bony osteophytes (Bailey et al. 
1997; Felson et al. 2000; Peat et al. 2001). The involvement of MSCs in OA is poorly 
understood, but the ability of MSCs isolated from OA patients to undergo 
chondrogenic differentiation has been shown to be reduced (Murphy et al. 2002). 
Our laboratory showed that MSCs are present in normal synovial fluid and more 
numerous in the synovial fluid of patients with early OA (Jones et al. 2008). There is 
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also a large body of evidence that validates an inverse relationship between OA of 
the hip and osteoporosis (OP) (Dequeker et al. 1996; Dequeker et al. 2003; 
Hopwood et al. 2007; Kumarasinghe et al. 2011). WNT signalling has been 
implicated as a possible mediator of this observation. Velasco et al showed 
differential expression of several WNT related genes in bone samples from OA 
patients and patients with hip fractures (Velasco et al. 2010). The apparent increase 
in WNT signalling observed in OA patients may be responsible for both the cartilage 
catabolism and degradation due to increased matrix metalloproteinase expression, 
and the formation of osteophytes as well as increased bone mineral density. 
A range of molecules from the TGF-β/BMP signalling pathway have been shown to 
be differentially expressed in OA as compared to healthy controls (Hopwood et al. 
2007; Sanchez-Sabate et al. 2009) Recently Zhen et al showed that inhibition of 
TFG-β signalling in MSCs, residing in the subchondral bone, attenuates the 
progression of OA. Conversely transgenic expression of active TGF-β in osteoblastic 
cells induced osteoarthritis (Zhen et al. 2013). This implicates enhanced 
mineralisation, driven by MSCs, as an important event in OA progression, and builds 
on much earlier studies of OA which indicate that changes in subchondral bone 
precede cartilage fibrillation (Carlson et al. 1994; Bailey et al. 1997). All these 
observations taken together make a compelling case for the involvement of MSC 
osteogenic differentiation in the development and progression of OA. 
 
1.8.2. Ankylosing spondylitis 
Spondyloarthritis is a group of heterogeneous diseases which include ankylosing 
spondylitis (AS) and psoriatic arthritis that share hereditary clinical and pathogenic 
features, the most frequent of which are sacroiliitis, enthesitis, iritis, oligoarthritis, 
psoriasis and inflammatory bowel disease. In common with other chronic 
inflammatory diseases AS affects bone, new aberrant bone formation in the form of 
syndesmophytes, is seen at the enthesis (Ball 1983). This particularly effects the 
vertebra of the spine eventually leading to fusion and progressive disability (Braem 
et al. 2012). 
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Conversely, AS is associated with the development of features associated with 
increased bone catabolism such as erosions, generalised osteoporosis and vertebral 
fractures (Uderhardt et al. 2010; Montala et al. 2011; Klingberg et al. 2012). One of 
the key mediators of joint remodelling in inflammatory disease is DKK-1. Diarra et al 
showed that in an inflammatory environment DKK-1 blockade stimulates bone 
formation in the joint both by inhibiting osteoclast formation and simultaneously 
stimulating osteophyte formation driven by enhanced WNT signalling (Diarra et al. 
2007). Blockade of DKK-1 induces fusion of sacroiliac joints in a transgenic mouse 
that develops bilateral sacroiliitis (Uderhardt et al. 2010). These studies suggest that 
an increase in osteogenesis, driven by enhanced WNT signalling, may be the 
underlying cause of aberrant bone formation. However, WNT independent 
mechanisms influencing MSC differentiation into osteoblasts cannot be ruled out.  
Current treatments for AS such as TNF blockade only address the inflammatory 
element of the disease. Although TNF blockade is very effective in reducing the pain 
associated with chronic inflammation of the joints, it does not alter the 
radiographic progression of the disease (van der Heijde et al. 2008a; van der Heijde 
et al. 2008b). New treatment are required to address the ongoing inappropriate 
bone formation associated with AS.  
 
1.9. Defining and identifying MSCs 
1.9.1. Current perspectives in defining MSCs 
A minimum criteria for the definition of MSC was set out in the International 
Society for Cellular Therapy 2006 position statement (Dominici et al. 2006). MSC are 
defined as adherent cells that can be maintained in culture and have in vitro tri-
lineage differentiation capacity (osteogenesis, adipogenesis and chondrogenesis). 
Cultured cells exhibit positive co-expression of three cell surface antigens: CD105, 
CD73 and CD90 and negative expression of CD45, CD34, CD14 or CD11b, CD79α or 
CD19 and HLA-DR. Although widely recognised and cited these criteria have drawn 
criticism due to their reliance on artificial conditions and stimuli, and have been 
shown to poorly reflect the nature of MSCs in vivo (Jones et al. 2002; Boxall et al. 
43 
 
2012; Bianco et al. 2013b). One example of this can be taken from our own 
laboratory, Jones et al immunomagnetically selected BM cells based on expression 
of the D7-FIB antigen. This enriched a population of cells that contained 100% of 
the colony forming capacity of BM but strongly and consistently expressed HLA-DR 
(Jones et al. 2002).  Some have suggested that the ISCT criteria are simply widely 
shared properties of connective tissue cells (Bianco et al. 2013b). Observations that 
MSCs derived from diverse tissues exhibit varying phenotypic characteristics 
particularly with respect to multi-lineage differentiation capacity (De Ugarte et al. 
2003; Baksh et al. 2007; Hayashi et al. 2008), implies some degree of lineage 
commitment. This has strengthened the notion that MSCs identified by ISCT criteria 
are more properly referred to as mesenchymal stromal cells rather than 
mesenchymal stem cells. 
Initial attempts to identify MSCs, based on the expression of cell surface markers,  
relied on the expression of a host of antigens including CD29, CD44, CD73, CD90 
and CD105 (Barry et al. 1999; Pittenger et al. 1999; Deans et al. 2000; Barry et al. 
2001; Goodwin et al. 2001). However, these antigens are expressed on a broad 
range of cell types.  For example, CD29 can be expressed on T-cells (Kurachi et al. 
2014) as can CD44 (Kurachi et al. 2014), whilst CD73, CD90 and CD105 are all 
expressed by fibroblasts (Haniffa et al. 2009; Holdsworth-Carson et al. 2014). The 
monoclonal IgM antibody STRO-1 appears to offer better specificity for MSCs but 
also cross reacts with erythroblasts (Simmons et al. 1991). Additionally, the target 
antigen for Stro-1 has yet to be identified despite a more than two decades since its 
original description (Simmons et al. 1991).   
Quirici et al first suggested the expression of CD271 on BM MSCs (Quirici et al. 
2002). This was Independently confirmed and refined by Jones et al by inclusion of 
CD45 as a negative gating parameter in FACS analysis (Jones et al. 2002).  The 
CD45low/- CD271+ population exhibits all the classical characteristics of MSCs, 
including the uniform expression of other MSC markers such as CD73, CD105 and 
CD90 (Jones et al. 2002; Boxall et al. 2012).  The high level of CD271 expression in 
BM MSC and the low level of expression of CD271 in all other cell populations 
(Jones et al. 2002; Jones et al. 2004b), makes CD271 expression a potentially 
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exploitable characteristic, for antibody based enrichment technology. Further 
supporting evidence in the utility use of CD271 as a BM MSC marker has been 
confirmed by several independent studies (Quirici et al. 2002; Jarocha et al. 2006; 
Buhring et al. 2007).  
The CD45- CD146+ population in BM transplanted by Sacchetti et al and found to 
have self-renewal potential (Sacchetti et al. 2007), also express CD271 (Tormin et al. 
2011). Tormin et al showed that colony forming units are present in CD45- CD271+ 
CD146-  cells as well as CD45- CD271+ CD146+ cells and that these population share a 
similar phenotype (Tormin et al. 2011). CD146 expression on BM MSCs is 
dependent on localisation specifically their proximity to blood vessels and is up or 
down regulated in response to normoxia or hypoxia, respectively (Tormin et al. 
2011). Table 2 shows positive markers used for identification of BM MSCs.  
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Table 2: Cell surface markers used to identify MSCs 
This table lists positive markers used to identify human MSCs in vivo. 
Marker 
 
Other names Function  Reference  
D7-FIB Fibroblast antigen Unknown (Jones et al. 2002) 
MSCA-1 TNAP Phosphatase 
ectoenzyme 
(Battula et al. 
2009) 
STRO-1  Unknown (Simmons et al. 
1991)   
SSEA-4 Stage specific 
antigen 4 
Regulation of 
differentiation 
(Battula et al. 
2007) 
CD10 Neprilysin Metalloprotease (Campioni et al. 
2003) 
CD13 Alanine 
aminopeptidase 
Ectoenzyme (Campioni et al. 
2003) 
CD44 H-CAM hyloronin 
receptor 
Cell adhesion (Goodwin et al. 
2001) 
CD56 NCAM Cell adhesion (Battula et al. 
2009) 
CD73 5’nucleotidase Ectoenzyme, catalysis 
of purine 5-prime 
mononucletides to 
nucleosides 
(Barry et al. 2001) 
CD90 Thy-1 Cell adhesion, highly 
expressed in sites of 
inflammation 
(Jones et al. 2002) 
CD105 Endoglin Receptor for TGF-βI 
and III 
(Barry et al. 1999) 
CD106 VCAM-1 INCAM-100 Cell adhesion (Simmons et al. 
1992) 
CD146 MUC-18, Mel-CAM, 
MCAM 
Cell adhesion (Sacchetti et al. 
2007) 
CD166 ALCAM Cell adhesion (Stewart et al. 
2003) 
CD200 OX-2 Regulation of myeloid 
cells 
(Delorme et al. 
2008) 
CD271 LNGFR, p75, p75NTR Neurotropin receptor (Jones et al. 2002) 
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1.9.2. Self-renewal 
Self-renewal is widely recognised as one of the key properties of a true stem cell. 
The ability of stem cells to generate copies of themselves but also give rise to more 
differentiated progeny is known as asymmetric division (Knoblich 2008; Gomez-
Lopez et al. 2014). Sacchetti et al demonstrated the presence of BM resident self-
renewing sub-endothelial cells in humans (Sacchetti et al. 2007). They were 
selected from BM based on positive expression of CD146 and negative expression 
of CD45 and were able to re-capitulate their initial microenvironment after 
transplantation into an immunodeficient mouse; resulting in the generation of a 
miniature bone organ (Sacchetti et al. 2007). Importantly, cells expressing the CD45- 
CD146+ phenotype were regenerated after transplantation demonstrating 
asymmetric cell division (Sacchetti et al. 2007). A similar study showed that mouse 
Nestin+ perivascular stromal cells were capable of self-renewal as demonstrated by 
serial transplantation (Mendez-Ferrer et al. 2010). These cells also expressed high 
levels of genes that regulate haematopoietic stem cell (HSC) maintenance and 
retention in the BM in mice (Mendez-Ferrer et al. 2007).   
These experiments demonstrated that cells expressing a defined range of cell 
surface markers are capable of giving rise to terminally differentiated cells and 
thereby re-constituting the BM microenvironment whilst maintaining their capacity 
for self-renewal. However, some argue that cells isolated based on expression of 
the CD45-CD146+ phenotype represent an enriched population rather than a single 
cell type (Pittenger 2013). 
 
1.9.3. Maintenance of the haematopoietic niche 
Another key role of BM MSCs is maintenance of the haematopoietic niche (Arai et 
al. 2004; Mendez-Ferrer et al. 2007; Mendez-Ferrer et al. 2010). The CD45-CD146+ 
cells isolated by Sacchetti et al were significant producers of angiopoietin-1 a ligand 
of the tyrosine kinase receptor 2. Tyrosine kinase receptor 2 is expressed 
specifically on endothelial cells and HSCs (Davis et al. 1996; Hsu et al. 2000) and acts 
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as a key component of in maintenance of the HSC niche by maintaining HSC 
quiescence (Arai et al. 2004). 
In mouse studies, MSCs co-localise with HSCs in the BM and express genes that 
regulate HSC maintenance including SDF-1, c-kit ligand, angiopoietin-1, interleukin-
7, vascular cell adhesion molecule-1 and osteopontin (Mendez-Ferrer et al. 2010). 
In addition, selective depletion of MSCs reduces bone marrow homing of HSCs 
(Mendez-Ferrer et al. 2010). However, it must be noted, that mice and human 
MSCs can be substantially different (Pittenger 2013), both in terms of surface 
epitope expression, requirements for optimal growth and rates of propagation in 
vitro (Peister et al. 2004). Although the study of mouse MSC is a useful tool in 
understanding MSC biology, caution should be exercised when applying findings in 
mice MSCs to human MSC biology. 
 
1.9.4. In vitro differentiation 
In vitro osteogenic MSC differentiation can be achieved by the addition of ascorbic 
acid 2-phosphate, β-glycerophosphate and the synthetic glucocorticoid DEX 
(Pittenger et al. 1999; Jones et al. 2002; Isaac et al. 2008). Ascorbic acid 2 
phosphate is important for extracellular matrix deposition, and acts as a cofactor 
for prolyl lysyl hydroxylase, a key enzyme in collagen biosynthesis (Temu et al. 
2010). β-glycerophosphate acts as a source of phosphate ions, it is required for the 
later stages of osteoblast differentiation and matrix mineralisation, which is 
stimulated by DEX (Coelho et al. 2000; Jurutka et al. 2007).  MSCs form aggregates 
or nodules and begin to express ALP, an enzyme required for hydroxyapatite 
crystallisation (Millan 2013). Calcium, a component of hydroxyapatite, then begins 
to accumulate. Both ALP and calcium accumulation can be used as indicators of 
osteogenic induction (Baboolal et al. 2014).  
Adipogenic differentiation can be achieved with incubation of MSCs with DEX, 
isobutylmethylxanthine, indomethacin and insulin. Isobutylmethylxanthine and DEX 
induce expression of CCAAT-enhancer binding protein alpha (C/EBPα) which is one 
of two critical transcription factors responsible for regulating the adipogenic 
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differentiation process (Farmer 2006). Indomethacin is included in the culture 
media due to its ability to activate the other important transcriptional driver of 
adipogenesis, peroxisome proliferator-activated receptor  (PPAR) (Lehmann et al. 
1997; Farmer 2006). Once adipocyte differentiation has taken place the presence of 
insulin stimulates glucose transport, eventually resulting in the formation of lipid 
rich vacuoles. These lipid vacuoles accumulate within cells and eventually combine 
and can be detected by oil red or Nile red staining after a period of 2-3 weeks 
(Pittenger et al. 1999; Jones et al. 2002; Aldridge et al. 2013). 
MSCs can be induced to undergo chondrogenic differentiation first by 
centrifugation into a cell pellet, then culturing in the presence of ascorbic acid 2 
phosphate, TGF-β3 and proline. Once again ascorbic acid 2 phosphate is included 
because of its importance for extracellular matrix deposition. TGF-β3 stimulates 
type II collagen gene expression and is essential for optimal synthesis and 
homeostasis of matrix molecules during chondrogenesis (Brady et al. 2014). The 
amino acid proline is also included since it is an essential component of mammalian 
collagen (De Sa Peixoto et al. 2013). Chondrogenesis can be measured by 
accumulation of glycosaminoglycans (GAGs), which can be detected by staining 
with toluidine blue (Pittenger et al. 1999; Jones et al. 2002). 
1.9.5. The function of CD271 
The function of CD271, also known as low affinity nerve growth factor receptor, p75 
and p75NTR, in the nervous system has been widely described. It is the common 
receptor for both neurotrophins and proneurotrophins (Ibanez et al. 2012; 
Tomellini et al. 2014). Activation of CD271 has been shown to increase the 
amplitude of excitatory post synaptic currents, affect myelination and neurite 
outgrowth (Luther et al. 2013; Tomellini et al. 2014). CD271 signal transduction 
pathways are extremely variable because they are dependent on cell type. CD271 
mediated signalling has also been shown to influence apoptosis, cell cycle 
regulation, cell migration and invasion (Tomellini et al. 2014).  
The function of CD271 in BM MSCs is not well understood, although some evidence 
suggests that it may play a role in mediating differentiation. Akiyama et al showed 
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that overexpression of CD271 in a pre-osteoblast cell line induced alkaline 
phosphatase activity and mRNA expression of osteoblast related genes, including 
OSX as well as stimulating proliferation (Akiyama et al. 2014). However, CD271 
expression on MSCs is known to decline rapidly during in vitro expansion (Jones et 
al. 2002); this does not correspond with loss of differentiation capacity which is 
known to persist for several passages (Dominici et al. 2006; Wagner et al. 2009). It 
is therefore reasonable to assume that CD271 expression is not essential for MSC 
differentiation, its expression in BM MSCs could be stimulated by cues in the BM 
microenvironment, but it may have a limited role in governing MSC behaviour.  
 
1.10. Strategies for manipulating MSCs for therapy 
development 
1.10.1. Culture expansion of MSCs prior to therapy 
Iliac crest BM aspirates are widely regarded as the gold standard source of MSCs. 
However, the low concentration of MSCs in BM aspirates (Friedenstein et al. 1992; 
Pittenger et al. 1999; Jones et al. 2006) limits the number that can be harvested 
from this source for MSC based therapy.  Recently there has been great interest in 
the application of MSCs for the treatment of GVHD (Tolar et al. 2011).  One study 
undertaken by Ringden et al involved the administration of MSCs to patients 
suffering from therapy resistant GVHD.  Patients received up to 2 doses of 1x106 
MSCs/kg, meaning that a 50kg patient would receive up to 5x108 MSC, this number 
was not achievable from iliac crest aspirates without several rounds of culture 
expansion (Ringden et al. 2006). 
Although culture expansion appears to offer an abundant source of MSCs amenable 
to therapy, it is well recognised that cultivation history has an important influence 
on resultant MSC characteristics.  The “in vitro age” of MSC cultures is critical in 
determining the proliferative and differentiation potential of the MSC product 
(Wagner et al. 2008).  The number of population doublings undergone by MSC 
cultures inversely correlates with both their proliferation rate and differentiation 
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potential, eventually resulting in loss of differentiation potential and culture 
senescence (Banfi et al. 2000; Banfi et al. 2002; Wagner et al. 2008).  Additionally, 
the chromosomal stability of MSCs subjected to extended culture expansion has 
been questioned leading to safety concerns surrounding this strategy (Wang et al. 
2005; Rosland et al. 2009; Sensebe et al. 2012). Therefore, it is desirable that MSC 
cultures undergo the minimum number of population doublings required to achieve 
therapeutic yield.  This is dictated by the starting number of MSCs and the required 
dose for therapy.  The highly variable concentration of MSCs in BM aspirates 
(Friedenstein et al. 1992; Pittenger et al. 1999; Jones et al. 2006) means that the 
number of population doublings required for therapy may vary considerably. 
Moreover, initiation of cultures with low numbers of MSCs may result in culture 
senescence and failure to achieve therapeutic yield.  For these reasons it is 
desirable that the MSC content of aspirates is assessed prior to expansion.  
 
1.10.2. Minimally manipulated MSCs  
The use of autologous, minimally-manipulated MSCs that have not been subject to 
tissue culture expansion is appealing, since it avoids many of the regulatory issues 
governing human cellular and tissue based products (HCT/Ps). Minimal 
manipulation is defined by the United States Food and Drug Administration (FDA) as 
processing that does not alter the relevant biological characteristics of cells or 
tissues. HCT/P that meet the 1271 criteria under section 361 of the Public Health 
Service Act are not subject to any premarket review requirements (Deasy et al. 
2013). Examples of such products include BM or blood transplants and organ 
transplants. The FDA has stated that cryopreservation, centrifugation, density 
gradient separation and cell selection constitute minimal manipulation. Whereas all 
processes that manipulate the cell or tissue product such as encapsulation, cell 
activation, gene modification and ex vivo expansion are considered more than 
minimally manipulated (Deasy et al. 2013).  
The European union regulatory framework mirrors that of the FDA whereby, stem 
cell products are defined as advanced therapy medicinal products (ATMPs), and 
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subject to more rigorous regulation (von Tigerstrom 2008), if they have been 
manipulated by ex vivo expansion or activation. Allogeneic and xenogeneic cells 
associated with medical devices used ex vivo or in vivo such as micro-capsules and 
scaffolds also fall under this definition which may be found in Annex 1 of directive 
2001/83/EC (von Tigerstrom 2008).  
Minimal manipulation avoids many of the safety issues surrounding cultured cells 
such as the possibility of spontaneous transformation (Rubio et al. 2005; Wang et 
al. 2005; Rosland et al. 2009) as well as the potential of animal pathogen 
contamination resulting from the use of foetal calf serum (FCS) as a culture 
component (Bernardo et al. 2011).  Additionally minimally-manipulated MSCs do 
not require costly manufacturing facilities and are, therefore, relatively inexpensive 
to obtain. However the low concentration (Friedenstein et al. 1992; Pittenger et al. 
1999; Jones et al. 2006) and high variability of MSC content in BM aspirates 
(Pittenger et al. 1999; Hernigou et al. 2005a; Veyrat-Masson et al. 2007) makes 
reliably achieving a therapeutic dose of MSCs problematic.  
The use of BM concentrator devices for autologous MSC grafting in orthopaedic 
surgery is widespread for indications including spine surgery (Oreffo 2005), the 
treatment of impaired fracture healing (Hernigou et al. 2005a; Hernigou et al. 
2005b; Kasten et al. 2008) and femoral head osteonecrosis (Hernigou et al. 2002), 
with no adverse events reported.  Despite the simplicity and strong rationale 
behind the application of MSCs to these conditions, controlling the number of MSCs 
administered has remained a problem, with only retrospective analysis possible.  A 
rapid means of evaluating the MSC content in aspirates prior to concentration 
would give surgeons an opportunity to improve the quality of aspirates and 
therefore the effectiveness of autologous MSC grafting.   
Alternatively, it has been demonstrated that large numbers of MSCs can be 
recovered from enzymatically treated femoral heads (Jones et al. 2010b) and are 
present in the liquid waste fraction generated by intramedullary reaming (Porter et 
al. 2009). MSCs isolated from these tissues have been shown to have phenotypic 
characteristics similar to those present in BM aspirates (Jones et al. 2010b; Cox et 
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al. 2012). These tissues may provide an alternative plentiful source of MSCs that 
could be used either in the orthopaedic setting or in the wider context of MSC 
therapy. Immunomagnetic cell selection could provide a means to isolate MSCs 
from a variety of potential sources, if performed using reagents and equipment 
suitable for clinical application. Additionally, depending of the purity obtained, 
MSCs may be utilised for allogeneic treatments as well as autologous therapy. 
CD271 is an ideal candidate surface marker for immunomagnetic cell selection due 
to its highly specific expression on BM MSCs (Boxall et al. 2012). 
 
1.10.3. Recruitment of endogenous MSCs 
Scaffolds that exert a regenerative effect by recruiting endogenous MSCs have been 
and continue to be of great interest in regenerative medicine. In bone defect repair 
and fracture non-union, barrier membranes are widely used (Cheung et al. 2007; 
Behring et al. 2008; Gloria et al. 2010; Dimitriou et al. 2011b). These may be 
synthetic (Cheung et al. 2007; Gloria et al. 2010) or bio-absorbable natural polymers 
(Behring et al. 2008; Dimitriou et al. 2012) and often rely on the passive recruitment 
of MSCs into the site of injury. However, a number of scaffolds are under 
development that actively recruit, stimulate proliferation or differentiation of 
endogenous MSCs. Examples of this include a  TGF-β3 infused scaffold for cartilage 
regeneration (Lee et al. 2010), and several examples of  scaffolds aimed at bone 
regeneration that incorporate growth factors such as BMP-2 and VEGF (Huang et al. 
2005; Niu et al. 2009) or chemotactic agents such as SDF-1  (Dashnyam et al. 2014; 
Jin et al. 2014).  
An alternative approach has been developed by Masquelet et al who by serendipity 
discovered that implantation of a bone cement spacer induced the formation of a 
thick vascularised membrane with impressive regenerative capacity (Giannoudis et 
al. 2011; Dimitriou et al. 2012; Gruber et al. 2012). A careful examination of this 
spontaneously generated membrane may elucidate the mechanisms by which it 
facilitates bone regeneration. Ultimately this could lead to the development of a 
53 
 
new generation of orthopaedic implants that exploit this phenomenon or mimic 
this induced membrane’s characteristics. 
 
1.10.4. Inhibition of aberrant bone formation 
In some situations inappropriate or excessive bone formation can have debilitating 
effects. Heterotopic ossification can occur following surgery or trauma or as a result 
of the rare genetic disorder fibrodysplasia ossificans progressiva (Yu et al. 2008; 
Kaplan et al. 2011). Ectopic bone formation occurs within soft tissues including 
muscles, connective tissue and near blood vessels or nerves (Vanden Bossche et al. 
2005; Shimono et al. 2011). It is thought to be as a result of localised inflammation 
leading to recruitment of MSCs, their differentiation into chondrocytes and 
eventually endochondral ossification (Shore et al. 2010). Resolving the initial 
inflammation by treatment with nonsteroidal anti-inflammatory drugs has had 
limited success, perhaps because by the time the condition has become clinically 
apparent the induction process is already complete (Kaplan et al. 2011). Inhibition 
of BMP type I receptor signalling using small molecule inhibitors has shown 
promising results in preventing heterotopic ossification in a mouse model (Yu et al. 
2008). However, inhibition was not sustained after treatment was discontinued (Yu 
et al. 2008) and concerns regarding long term administration BPM type I receptor 
antagonists stem from various off target effects and lack of specificity of these 
compounds, which target multiple BMP type I receptors (Hong et al. 2009). 
Shimono et al reported potent inhibition of heterotopic ossification by inhibition of 
chondrogenesis in several mouse models of heterotopic ossification using RAR 
agonists with minimal side effects (Shimono et al. 2011). Moreover, inhibition of 
heterotopic ossification by RAR agonists seemed to be permanent and effective 
over a wide treatment window (Shimono et al. 2011). However its wider application 
to treating aberrant bone formation is likely limited to instances where bone 
formation is driven by endochondral ossification. 
The degenerative diseases, such as OA and AS, are also characterised by aberrant 
bone formation (Braem et al. 2012; Zhen et al. 2013). It has recently been shown 
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that the inhibition of TGF-β signalling is able to halt disease progression by 
attenuating the excessive mineralisation of matrix, driven by osteogenic 
differentiation in OA (Zhen et al. 2013). In AS excessive bone formation at the 
enthesis causes progressive loss of mobility, this particularly affects the spine. Here 
aberrant osteogenesis is linked to inflammation and low levels of DKK-1 (Diarra et 
al. 2007). However, resolution of the inflammatory aspect of AS has little or no 
effect on aberrant bone formation (van der Heijde et al. 2008a; van der Heijde et al. 
2008b). Drugs that modulate the differentiation capacity of MSCs have the 
potential to transform the lives of patients suffering from AS. However, blocking 
inflammation remains an important clinical goal since doing so alleviates the pain 
associated with joint inflammation and significantly improves quality of life (van der 
Heijde et al. 2008a; van der Heijde et al. 2008b). One drug marketed by Pfizer under 
the name tofacitinib can inhibit joint inflammation and has clinical application to in 
rheumatoid arthritis (RA) (Kyttaris 2012). It elicits this effect by inhibition of the 
JAK/STAT signalling cascade and thereby disrupts inflammatory cytokine signalling 
(Kyttaris 2012). This potentially leads to the exciting prospect of simultaneously 
blocking inflammation as well as aberrant bone formation through inhibition of 
JAK/STAT signalling. 
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1.11. Thesis aims and objectives 
The aim of this thesis was to test the hypothesis that knowledge of MSCs in vivo can 
be used to improve and develop cellular therapy strategies that utilise minimally 
manipulated MSCs. This thesis also aims to demonstrate that the understanding of 
the in vivo characteristics of MSCs may be used as a tool for therapy development, 
by elucidating the mechanisms in which clinical procedures or drugs have beneficial 
effects. 
Objectives: 
1. The first objective of this thesis was to test the hypothesis that flow 
cytometry may be used as a rapid means of assessing the MSC content of 
BM aspirates and develop a method of standardising BM aspiration with 
the goal of improving MSC yield. 
2. The second objective of this thesis was to evaluate current available 
technologies aimed a concentrating BM MSCs and test the hypothesis that 
the expression of CD271 could be used as a means of isolating MSCs from 
osseous tissues. 
3. The third objective of this thesis was to test the hypothesis that the 
impressive bone formation, observed as a result of the induced 
membrane (IM) or Masquelet technique, is mediated by MSC recruitment 
into the IM, and to determine how this drives tissue regeneration. 
4. The fourth objective of this thesis was to test the hypothesis that the drug 
tofacitinib is able to inhibit MSC differentiation into bone and thus provide 
a new therapeutic approach to the treatment of AS.  
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2. General materials and methods 
2.1. Patient recruitment and sample collection 
All patients gave informed consent and research was carried out in compliance with 
the Helsinki Declaration. Ethics committee approval was obtained from local 
National Health Service Research & Development Departments, National Research 
Ethics Service, Leeds East and Leeds West Research Ethic Committees under permit 
numbers 06/Q1206/127 and 07/Q1205/27 respectively (Appendix 1). In total 61 
patients were recruited, 34 male, 27 female, mean age 46 (18-85).  
 
2.2. Harvest of BM aspirate 
BM aspirates were obtained from the Iliac crest of acute trauma patients or 
patients undergoing elective orthopaedic surgery. All samples were collected into 
K3EDTA vacuettes (Greiner bio-one) using a syringe/s and trocar (Stryker), both of 
which were first flushed with 1000U/ml sodium heparin solution (Leo Pharma) to 
avoid clotting. Heparin solution was drawn into each syringe in turn to coat the 
surface of the plastic interior, following removal of the central stilet; the trocar 
(aspiration needle) was also treated with heparin.  In the majority of cases samples 
were taken from the anterior iliac crest, a small incision was made in the skin and 
the trocar was inserted through the cortical bone.  Once the cortical bone was 
penetrated, the needle was pushed approximately 1cm through the cancellous 
bone, the stilet was removed and a heparin coated syringe attached, a volume of 
BM was then aspirated. 
 
2.3. Manual cell counting 
The total number of nucleated cells was measured using a haemocytometer and an 
inverted light microscope.  Whole, well mixed BM was diluted 1/20 with Phosphate 
buffered saline (PBS, invitrogen), then diluted 1/2 with 4% (v/v) acetic acid and 
incubated at room temperature (RT) for 1 minute to lyse erythrocytes.  For cell 
suspensions that did not contain erythrocytes such as passaged MSCs, an 
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appropriate dilution was made with PBS and the suspension was subsequently 
diluted 1:1 with trypan blue (Sigma Aldrich). A 10µl volume of the resulting mixture 
was then loaded onto a haemocytometer with an improved Neubauer counting 
chamber which consists of a large square divided into 9 smaller squares each 
representing a volume of 0.1µl.  The following formula was used to calculate the 
total number of nucleated cells. 
𝑁𝑢𝑐𝑙𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠/𝑚𝑙 =
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑 𝑥 𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑥 10
𝑉𝑜𝑙𝑢𝑚𝑒 𝑐𝑜𝑢𝑛𝑡𝑒𝑑 (𝜇𝑙)
3
 
In order on maintain accuracy, a minimum number of 100 cells were counted; if this 
was not possible the procedure was repeated using a lower dilution of PBS.  
 
2.4. Enzymatic digestion of solid tissue 
Tissue was broken into small fragments either by shredding with a scalpel or using a 
bone mill (De Puy) and then weighed. Tissue fragments were incubated with 3000 
units of collagenase per gram of tissue at a concentration of 600U/ml 
(Worthington) in 20%v/v FCS (PAA) and 80%v/v PBS (Gibco) for 4 hours at 37oC with 
manual agitation every 30 minutes. Following digestion, cell suspension was passed 
through a 70µM nylon filter (BD) to remove any remaining tissue aggregates. 
Filtered cell suspension was diluted with 20ml PBS and centrifuged at 400xg, the 
supernatant was discarded and the cells were resuspended in sterile FACS buffer 
prior to culture expansion or flow cytometry. 
  
2.5. Volumetric flow cytometry for cell enumeration 
Multi-parameter flow cytometry was used to enumerate cell populations in mixed 
cell suspensions based on the expression of surface antigens (Appendix 4).  
Accuchecktm counting beads (Invitrogen) were used to enable enumeration on a 
volumetric basis (number of cells/ml). To perform the staining, 50l of cell 
suspension was incubated with directly conjugated mouse monoclonal antibodies 
for 15 minutes at RT at manufacturer’s recommended concentration (Appendix 4).  
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Erythrocytes were then lysed by the addition of 2ml red blood cell (RBC) lysis buffer 
(Appendix 2) containing 0.5g/ml 4’,6-diamidino-2-phenylindole (DAPI, Sigma 
Aldrich) and incubation at RT for 10 minutes.  Immediately following red cell lysis, 
50l of Accuchecktm counting beads (Invitrogen) was added and the cell/bead 
suspension was analysed immediately using a LSR II flow cytometer (BD). Single 
antibody stained and unstained controls were used before each experiment to 
ensure accurate spectral compensation and isotype controls (Appendix 4) were 
used to confirm gating position for all cell populations studied. Centrifugation and 
re-suspension was avoided since this would result in inaccurate reporting of cell 
concentration due to loss of cells in the centrifuged supernatant. 
  
2.6. Calculation of total cell number using volumetric counting 
beads 
Flow cytometry data were analysed using FACSDiva Version 5.02 (BD).  Beads were 
identified based on their size and fluorescent properties (Figure 1A-B).  As an 
internal control, the bead preparation is supplied with an equal mix of two types of 
beads with unique characteristics that allows monitoring of bead sampling 
homogeneity.  Bead 1 is a 6.4m sphere and presents a low forward and high side 
scatter signal.  Bead 2 is a 6.36m sphere and presents a high forward and low side 
scatter signal.  To confirm homogeneity, the proportion of bead type A or B with 
respect to total number of beads must be 45-55%; outside this range the count was 
regarded as unreliable. A small proportion of counting beads were observed to 
aggregate despite careful mixing; this was confirmed using doublet discrimination 
(data not shown).  To compensate for this, each doublet bead event was counted as 
two beads. Cell debris was excluded based on forward and side scatter (Figure 1C).  
Dead/dying cells were identified by uptake of DAPI (Figure 1D). Once dead cells and 
debris had been removed from analysis, cells of interest were identified based on 
the expression of cell surface antigens labelled with specific monoclonal antibodies 
(Figure 1E). To calculate the absolute count of the cells of interest per ml the 
following formula was used: 
59 
 
𝑪 = (
𝑵
𝑻
) × 𝑺 
Where C=Number of cells of interest, N=Number of events of interest, T=Total 
number of bead events and S=Stock concentration of Beads. 
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Figure 1: An example of flow cytometry gating strategy for absolute cell 
quantification using volumetric counting beads  
Counting beads were discriminated by fluorescence in the FITC channel (A). Bead 
types 1 and 2 and bead doublets were discriminated by forward and side scatter 
profile (B).  Cellular debris was removed from analysis using forward and side 
scatter profile (C).  Dead/dying cells were identified and removed by uptake of DAPI 
(D). Finally cellular populations are identified based on expression of cell surface 
antigens; in this case BM MSCs are identified by high expression of CD271 and 
negative to low expression of CD45 (E). 
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2.7. CFU-F assay 
Unless otherwise stated, the CFU-F assay was performed as a modification of the 
original method described by Galotto et al (Galotto et al. 1999) and was used to 
enumerate MSCs volumetrically. 200l of BM aspirate was seeded into duplicate 
100mm diameter tissue culture dishes (Corning) containing 15ml of Non-
hematopoietic stem cell media (NH media, Miltenyi Biotec).  The cells were 
incubated at 37oC, 5% CO2. After 48 hours non-adherent cells were removed by 
washing once with 5ml of PBS and 15ml of fresh media was added. Subsequently, 
half media changes were performed twice a week for 14 days.  At the end of the 
culture period the adherent cells were washed with PBS and fixed with 10ml of 4% 
v/v formaldehyde (Sigma Aldrich) at RT for 15 minutes. Colonies were stained by a 
30 minute RT incubation in 1% w/v methylene blue solution (Appendix 2); a colony 
was defined as a tight macroscopically-visible cluster of 50 or more cells with a 
defined focal origin (clusters of less than 50 cells were excluded as were diffuse 
patches of single cells).  
 
2.8. Measurements of colony area 
CFU-F assays were performed on BM aspirates as previously described (2.7). 
Because manually counting colony number and size is considered fairly subjective 
(Seebach et al. 2007), digital measurements of total colony area were performed in 
parallel with manual scoring. For this, CFU-F dishes were scanned using an Epson 
3590 digital scanner and digital images were analysed using NIS elements BR 2.20 
imaging software (Nikon). The area occupied by colonies was identified based on 
the intensity of the methylene blue stain.  Dish area was classified into un-colonised 
and colonised regions and the area taken up by each region was calculated.  No 
determination was made of individual colony size or morphology. 
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2.9. Culture expansion 
For expansion of MSCs from mixed cell suspensions such as BM aspirates, nucleated 
cells were counted manually (2.3), cells were seeded at a density of 8x104 cells/cm2 
in tissue culture grade, flasks (Corning) in an appropriate volume of non-
haematopoietic  (Appendix 3) stem cell (NH) media (Miltenyi Biotec) and incubated 
at 37oC, 5% CO2 . After 48 hours the media was removed and the culture vessel was 
washed with 5ml PBS to remove non-adherent cells. The media was renewed and 
expansion was allowed to continue until cells achieved approximately 70-80% 
confluence (denoted passage 0, p0); at this point cells were detached by first 
washing with 5ml of PBS then incubation with 5ml 0.05%w/v trypsin solution 
(Invitrogen) at 37°C for up to 5 minutes. Trypsin is a protease used to lift cells from 
plastic surfaces and works by digesting the proteins responsible for attachment. 
Flasks were tapped sharply to dislodge any remaining adherent cells and 5ml of NH 
media was added to the cell suspension. Cells were manually counted using a 
haemocytometer then centrifuged at 400xg for five minutes. The supernatant was 
discarded and cells were re-seeded in NH media at 4.5x103/cm2 and returned to 
incubation in the same conditions. Once cells had reached 70-80% confluence 
(denoted p1) and were again detached, counted and re-seeded as previously 
described, this was repeated until the desired number of cells was achieved.  
 
2.10. In vitro osteogenic differentiation.  
Following culture 3x104 MSCs were seeded in triplicate into 6 well tissue culture 
grade plates (Corning), to give 9 replicates in total, with  osteogenic media 
(Appendix 2) and incubated at 37°C, 5% CO2 (Jaiswal et al. 1997; Jones et al. 2004a).  
Twice weekly 50% of the culture medium was replaced and cultures were 
maintained for 14 or 21 days.  
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2.11. Detection of alkaline phosphatase activity 
For determination of ALP activity, osteogenic cultures were terminated on day 14 
post-induction. The media was aspirated from the wells, which were washed with 
1ml PBS and subsequently fixed with the addition of 2ml of citrate fixative solution 
(Appendix 2) for 30 seconds at RT. The fixative was then removed and wells were 
washed twice with dH2O before the assessment of ALP activity using fast blue salt 
solution (Jaiswal et al. 1997). After 1ml fast blue dye solution (Appendix 2) was 
added to each well, the plate was placed in the dark at RT for 30 minutes to allow 
colour development. Following incubation, the wells were washed twice with 1ml 
dH2O and allowed to air dry; dishes were subsequently scanned using an Epson 
3590 digital scanner. 
 
2.12. Determination of total calcium accumulation 
At termination cells were washed gently with tissue culture grade PBS without 
calcium (Invitrogen) and subsequently incubated for 5 minutes in 1ml of 600mM 
HCl to extract Ca2+ from mineralized extracellular matrix. Using a disposable cell 
lifter (Fisher Scientific) HCl and cell debris was removed from each well and 
transferred into 1.5ml microcentrifuge tubes. Calcium was extracted by incubating 
for 4 hours at 4°C with constant agitation, and subsequently stored at -20oC. Prior 
to analysis, samples were brought to RT and centrifuged at 5000xg to remove any 
remaining cellular debris. 
For determination of calcium content, 6µl of supernatant was loaded in triplicate 
wells of a flat bottomed 96 well plate and the calcium content was measured using 
a calcium liquid detection kit (Sentinel Diagnostics). 210µl of a buffered 0.3mM 
cresolphthalein complexone solution was introduced to each sample well or well 
containing a known concentration of a calcium standard. Cresolphtalein 
complexone reacts with calcium ions at pH>10 to form a red coloured complex, 
colour intensity is directly proportional to the concentration of calcium; this was 
quantified by measuring absorbance at 570nm using an Opsys MR plate reader 
(Dynex Technologies). Once measured, absorbance can be converted to 
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concentration of calcium by comparing the absorbance of the calcium standards to 
the sample absorbance. 
 
2.13. In vitro adipogenic differentiation and detection of lipid 
vacuoles by uptake of oil red  
Following culture expansion, 5x104 MSCs per well were seeded in triplicate into 24 
well tissue culture plates (Corning) containing 1ml adipogenic media (Appendix 2) 
and incubated at 37°C, 5% CO2. Twice weekly half of the culture media was 
replaced and cultures were terminated on day 21 post-induction by washing twice 
with 1ml PBS followed fixation at RT for 15 minutes with 4% v/v formalin solution, 
1ml/well. Oil Red solution (Appendix 2) was then applied at 1ml/well, for 20 min at 
RT before washing twice with 1ml PBS followed by counterstaining with 1ml of 
Harris’ haematoxylin (Sigma Aldrich) for 2 minutes at RT. This was aspirated and 
wells were washed with running tap water and subsequently incubated with 1ml of 
Scott’s tap water substitute (Appendix 2) for 1 minute at RT, before a further wash 
with running tap water. For quantitative assessment of oil red uptake a random low 
powered field of view (40X magnification) was captured using a C7070 digital 
camera (Olympus, Tokyo, Japan). These images were then analysed using NIS 
elements BR 2.20 imaging software (Nikon), the area occupied by lipid vacuoles was 
identified based on the intensity of oil red staining giving a percentage area 
occupied by lipid vacuoles on each photomicrograph. 
 
2.14. In vitro chondrogenic differentiation 
For chondrogenic differentiation, 2.5x105 MSCs suspended in 0.5ml of complete 
chondrogenic media (Appendix 2) were centrifuged 5 minutes in screw top 1.5ml 
microcentrifuge tubes at 400xg to create a pellet. Screw caps were fastened loosely 
in order to allow gas exchange and incubated at 37oC, 5% CO2; half the media was 
replaced every 3 days for a total culture period of 21 days.  Pellets were either 
snap-frozen in optimal cutting temperature (OCT) compound (Fisher Scientific) 
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using the vapour phase of liquid nitrogen prior to cryo-sectioning and staining with 
toluidine blue or prepared for GAG assay as described in chapter 6 (6.2.6). For 
toluidine blue staining 7µm sections were prepared using a CM3050S cryostat 
(Leica) and adhered to superfrost histology slides (Fisher). Slides were allowed to air 
dry overnight then incubated with methanol (Sigma Aldrich) for 20 minutes at -
20°C. Subsequently, slides were removed from methanol and allowed to air dry for 
30 minutes. Once dry, slides were incubated in toluidine blue solution (Appendix 2) 
at 37°C for 30 minutes, slides were then transferred to isopropanol (Sigma Aldrich) 
to remove excess toluidine blue. Slides were incubated in xylene (Sigma Aldrich) for 
5 minutes at RT before coverslips were mounted using DPX mounting media (Sigma 
Aldrich). Slides were then examined using an Eclipse 1000 (Nikon) microscope and 
images captured using a C7070 digital camera (Olympus, Tokyo, Japan). 
 
2.15. Statistics 
The Shapiro-Wilk normality test was used to assess distribution normality and to 
determine appropriate correlation and significance testing.  For data sets with 
fewer than 6 data points per group a non-gaussian distribution was assumed. 
Statistical significance was defined as p<0.05, * indicates p<0.05, ** indicates 
P<0.01, *** indicates P<0.001. All statistics were calculated using SPSS® Version 19. 
Graphs were generated using GraphPad Prism® Version 5.04. All box and whisker 
plots show median (line) interquartile range (box) and extreme values (whiskers). 
All bar charts show mean (bar height) and standard deviation (whiskers). The 
Spearman rank correlation coefficient was used to describe statistical dependence. 
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3. A rapid single platform assay for MSC enumeration 
in BM aspirates 
3.1. Introduction 
3.1.1. The CFU-F assay 
Following the initial experiments by Friedenstein et al demonstrating the presence 
of multipotential CFU-Fs in the BM (Friedenstein et al. 1970), the importance of 
accurately enumerating and determining the biology of MSC in vivo has become 
clear. This is particularly relevant in the context of minimally manipulated MSC 
therapy (Hernigou et al. 2005a) and the study of aging (Stolzing et al. 2008). The 
first comprehensive CFU-F assay for determining the MSC content of human BM of 
was described by Castro-Malaspina et al (Castro-Malaspina et al. 1980). This initial 
technique relied on density gradient sedimentation to separate erythrocytes from 
mononuclear cells (MNCs) prior to seeding in alpha-MEM supplemented with 20% 
FCS and culture expansion for 8 to 14 days.  
An alternative technique was later described by Galotto et al (Galotto et al. 1999) 
who dispensed with the initial MNC separation step and instead seeded 
unprocessed whole BM volumetrically prior to culture expansion. This simplification 
does away with several washing and centrifugation steps reducing the potential for 
experimental error. In either case following a period of culture expansion, cells 
were fixed, stained and macroscopically visible colonies counted. By counting the 
number of these colonies, a determination of the initial starting number of MSCs is 
therefore possible based on the assumption that one colony is generated from one 
MSC. 
 
3.1.2. Limitations of the CFU-F assay 
Although the development of the CFU-F assay was a critical advance for the 
measurement of MSC content in a given tissue sample, it has several important 
limitations. These include dependence on serum source (Castro-Malaspina et al. 
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1980), plating density (Veyrat-Masson et al. 2007) and subjective and poorly 
defined scoring criteria (Stolzing et al. 2008). Most importantly, the assay is 
hindered by the long culture period required (14 days), therefore only retrospective 
evaluation of MSC content is possible (Hernigou et al. 2005a). In MSC based 
therapies, regardless of whether MSCs are to be administered with or without 
expansion, their absolute number in the aspirate is critical in determining efficacy  
(Hernigou et al. 2005a; Wagner et al. 2008; Wagner et al. 2009).  
 
3.1.3.  The importance of prospective MSC enumeration 
Although culture expansion appears to offer an abundant source of MSCs amenable 
to therapy, it is well recognised that cultivation history has an important influence 
on resultant MSC characteristics.  The “in vitro age” of MSC cultures is critical in 
determining the proliferative and differentiation potential of the MSC product 
(Wagner et al. 2008; Wagner et al. 2009).  The number of population doublings 
(PDs) undergone by MSC cultures inversely correlates with both their proliferation 
rate and differentiation potential, eventually resulting in loss of differentiation 
potential and culture senescence (Banfi et al. 2000; Banfi et al. 2002; Wagner et al. 
2008).  Additionally concerns have been raised as to the safety of MSC therapy after 
extended expansion due several reports of spontaneous transformation in culture 
(Wang et al. 2005; Rosland et al. 2009; Sensebe et al. 2012).  Therefore it is 
desirable that MSC cultures undergo the minimum number of PDs required to 
achieve therapeutic yield.  For these reasons it is desirable that the MSC content of 
aspirates is assessed prior to expansion. 
BM derived MSCs that have been obtained by iliac crest aspiration and 
administered following concentration or cell selection are classed as a minimally 
manipulated product (Deasy et al. 2013). However, the low concentration 
(Friedenstein et al. 1992; Pittenger et al. 1999; Jones et al. 2006) and high variability 
of MSC content in aspirates (Pittenger et al. 1999; Hernigou et al. 2005a; Veyrat-
Masson et al. 2007) makes reliably achieving a consistent dose of MSCs 
problematic; this problem is compounded by the possibility of marrow dilution with 
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blood (Hernigou et al. 2005a; Veyrat-Masson et al. 2007; Hernigou et al. 2013).  A 
rapid means of evaluating the MSC content in aspirates would give surgeons an 
opportunity to assess the quality of aspirates prior to administration. This would 
improve effectiveness of autologous MSC grafting particularly in the context of 
bone regeneration (Hernigou et al. 2005a). 
 
3.1.4.  The CD45-/lowCD271+ population as a candidate for 
measuring in vivo MSC number 
The utility of a cell surface or intracellular marker to identify any cell type is 
primarily driven by specificity. Previous studies have shown that the CD271 antigen 
has excellent specificity for human BM MSCs with limited cross reactivity with other 
cell types (Jones et al. 2002; Kuci et al. 2010; Tormin et al. 2011).   
CD271 has been found to have superior specificity for BM MSCs compared to 
alternative markers (CD13, CD90, CD105, CD10 and STRO-1) (Jones et al. 2002), 
additionally CD271 is not expressed on uncultured skin fibroblasts (Jones et al. 
2002). CD146 and MSCA-1, two other BM MSC markers, are also expressed on 
CD45-/low CD271+ cells (Buhring et al. 2007; Tormin et al. 2011). These studies 
provide evidence that CD271 could be a useful marker for the enumeration of MSCs 
in BM aspirates.   
Although CD73 is widely expressed on a range of cell types including T-cell, B-cells 
and fibroblasts (Haniffa et al. 2009; van de Veen et al. 2013; Schuler et al. 2014) 
making it a less attractive prospect for MSC identification, positive expression of 
CD73 in conjunction with negative expression of CD45 has been proposed as a 
means of quantifying BM MSCs (Veyrat-Masson et al. 2007). Although this study did 
show positive correlation between the percentage of CD45-CD73+ cells and CFU-F 
concentration, enumeration relied on density gradient centrifugation and manual 
cell counting, both potential sources of experimental error. Nevertheless strong 
correlations observed in this study suggested that CD73 may prove to be a useful 
addition or even an alternative to CD271 for assessment of MSC number in BM 
aspirates. 
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3.1.5.  Volumetric flow cytometry as an alternative to CFU-F 
assay 
The International Society for Cell Therapy position statement defines MSCs by cell 
surface antigen expression based on the positive co-expression of 3 cell surface 
antigens (CD105, CD73 and CD90) and the negative expression of at least 5 cell 
surface antigens (CD45, CD34, CD14 or CD11b, CD79α or CD19 and HLA-DR) 
(Dominici et al. 2006). Based on these criteria any flow cytometry assay designed to 
quantify MSCs would be technically challenging and impractical for use in routine 
clinical laboratories. These issues are further compounded by the high processing 
speeds and data buffering capacity required for this type of rare cell analysis. 
The identification of a BM MSC phenotype based on expression of a single positive 
marker (CD271) and a single negative marker (CD45) (Jones et al. 2002; Quirici et al. 
2002; Jones et al. 2004b), greatly simplifies assay design. This, together with recent 
advances in flow cytometry, such as the introduction of volumetric counting beads 
and improved computing technology, allows the possibility of developing a rapid 
and relatively simple assay.  
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3.1.6.  Chapter aim and objectives 
The aim of this chapter was to develop a rapid protocol for the evaluation of the 
MSC content in BM aspirates. This would for the first time provide a means of 
assessing total MSC content in aspirates volumetrically without the need for culture 
expansion and make intra-operative assessment of MSC content possible. 
Objectives: 
1. To validate a flow cytometry based MSC enumeration assay against the 
current gold standard CFU-F assay, and to demonstrate how this may be 
used to predict the MSC content of BM aspirates. 
2. To use the above assay coupled with the CFU-F assay in order to provide 
some simple guidelines to surgeons harvesting MSCs by BM aspiration, in 
order to improve the quality of aspirates taken for experimental or clinical 
use.   
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3.2. Materials and methods 
3.2.1.  Harvest of BM aspirate 
Aspiration of BM was performed from the anterior iliac crest, as previously 
described (2.2). Patents undergoing elective orthopaedic surgery were selected for 
this study (n=32, 18 male, 14 female, mean age 43 years).   Initially, 20ml of BM was 
aspirated from a single needle position from each donor (n=10).  For later donors 
(n=15), 5ml of BM aspirate was obtained from a single aspiration site; the position 
of the needle was then altered by removal and repositioning of the trocar ensuring 
that the trocar entered the cortical bone at a different angle. This procedure was 
performed a total of 4 times to give a final volume of 20ml. These two harvesting 
techniques were performed to address objective 2 and to explore the effect of 
aspiration technique on BM aspirate quality. Additionally, a subgroup of these 
samples was collected from BM aspirates used for the treatment of fracture non-
union by autologous grafting (n=7). In this case 50ml of BM was aspirated from a 
single needle position.  
 
3.2.2.  Flow cytometry on whole BM aspirates  
Since CD271 has been shown to be a highly specific marker for BM MSCs (Jones et 
al. 2002; Quirici et al. 2002; Buhring et al. 2009; Tormin et al. 2011; Boxall et al. 
2012), the utility of measuring the absolute number of cells expressing the CD45-
/lowCD271+ phenotype was assessed as a means of predicting the colony forming 
potential of a BM aspirate. Additionally, because Veyrat-Masson et al have already 
demonstrated impressive correlation between the colony forming potential of 
femoral head aspirates and the CD45-/low CD73+ population (Veyrat-Masson et al. 
2007), this population was also investigated in iliac crest aspirates. The proportion 
of T-cells in BM has been suggested as a potential indicator of BM dilution with 
blood (Veyrat-Masson et al. 2007). To investigate the utility of using T-cells as an 
indicator of BM dilution with blood, cells expressing a CD45+ CD3+ phenotype (T-
cells (Gerondakis et al. 2014) were measured. Volumetric flow cytometry was 
performed as previously described (2.5).  
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All populations were identified based on binding of antibodies listed in Appendix 4. 
A minimum of 250,000 events in the live cell gate were collected for each sample. 
Acquisition time was dependent on the cellularity of the sample; the mean 
acquisition time was 7 minutes, 23 seconds (range 3:16-14:42), with the event rate 
being set as approximately 2000 events/second. If more than 5 minutes was 
required to collect a sufficient number of events, the sample was re-mixed to 
ensure sample homogeneity. CD45-/lowCD271+ cells were identified by high 
expression of CD271 and negative to low expression of CD45 (Figure 1E). In order to 
investigate variability between different CD271 antibody clones, three BM samples 
were also stained with CD271-PE (Miltenyi Biotec) and CD271-PE (BD) (Appendix 4).  
The number of cells expressing the CD45-CD73+ phenotype was also measured 
simultaneously, in a subset of samples (n=23) to investigate the utility of CD73 as an 
alternative or additional marker for MSC enumeration.  
 
3.2.3.  Statistics 
Friedman’s two way analysis of variance by ranks was used to assess differences in 
cell survival during data acquisition. The Wilcoxon matched-pairs signed rank test 
was used to detect differences between draw volumes. The Mann Whitney U test 
was used to detect differences between BM aspiration techniques. The Spearman 
Rank Correlation Test was used to measure statistical dependence of CFU-F data, 
flow cytometry and manual counting data as well as to generate a 95% confidence 
interval of predicted individual values. 
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3.3. Results 
3.3.1. Method validation 
3.3.1.1. Linearity and precision of absolute cell counting  
A direct linear relationship was observed between automated cell counting using 
flow cytometry (2.5) with counting beads and manual cell counts using a 
haemocytometer (2.3) (R=0.98, P<0.001 (Figure 2). This high degree of correlation 
confirmed that automated counting was a reliable means of measuring the number 
of nucleated cells in BM aspirates, enabling absolute quantification of cell numbers.  
This also confirmed that the chosen gating strategy for the discrimination of cellular 
debris from the cells was effective, thus reducing the risk of experimental error as a 
result of non-specific antibody binding to debris. 
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Figure 2: Comparison of manual and automated counting methods 
Manual cell counts using a haemocytometer and automated cell counts using 
volumetric flow cytometry, n=17. 
  
R=0.980
P<0.001
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3.3.1.2. Cell viability 
Since the CD45-/low CD271+ population is extremely rare and the event rate was kept 
to 2000 events/second to avoid blockage of the cytometer flow cell, up to 10 
minutes was required to collect a sufficient number of events for analysis (a 
minimum of 250,000 events in the live cell gate).  It is possible that incubation in 
RBC lysis buffer could lead to reduced general cell viability and therefore inaccurate 
reporting. To investigate this, the number of cells that had not taken up DAPI (live 
cells) was analysed over a 10-minute period following to the initial 10-minute 
incubation in RBC lysis buffer. This 10-minute period was divided into five 2-minute 
intervals and the number of cells detected was expressed as a proportion of the 
total number of similar events; this was repeated using five separate BM aspirates 
(n=5).  
The total number of live cells (Figure 3A) and the number of CD45-/low CD271+ cells 
(Figure 3B) did not change over the analysis period. This indicated that prolonged 
RBC lysis buffer exposure did not have any detrimental effect on cell viability and 
detection. The relatively constant cell acquisition rate at the later time points also 
suggested that samples retained homogeneity over this period. Similarly, detection 
of CD45-/low CD271+ cells was not affected by prolonged incubation in ammonium 
chloride-containing buffer.  
To characterise the intra assay variability of this technique, a single aspirate was 
split into 6 tubes, which were analysed consecutively.  The coefficient of variation 
for the proportion of CD45-/low CD271+ cells was measured at 0.105 indicating a 
signal to noise ratio of approximately 10:1. 
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Figure 3: Cell viability in RBC lysis buffer 
No change in total cell viability (A) or viability of the CD45-/low CD45-/low CD271+ 
population (B) at any time interval following start of data collection. Data expressed 
as the proportion of the total events collected between 0 and 10 minutes. All data 
n=5. 
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3.3.1.3. Confirmation of antibody selection 
Reproducibility is an important quality for any assay. Therefore, the influence of 
different anti-CD271 antibody conjugates or clones on the detection of CD45-/low 
CD271+ cells was investigated. Enumeration data obtained using anti-CD271 
conjugated to APC and anti-CD271 conjugated to PE (both from Miltenyi Biotec, 
clone ME20.4-1.H4) were compared with each other as well as with data obtained 
with anti-CD271-PE (clone C40-1457, BD) (n=3, Appendix 4). The representative 
experiment shown in Figure 4A-C illustrates the very similar results obtained with 
all three CD271 antibody variants, no statistical significant difference was found 
between the clones (average values of 4180, 3954 and 4198 CD45-/low CD271+ 
cells/ml for CD271-APC, CD271-PE clone ME20.4-1.H4 and CD271-PE clone C40-
1457, respectively). Additionally, since CD73 has been proposed as a useful marker 
for the assessment of BM MSCs (Veyrat-Masson et al. 2007), CD73-PE was 
evaluated alongside CD271-APC, with CD45 as a negative gating parameter (Figure 
4D). The abundance of the CD45-/lowCD73+ population as well as the CD45-/low 
CD271+ population were examined in 23 BM aspirates. There was an exceptionally 
high degree of correlation between these two populations (R=0.985, p<0.001, 
Figure 4E). This data confirmed the utility of CD73 as an alternative or additional 
marker to CD271. 
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Figure 4: MSC identification and quantification using alternative antibodies 
CD45-/low CD271+ cells enumerated from a  single BM aspirate using anti CD271 
antibody clone ME20.4-1.H4 conjugated to APC (A) or PE (B) or using CD271 
antibody clone C40-1457 conjugated to PE (C). CD45-/low CD73+ cells enumerated 
from the same sample (D). The correlation between the CD45-/low CD271+ and CD45-
/lowCD73+ populations in BM aspirates n=23 (E).  
79 
 
3.3.2. The relationship between the concentration of CD45-/low 
CD271+ cells and CFU-Fs  
Examination of 25 BM aspirates showed, a close linear relationship was observed 
between the number of CFU-F colonies counted manually after 14 days of culture 
and the number of CD45-/low CD271+  cells/ml of aspirate (R=0.812, p<0.001, Figure 
5A).  The median values of CFU-F/ml and CD45-/low CD271+ cells/ml for the studied 
cohort were 280 and 7230 (ranges 3-1503 and 398-28210), respectively. The line of 
best fit suggested that approximately 1 in 17 CD45-/low CD271+ cells formed a CFU-F 
colony in these experimental conditions.  
The numbers of CD45-/low CD271+ cells also correlated strongly with the total area 
occupied by CFU-F colonies (R=0.66, P<0.001, Figure 5B). The total area occupied by 
CFU-F colonies and CFU-F colony number correlated closely with each other 
(R=0.86, P<0.001).  
 
3.3.3. Can enumeration of the CD45-/low CD271+ population be 
used to predict CFU-F concentration 
The ability of CD271-based enumeration assay to predict an aspirate’s CFU-F 
content was next explored. A logarithmic data transformation was used to better 
display the whole range of values (particularly, bottom range) and a 95% 
confidence interval of predicted individual values was calculated to establish a cut-
off point for the exclusion of specimens with potentially poor CFU-F content (<100 
CFU-F/ml). As seen in Figure 5C, samples with greater than 104 CD45-/low CD271+ 
cells/ml (or 10 cells/µl) were 95% likely to produce good yields of CFU-F colonies 
(>100 CFU-F/ml).  In contrast, the total cellularity of BM samples was a poorer 
indicator of the CFU-F content (R=0.516, p=0.003, Figure 5D). Representative 
photographs of duplicate CFU-F cultures with corresponding flow cytometry data of 
a low yield and high yield aspirate are shown in Figure 5E and F, respectively.  
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Figure 5: CFU-F colony measurements and correlations with CD45-/low CD271+ 
population measurements. 
Correlation between  of CD45-/low CD271+ population and number of colonies 
observed following CFU-F assay (A). Correlation between total colony area and the 
concentration of CD45-/low CD271+ cells (B). Data from panel A plotted on 
logarithmic scale; dotted line represents upper 95% prediction interval (C). 
Correlation between BM cellularity and number of CFU-F colonies (D). All data A-D 
n=25. Representative image of duplicate dishes showing a low yield CFU-F sample 
(E) and high yield CFU-F sample (F), corresponding CD45-/low CD271 + cell numbers 
are shown on the bottom. 
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3.3.4. Investigation of the CD45+CD271low cell population 
Aspirated BM consistently contained a population of cells that expressed CD45 and 
the CD271 antigen at a low level (CD45+ CD271low, Figure 6A). In fact, this 
population was more numerous than CD45-/low CD271+ cells (median frequencies of 
0.073% and 0.026%, respectively). The absolute number of CD45+ CD271low cells 
positively correlated with total sample cellularity (R=0.681, p<0.001, Figure 6B) 
suggesting that these cells originated from BM rather than blood, since blood has a 
much lower concentration of nucleated cells (Hollowell et al. 2005). 
When the concentration of CD45+ CD271low cells was compared to that of CD45-/low 
CD271+ cells in matched donors, only a weak relationship was found (Figure 6C) and 
the same was observed for the correlation between CD45+ CD271low cells and CFU-F 
data (Figure 6D). The presence of CD45 and the lack of a strong correlation with 
CFU-F indicated that CD45+ CD271low cells were most likely haematopoietic in 
origin. A study published by Tormin et al came to the same conclusion based on 
morphology (Tormin et al. 2011).  
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Figure 6: The CD45+ CD271low population strongly correlates with sample 
cellularity but weakly correlates with CFU-F colony concentration. 
(A) Representative flow cytometry plot showing gating for the CD45+CD271low cell 
population (boxed). (B) Correlation between BM cellularity and the concentration 
of the CD45+ CD271low population. (C) Weaker correlation between CD45-/low 
CD271+ and CD45+ CD271low populations. (D) Weak correlation between number of 
CFU-F colonies and the concentration of CD45+ CD271low cells. All data B-D n=25.   
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3.3.5.  Optimising BM aspiration 
As shown on Figure 5, the MSC content of aspirates varies considerably. Although 
MSC content has been shown to vary in relation to donor age (Stolzing et al. 2008) 
(cohort’s age range was 21-85), dilution of BM with blood may provide an 
additional source of variability (Veyrat-Masson et al. 2007; Hernigou et al. 2013). 
This may be the prime reason for the huge (up to 500-fold) variability in the MSC 
concentration observed. 
In order to examine marrow dilution with blood and to optimise the collection of 
MSCs in BM aspirates (Objective 2), the effect of continuous aspiration was studied. 
The concentration of CD45-/low CD271+ cells in the first 5ml of the aspirate was 
compared to that in the following 15ml aspirated from the same site, without any 
change to the insertion angle of the trocar (Figure 7A).  The results demonstrated a 
significant 7-fold drop in the concentration of CD45-/low CD271+ cells in the second, 
15ml draw fraction (median concentration 2197 cell/ml, range 434-5391, n=7) 
compared to the first 5ml draw (median concentration 14450 cell/ml, range 3350-
43936, p=0.018). The same trends were observed for CFU-F concentration, a 9-fold 
drop (p=0.028) in the 15ml draw fraction (median concentration 45 colonies/ml, 
range 23-274) compared to the first 5ml draw fraction (median concentration 410 
colonies/ml, range 185-1515, Figure 7B).   
Avoiding the dilution of BM with blood is recognised as an important factor in 
determining the MSC content in BM aspirates (Hernigou et al. 2002; Hernigou et al. 
2005a; Hernigou et al. 2013). To examine the overall difference in aspirate quality 
between a single 20ml draw and 4 separate 5ml draws (n=7 and 13 donors, 
respectively), the total yield of CD45-/low CD271+ cells (Figure 7C) and CFU-F colonies 
(Figure 7D) was compared.  Although both these measures recorded higher median 
values in the 4x5ml category, these differences failed to reach statistical 
significance, most likely due to high donor variability, relatively low sample size and 
the fact that the two groups were not donor-matched. However, these data 
indicated that small draw volumes may provide higher concentrations of MSCs, this 
has recently been confirmed independently (Hernigou et al. 2013). 
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Figure 7: MSC concentration is dependent on BM aspiration technique 
A higher number of CD45-/low CD271+ cells/ml (A) or CFU-F colonies/ml (B) was 
observed in the first 5ml of aspirate compared with the following 15ml (n=7). Total 
number of CD45-/low CD271+ cells (C) and CFU-Fs (D) collected by either one 20ml 
draw (n=7) or 4x5ml draws (n=13).  
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3.3.6.  Further investigation of BM dilution with blood by 
studying the T-cell content of BM aspirates 
The presence of T-cells in aspirates has been suggested to be an indicator of BM 
dilution with blood (Veyrat-Masson et al. 2007). To investigate the relationship 
between the MSC content of aspirates and dilution with blood, the absolute 
numbers and proportions of T-cells in aspirates was measured in a subset of 
samples (n=15). T-cells were identified by positive expression of CD3 and CD45 
(CD3+ CD45+, Figure 8A). The median number of T-cells was 1.2x105/ml (range 
0.8x105 – 2.6x106) representing a median proportion of 7.13% of the total cells 
detected (range 3.64–9.46).  This percentage is significantly below the reported 
median for CD3 T-cells in blood of 24.5% (Hulstaert et al. 1994). There was a close 
inverse relationship between the proportion of T-cells in the aspirate and the 
number of colonies formed in CFU-F assay (R=-0.761, p=0.001, Figure 8B).  A much 
weaker but significant positive correlation was observed between the absolute 
number of T-cells/ml of aspirate and number of CFU-Fs/ml (R=0.581, p=0.023, 
Figure 8C). The apparent disparity between these two results can be partly 
explained by the observation that proportions and absolute numbers of T-cells in 
aspirates correlated poorly (R=-0.236, p=0.398, Figure 8D), meaning that T-cell 
proportion is a poor indicator of T-cell concentration in BM. 
Furthermore, there was a positive correlation between the concentration of T-cells 
and CD45-/low CD271+ cells (R=0.571, p=0.026, data not shown) as well as a tight 
positive correlation between T-cell number and the total cellularity of the aspirate 
(R=0.807, p<0.001, Figure 8E).  Additionally, there was an inverse correlation 
between the proportion of T-cells and the total cellularity of the sample (R=0.729, 
p=0.002, Figure 8F).  Blood is less cellular than BM; in agreement, BM cellularity 
was found to be in the range of 10-55x106 nucleated cells/ml (Figure 2), this is 
higher compared to a normal range of 4-12x106 nucleated cell/ml in peripheral 
blood (Hollowell et al. 2005). Therefore, aspirate cellularity is inversely proportional 
to inclusion of blood.  Data collected on concentration and proportion of T-cells in 
aspirates indicates that T-cells represent a higher proportion of nucleated cells in 
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blood making the proportion rather than concentration of T-cells a more 
appropriate indicator of BM dilution with blood (Figure 9). 
 
Figure 8: T-cells as an indicator of marrow dilution with blood  
Identification of T-cell population (A). Inverse correlation of the proportion of T-
cells present in the aspirate and CFU-F colony number (B). Positive correlation 
between absolute number of T-cells and CFU-F colony number (C).  No significant 
correlation between T-cell proportion and their absolute number (D).  Positive 
correlation between T-cell absolute number and total cellularity (E).  Inverse 
correlation between the proportion of T-cells and the total cellularity of the 
aspirate (F). All data B-F n=15. 
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Figure 9: The relationship between total cellularity, T-cell concentration and T-cell 
proportion. 
Figure illustrates BM mixing with blood, T-cells represented by filled circles, all 
other cells types represented by open circles. 
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3.4. Discussion 
This chapter has demonstrated that a flow cytometry based technique could be 
used to predict the number of CFU-Fs that will develop from a given volume of 
aspirate and that the absolute number of the CD45-/low CD271+ cells per ml of 
aspirate was a strong indicator of its MSC content. This is supported by the strong 
correlation between CD45-/low CD271+ cell concentration and total colony area, 
indicating that once seeded CD45-/low CD271+ cells are capable of expansion.  
In therapies that involve autologous MSC grafting, for example in the treatment of 
fracture non-unions, the dose of MSC has been shown to be critical in determining 
efficacy (Hernigou et al. 2005a). Therefore, the technique described herein may 
have value as an intra-operative quality control measure of BM aspirate. The utility 
of this approach is enhanced by the short duration of the assay (<40 minutes). If an 
aspirate is found to be of poor quality (below 100 CFU-F/ml equivalent to <1720 
CD45-low CD271+ cells/ml, Figure 5), a second aspirate could be quickly obtained to 
supplement or replace a poor first sample. It is possible that the application of 
acoustic focussing technology (Goddard et al. 2007) to this technique may further 
reduce assay time, perhaps to as little as 15 minutes. This is possible because 
acoustic focusing enables far faster data acquisition than can be achieved using 
conventional hydrodynamic focussing, this has the added advantage of not 
requiring large volumes of sheath fluid, thereby increasing instrument portability 
(Goddard et al. 2007).   
In the bulk manufacture of MSCs the number of PDs needed to achieve a 
therapeutic yield of MSCs is critical in determining the characteristics of the 
resulting MSC product (Banfi et al. 2000; Banfi et al. 2002; Wagner et al. 2008). The 
MSC enumeration technique described in this chapter could provide a means of 
estimating the number of PDs required to achieve therapeutic yield prior to culture 
initiation, enabling the production of an MSC product with more predictable and 
consistent biological properties. Additionally the risk of cultures reaching 
senescence before achieving the required number of MSCs would be greatly 
reduced if low quality aspirates could be identified beforehand and excluded.  
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In order to maximise the absolute number of MSCs the technique used to obtain 
aspirates was also examined; this was addressed by objective 2 in this chapter.  In 
the treatment of long bone non-unions large volumes of marrow (up to 300ml) are 
commonly harvested prior to volume reduction and percutaneous injection 
(Hernigou et al. 2005a; Kasten et al. 2008). This work has shown that following the 
first 5ml of BM aspirate, the MSC concentration drops dramatically. This may be 
due to the adherent nature of MSCs and their close association with bone (Jones et 
al. 2010b; Tormin et al. 2011) as well as gradual dilution of marrow with blood.  
In order to maximise the number of MSCs aspirated from the iliac crest for the 
purpose of MSC expansion or direct therapy, this data suggests that each draw 
should be limited in volume, ideally to no more than 5ml, at a single site. 
Furthermore, a precise description of the aspiration technique used to attain BM 
samples should always be included in any publication seeking to identify changes 
related to aging or disease. The failure to standardise aspiration volume is a 
potential source of a large degree of variability in MSC content. Indeed, age related 
changes to MSC content in BM are a subject of some controversy, with widely 
disparate results reported (Oreffo et al. 1998; D'Ippolito et al. 1999; Baxter et al. 
2004; Stolzing et al. 2008; Zhao et al. 2008). Although this may partly be explained 
by differences in cohort size and demographics as well as differences in 
enumeration methodology (Stolzing et al. 2008), it is important to note that in 
many cases no information is provided with regards to aspiration volume or 
technique (Oreffo et al. 1998; D'Ippolito et al. 1999; Baxter et al. 2004; Stolzing et 
al. 2008; Zhao et al. 2008).  
The ability to detect the degree of blood dilution in BM would be advantageous for 
many fields of study. Hernigou et al proposed a method based on the relative 
haematocrit of BM compared to blood (Hernigou et al. 2013). Haematocrit is 
defined as the percentage of red cells in the blood, hence Hernigou’s method relies 
on the assumption that BM makes a negligible contribution to haematocrit. Veyrat-
Masson et al have proposed another method, namely that the proportion of T-cells 
may be used as an indicator of marrow dilution with blood; although not explicitly 
explained by the authors this may have been based on the fact that T-cells mature 
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outside of the BM (Gerondakis et al. 2014). Therefore, any T-cells detected in BM 
must originate from the blood. Veyrat-Masson et al did not establish a correlation 
between T-cell proportion and aspirate quality in femoral head aspirates (Veyrat-
Masson et al. 2007). However, I observed a tight inverse correlation between the 
proportion of CD3+ cells and the MSC content of iliac crest aspirates. This disparity 
may be explained by the different anatomical regions aspirated as well as 
differences in the enumeration protocols used in each study. The percentage of cell 
expressing CD3 might be a useful indicator of blood dilution in iliac crest aspirates. 
This could easily be tested by deliberate mixing of matched blood and BM samples. 
It is possible that by taking matched peripheral blood at the same time as BM 
aspirates, a protocol for the quantitative measurement of BM dilution with blood 
could be developed. 
The variability of MSC content in BM aspirates remains a challenge for research 
aimed at describing the in vivo characteristics of MSCs. Whilst dilution with blood is 
undoubtedly partly responsible, clotting of BM following aspiration can also 
influence MSC concentration. I have often observed clotting of BM aspirates even in 
the presence of anticoagulant, and associate clotting with poor aspirate quality. 
Also MSCs have been also shown to form aggregates with haematopoietic cells 
(Miao et al. 2004; Ahmadbeigi et al. 2012), and it is possible that MSCs are not 
distributed evenly throughout BM but are instead clustered into aggregates 
consisting of perhaps several hundred MSCs and other cell types. Indeed, non-
homogenous distribution of MSCs is supported by the observations that total 
cellularity correlated only weakly with CFU-F concentration. These aggregates may 
themselves have a specific distribution being more or less common in a particular 
region; if this were the case, it would also contribute to sampling variability, 
particularly when comparing aspirate samples from disparate sites such as the 
posterior and anterior iliac crest. To address these issues investigators should 
aspirate from multiple sites, carefully report aspiration location and discard any 
clotted samples, in order to accurately report MSC numbers. 
In summary, this chapter has described work to validate a robust, rapid and 
relatively straightforward assay for the determination of the absolute number of 
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MSC in a BM aspirate.  This assay has the potential to improve bulk manufacturing 
of MSCs by enabling the production of a more standardised and therefore more 
predictable MSC product.  As an intra-operative quality control it would allow 
clinicians to determine the number of autologous MSCs administered to patients or 
loaded onto scaffolds prior to implantation and therefore has potential to improve 
the efficacy of minimally-manipulated MSC therapy. 
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4. Optimising strategies for minimally manipulated 
MSC therapy 
4.1. Introduction 
4.1.1.  Current clinical applications of culture expanded MSCs 
The potential use of cultured MSCs as therapeutic agents has been recognised since 
their original description (Caplan 1991). To date clinical trials for a range of 
conditions including those of the skeletal system and non-skeletal system 
applications including cardiovascular, gastroenterological, and neurologic have 
been proposed (Table 1).  Skeletal applications have included cartilage and bone 
repair in both the experimental and clinical settings (Hernigou et al. 2002; Wakitani 
et al. 2002; Hernigou et al. 2005a; Hernigou et al. 2005b; Dashtdar et al. 2011; 
Nakamura et al. 2012) and rarer indications including the therapy of osteogenesis 
imperfecta (Horwitz et al. 1999; Horwitz et al. 2002). Prominent examples of non-
skeletal applications of cultured MSCs as cell therapy include acute myocardial 
infarction (Hare et al. 2009) and steroid resistant graft versus host disease (Le Blanc 
et al. 2004). Unfortunately many of these trials have produced variable outcomes 
(Trounson et al. 2011; Galipeau 2013; Raynaud et al. 2013). This may be due to  
differences in culture conditions, inadequate control of the number of cell divisions 
required to achieve a therapeutic yield and issues relating to cryopreservation 
leading to a loss of desirable phenotypic properties (Francois et al. 2012; Bianco et 
al. 2013a; Bianco et al. 2013b; Galipeau 2013).   
 
4.1.2.  The potential of minimally-manipulated MSCs for cell 
therapy 
Non-expanded, minimally-manipulated cell therapies are subject to far less 
regulatory burden compared to culture expanded cell therapies (von Tigerstrom 
2008; Deasy et al. 2013). Haematopoietic-cell (HC) transplantation is one example 
of a minimally manipulated cell therapy and represents the most successful and 
widely used cell based therapy after blood transfusion. In 2006 50,000 people in 
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500 or more centres were treated with HC transfusion worldwide for a range of 
haematological conditions (Appelbaum 2007). The development of similar 
technologies for homologous use of minimally-manipulated MSCs is therefore an 
attractive prospect. 
However, several technical challenges have so far hampered the development of 
uncultured MSC based therapies, the most problematic of which is the low and 
variable concentration of MSCs in BM aspirates (Friedenstein et al. 1992; Pittenger 
et al. 1999; Jones et al. 2006). This was noted and addressed in the previous 
chapter as was the notion that the number of CD45-/low CD271+ cells/ml could be 
used to predict the MSC content of BM aspirates. In this chapter a clinically-
applicable MSC selection technology based on positive selection of CD271+ cells 
able to obtain uncultured BM MSCs is explored. 
 
4.1.3.  Autologous BM implantation in clinical orthopaedics  
One strategy currently being utilized in clinical orthopaedics for the treatment of 
large bone defects and fracture non-union is to take a large amount of BM aspirate 
and reduce its volume. Concentrated BM can then be administed directly to the site 
of deficient bone healing, either by percutaneous injection or by mixing with an 
appropriate bone scaffold prior to implantation (Hernigou et al. 2005a; Hernigou et 
al. 2005b; Homma et al. 2014). Several systems have been developed that use 
filtration (Dawson et al. 2013; Otsuru et al. 2013), but most available systems utilise 
centrifugation to select nucleated cells based on their relative density  (Hernigou et 
al. 2005a; Kasten et al. 2008; Giannini et al. 2009; Betsch et al. 2013; Lee et al. 
2014).  This approach has been employed by the MarrowStim (Biomet) and 
SmartPrep 2 (Harvest) concentrator devices (Appendix 6). Although several studies 
have confirmed the safety of this strategy and examined its clinical effectiveness 
(Hernigou et al. 2005a; Hendrich et al. 2009; Lee et al. 2014), relatively few studies 
have examined the effectiveness of individual concentrators in terms of their ability 
to concentrate MSCs.  
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4.1.4.  Limitations of BM concentration approaches 
The use of BM concentrates has limitations. Simply reducing the volume of the 
aspirate by removing erythrocytes and plasma is unlikely to substantially increase 
the proportion of MSCs in the concentrate.  Since the majority of cells in a BM 
aspirate are of hematopoietic lineage (Jones et al. 2002; Jones et al. 2006; Veyrat-
Masson et al. 2007), there is no reason to suggest that these cells do not constitute 
the overwhelming majority of the cellular content of BM concentrates. If 
considering allogeneic use, the administration of large numbers of unmatched 
hematopoietic cells to patients with an intact immune system is bound to result in 
dangerous immune reactions.  Consequently, BM concentrators have not been 
considered for any allogeneic MSC therapy. Additionally, the reliance on 
centrifugation makes dealing with large volumes of liquid problematic, hence most 
concentrators are designed to concentrate no more than 60ml of BM (Kasten et al. 
2008; Giannini et al. 2009; Lee et al. 2014). Also this strategy relies on the 
separation of a “buffy coat” of intermediate density (Hernigou et al. 2005a; Kasten 
et al. 2008; Giannini et al. 2009; Betsch et al. 2013; Lee et al. 2014), which may be 
difficult to identify and isolate in solutions other than blood and BM. These issues 
potentially limit the effectiveness of centrifugation for obtaining MSCs from sources 
other than BM aspirates. 
 
4.1.5.  CD271 expression as a means of MSC isolation 
An alternative strategy is the use of a clinical grade cell separation system such as 
CliniMACS (Miltenyi Biotec) to positively select for uncultured MSCs (Figure 10A). 
Here, a cell suspension such as a BM aspirate (Figure 10B), is incubated with a 
magnetic microbead conjugated to a monoclonal antibody specific to an antigen of 
interest. Incubation of a cell suspension with magnetic beads results in specific 
antibody/bead binding to cells expressing a chosen antigen. Cells are then passed 
through a column in the presence of a magnetic field, bead bound cells are 
retained, whereas unlabelled cells are eluted. The magnetic field is then released 
and bead labelled cells are eluted.  
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This technology has already been used in clinical practice and has been confirmed 
to be safe for positive selection and administration of CD34+ HSCs (Ringhoffer et al. 
2004), CD133+ HSCs and endothelial progenitor cells (Stamm et al. 2007),  CD14+ 
monocytes (Holtl et al. 2005) and CD4+ CD25+ regulatory T-cells (Di Ianni et al. 
2011), but has not been applied to MSCs. CD271 expression offers an attractive 
target for magnetic isolation of human BM MSCs due to its specificity for MSCs and 
relatively low cross-reactivity with hematopoietic lineage cells, as stated in previous 
chapters (Jones et al. 2002; Jones et al. 2006; Tormin et al. 2011; Bianco et al. 
2013b).  
A research grade bead has already been used for the selection of BM MSCs in the 
laboratory setting and has been proven to be effective (Jarocha et al. 2006; Jones et 
al. 2006; Jarocha et al. 2008). Recently, the development of a clinical grade CD271 
microbead has opened the possibility of using this technology as the basis of a new 
non-expanded MSC therapy. 
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Figure 10: The CliniMACS system and three intra-osseous sources of MSCs used on 
this study 
The CliniMACS device and a cartoon explanation of the microbead technology used 
(A) (adapted from Miltenyi Biotec). A freshly drawn BM aspirate (B). A femoral head 
prior to processing (C). A reaming procedure and a bag of RIA waste fluid (D) 
(Adapted from Churchman et al 2013). Operating theatre images were kindly 
provided by P.V. Gainnoudis. 
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4.1.6.  Alternative sources of BM MSCs 
Several investigations have shown that large numbers of MSCs can be recovered 
from trabecular bone with enzymatic extraction (Noth et al. 2002; Tuli et al. 2003; 
Sakaguchi et al. 2004), this lead to the hypothesis that aspiration is a relatively 
inefficient means of collecting MSCs from the marrow. Recently, Jones et al 
demonstrated that upon digestion with collagenase, MSCs could be recovered as a 
far greater proportion of total cellularity from pelvic bone fragments compared to 
BM aspirates (Jones et al. 2010b). Cell sorting based on the negative or low 
expression of CD45 and positive expression of CD271 isolated cells with equivalent 
proliferative, osteogenic, and phenotypic properties to BM MSCs (Jones et al. 
2010b). This dispels the dogma that BM MSCs are an extremely rare population and 
gives a potential source of large numbers of clinically useful MSCs. Additionally the 
high incidence of total hip replacement (National Joint Registry for et al. 2011), 
provides a plentiful source of otherwise discarded femoral heads (FHs), that could 
serve as the starting material for MSC extraction (Figure 10C).  Similarly, Porter et al 
showed that both the solid and liquid waste fractions of intramedullary reaming 
waste following use of the reamer irrigator aspirator (RIA) device contained large 
numbers of MSCs (Porter et al. 2009).  Cells sorted based on CD271 expression from 
the liquid waste fraction (Figure 10D) were later shown to have similar phenotypic 
and transcriptional profiles to BM MSCs (Churchman et al. 2013), making this 
another source of large numbers of CD271+ MSCs. 
Fluorescence activated cell sorting has been an invaluable tool for phenotypic 
identification of MSCs. However, this technique is not suitable for clinical isolation 
of MSCs, due to lengthy sort times and high potential for pathogen carry over. 
Therefore, cell selection using a single antigen (CD271) using a fully clinical grade 
system could offer a viable alternative to cell sorting. 
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4.1.7. Chapter aim and objectives 
The aim of this chapter is to test the currently available technology for MSC 
concentration and enrichment and to assess their potential for therapy 
development. 
Objectives: 
1. To evaluate and compare two commercially available BM concentrators, the 
MarrowStim and SmartPrep 2, with respect to their ability to concentrate 
MSCs.  
2. To develop a protocol for the positive selection of MSCs from iliac crest 
aspirates, using clinical-grade CD271 microbeads and the CliniMACS cell 
separator, using equipment and reagents which comply with good 
manufacturing practice standards throughout. 
3. Given the low numbers of MSCs in aspirates, to investigate enzymatically 
digested femoral heads and the liquid waste component generated by the 
RIA device as potential sources of MSCs suitable for clinical-grade CD271 
based cell selection. 
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4.2. Materials and methods 
4.2.1. Patient recruitment 
For BM aspirate samples, patients undergoing elective orthopaedic surgery for 
metalwork removal or non-union revision were invited to participate. For the 
comparison of BM concentrator devices, aspirates were collected for concentration 
using the SmartPrep 2 device (Harvest) (n=8, mean age 52 years, 2 male 6 female) 
or the MarrowStim BM concentrator (Biomet) (n=10, mean age 57 years, 6 male 4 
female). For CliniMACS experiments, BM samples were selected based on high MSC 
content using the enumeration assay described in chapter 3 (n=3, 1 male 2 female 
with a mean age of 32). Patients with any underlying disease for example 
osteoporosis, osteosarcoma and osteogenesis imperfecta were excluded.  
For the collection of FH samples, patients admitted for total hip arthroplasty for the 
relief of osteoarthritis pain were invited to participate (n=3, all male mean age 72; 
patients that underwent arthroplasty for any other reason for example as a result 
of hip fracture or rheumatoid arthritis were excluded. For RIA waste fluid samples, 
patients admitted for the treatment of fracture non-union involving autologous 
grafting of cortical bone were invited to participate (n=3,1 male 2 female mean age 
47). 
 
4.2.2. Concentration of BM aspirates using the MarrowStimTM 
and SmartPrep 2® BM devices 
A concentrated BM aspirate was prepared by the operating surgeon, using either 
MarrowStim or SmartPrep 2 device as a part of the elective procedure undertaken 
for non-union revision surgery, according to the manufacturer’s instructions 
(Appendix 6). For both devices, a trocar was inserted in the anterior iliac crest and 
50ml of BM was then drawn from a single insertion. This was loaded into the 
devices in the presence of 5ml anticoagulant citrate dextrose solution A (ACDA) and 
subsequently centrifuged. In the case of MarrowStim, this procedure results in BM 
being separated into three compartments containing serum, erythrocytes or 
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nucleated cells; the latter were then drawn off using a syringe and had a mean 
volume of 7.5ml (n=10). In the case of SmartPrep 2, BM is separated into two 
compartments containing erythrocytes or nucleated cells below a layer of serum. 
Serum is removed prior to collection of the nucleated cells which occupied a mean 
final volume of 6.7ml (n=8). A small sample of the BM before concentration (1ml, 
denoted Pre) as well as the concentrated sample (1ml, Post) were taken for analysis 
of their MSC content by the CFU-F assay (2.7) and flow cytometry (2.5). 
 
4.2.3. Femoral head processing using bone mill and collagenase 
digestion 
Removed, FHs were bisected by the operating surgeon and stored immersed in 
sterile saline, overnight at 4oC in a specimen pot. The following morning FHs were 
removed from saline, and broken into small fragments (<1g) using a sterile 
Noviomagus bone mill (De Puy). The wet weight of fragments was recorded and the 
sample was digested with collagenase to release single cells, as previously 
described (2.4). Once filtered to remove larger aggregates, the cell suspension was 
taken for MSC isolation as described (4.2.5) without washing or centrifugation. 
 
4.2.4. Reamer irrigator aspirator waste fluid processing 
The RIA device (Synthes Inc) was operated by the surgical team during the revision 
of long bone non-unions (Giannoudis et al. 2009; Porter et al. 2009; Cox et al. 
2011a; Cox et al. 2011b). It is a one-pass reamer that allows simultaneous irrigation 
and aspiration of tibial or femoral contents disrupted during reaming (Giannoudis 
et al. 2009; Porter et al. 2009; Cox et al. 2011a; Cox et al. 2011b). The system was 
developed in order to eliminate the risk of systemic embolism caused by increased 
inter-medullary temperature and pressure during conventional reaming (Muller et 
al. 2006; Giannoudis et al. 2009).  After its adoption into clinical practice both the 
solid and liquid phases of the RIA aspirate were shown to contain substantial 
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amounts of bioactive and osteogenic factors and cells including MSCs (Porter et al. 
2009; Cox et al. 2011b; Cox et al. 2012). 
For this study, only patients undergoing femoral reaming were selected in order to 
maximise the amount of cellular material collected. Briefly, a drill was used to open 
the tip of the greater trochanter and a guide wire was inserted down to the distal 
metaphyseal region of the femur (Giannoudis et al. 2009). The RIA device was 
mounted onto a guide wire and reaming began; a constant flow of sterile saline was 
directed toward the reamer head where it mixed with disrupted femoral canal 
contents. The saline/tissue mixture was then drawn away by suction and the solid 
phase was retained in a collection filter; this material was used by the surgeon as 
autologous graft (Giannoudis et al. 2009). The liquid phase passed to a waste bag; it 
is this material that has been utilized in these experiments. The volumes of fluid 
collected were 859, 958 and 783ml.  
 
4.2.5. MSC isolation from BM aspirate, FH cellular fractions and 
RIA fluid using the CliniMACS system 
A small volume (1ml) of BM aspirate, digested FH cell suspension and RIA liquid 
phase waste was retained for analysis by CFU-F assay and flow cytometry; this will 
be referred to as the pre enrichment fraction (Pre).  
The remaining sample was transferred into a sterile silicone transfer bag (Miltenyi) 
and transported to the Seacroft NHS blood and tissue facility. The volume of liquid 
in the bag was adjusted to 500ml by addition of GMP-grade PBS, with EDTA 
(Miltenyi) containing 5% w/v GMP-grade human serum albumin (HSA) (Bio Products 
Laboratory). This was done by attaching a separate bag containing the 
PBS/EDTA/HSA solution to the transfer bag using a TSCDI sterile tube welder 
(Terumo) and allowing buffer to flow into the transfer bag. Once the correct volume 
had been achieved, the buffer bag was detached using a sterile tube fuser (Terumo) 
and the transfer bag was centrifuged at 400xg for 20 minutes. The supernatant was 
subsequently removed, into a second transfer bag, attached using a sterile tube 
welder, by gently squeezing the bag using a plasma expresser (Fenwal) until a 
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minimal volume (<50ml) of supernatant remained. The second transfer bag was 
then detached using a sterile tube fuser (this will be referred to as the 1st wash 
fraction) and the cell pellet was re-suspended in the remaining supernatant. If more 
than one transfer bag was required due to the large initial volume of the cell 
suspension, the contents of both transfer bags were combined in a single transfer 
bag at this point.  
The volume in the final transfer bag was adjusted to 95ml by addition of PBS/ 
EDTA/HSA solution as above, to which the contents of one vial of anti-CD271 
clinical-grade microbeads were added using a syringe and needle. The cell 
suspension was then incubated for 30 minutes on a tilting shaker (Stuart) at RT.  
Subsequently, the volume was adjusted to 500ml with addition of PBS/EDTA/HSA, 
followed by centrifugation, removal of supernatant (referred to the 2nd wash 
fraction), and volume adjustment to 95ml, as detailed above.  At this stage, 1ml of 
the cell suspension was taken using a sterile syringe for CFU-F/flow cytometry 
analysis; this will be referred to as the before separation (BS) fraction. The transfer 
bag was loaded onto the CliniMACS device and attached to a CliniMACS tubing set 
(Miltenyi). An automated protocol originally intended for CD34 isolation (Dvorak et 
al. 2013) was initiated resulting in separation of the cell suspension into two 
fractions: a positive fraction containing CD271 expressing cells (Post) and a negative 
fraction containing all other cell types (Negative fraction). 
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4.3. Results 
4.3.1.  Comparison of MarrowStim and SmartPrep 2 
concentrator devices for their ability to concentrate MSCs 
Total nucleated cells were concentrated 5.0-fold using the MarrowStim device 
(p=0.028, Figure 11A) and 6.3-fold using the SmartPrep 2 device (p=0.012, Figure 
11B). In terms of concentrating MSCs, the MarrowStim was successful on 9 of 10 
trials resulting in a median 7.3-fold increase in the numbers of MSCs/ml, as 
measured by the CFU-F assay (p=0.007, Figure 11C). The SmartPrep 2 concentrator 
was successful on 7 of 8 trials resulting in a median of 2.8-fold increase in MSCs , 
but this was short of significance due to one failed trial (p=0.093, Figure 11D).  
To assess whether MSCs were enriched or simply concentrated in a smaller volume, 
the proportion of MSCs in the Pre and Post-concentration fractions was analysed in 
relation to total nucleated cells. No enrichment in MSCs was observed following the 
use of either device (Figure 11E). The proportions of CD45+ leukocytes remained 
unchanged following processing with either device (Figure 11F). 
The MSC contents of BM aspirates Pre-concentration using the MarrowStim device 
were particularly low (median of 11 CFU-F/ml), this may be were related to the 
requirement of collecting an aspirate as a single large-volume (50ml) draw, leading 
to dilution of marrow with blood (Hernigou et al. 2013). Aspirates collected, using a 
single 50ml draw, prior to SmartPrep 2 concentration had higher concentrations of 
MSCs (median of 258 CFU-F/ml), but were still poorer compared to those harvested 
using an optimised low volume draw technique (4x5ml) as detailed (2.2) (a median 
of 455 CFU-F/ml, Figure 11G).  
These results clearly showed that both devices were able to concentrate MSCs (and 
other cells) into a smaller volume, but they did increase the purity of MSCs.  
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Figure 11: Comparison of MarrowStim and SmartPrep 2 concentrator devices  
The total nucleated cell content of the Pre and Post concentration fractions 
processed using the MarrowStim (A) and SmartPrep 2 (B) devices. MSC content Pre 
and Post concentration using MarrowStim (C) and SmartPrep 2 (D) devices. The 
percentage  of MSCs (E) and CD45+ cells (F) in Pre (white box) and Post (grey box) 
fractions following the use of MarrowStim (MS) and SmartPrep 2 (SP) devices. MSC 
content of BM aspirates prior to concentration with MS or SP compared to 
optimised (O) aspiration technique n=13 (G). All MS data n=8 donors, all SP data 
n=10 donors, box plots show interquartile range (box) median (line) and extreme 
values (whiskers), *p<0.05, **p<0.01, ***p<0.001. 
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4.3.2.  Enrichment of MSCs using the CliniMACS System 
Given that magnetic bead technology relies on binding of microbeads to surface 
CD271 molecules, there is a possibility that this could compromise further binding 
of ‘detection’ anti-CD271 antibodies. Furthermore, transient binding of microbeads 
could also result in internalisation of the CD271 molecule (Carcenac et al. 2001); 
both factors could therefore affect MSC purity determination following selection if 
relying on detection of CD271 expression. In order to ensure accurate 
determination of MSC number and purity by flow cytometry following anti-CD271 
CliniMACS separation, CD73 was utilized as an alternative marker for quantification 
of MSCs, since this has already been demonstrated as a useful alternative marker to 
CD271 as detailed in (Figure 4E).   
Following CliniMACS cell separation, the proportion of cells expressing a CD45-/low 
CD73+ phenotype was measured in the Pre  (Figure 12A) and Post-enrichment 
fractions (Figure 12B). The proportion of cells expressing a CD45-/low CD73+ CD271+ 
phenotype was also measured Pre and Post enrichment (Figure 12C-D).  
In the Pre enriched BM, FH and RIA the mean proportion of cells expressing a CD45-
/low CD73+ phenotype was 0.078%, 7.31% and 0.25%, respectively. This was 
consistent with previously-published data from Leeds and elsewhere (Jones et al. 
2006; Jones et al. 2010b; Alvarez-Viejo et al. 2013; Churchman et al. 2013). These 
proportions were increased in the Post fraction to 14.5%, 60.0% and 40.8% for BM, 
FH and RIA samples, respectively (Figure 13A). Similarly, the proportion of cells 
expressing a CD45-/low CD73+ CD271+ phenotype was also increased in BM, FH and 
RIA from a mean of 0.066%, 3.72% and  0.12% to 13.5%, 52.4 and 34.9%, 
respectively (Figure 13B). This data suggests that the potential effect of antigen 
masking or internalisation as a result of microbead binding was minimal. 
However, some disparity was observed between the proportion of CD45-/lowCD73+ 
and CD45-/lowCD73+CD271+ cells after enzymatic digestion of FH. This could have led 
to over estimation of the number of MSCs as defined by the CD45-/lowCD73+ 
phenotype in the Pre enrichment fraction. Inclusion of CD271 as a gating parameter 
using the same antibody clone used for selection resulted in only a minor alteration 
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to the proportion of MSCs detected in the Post enrichment fraction, one possible 
explanation for these observations is that microbeads are not present in excess 
allowing further binding of detection antibody. 
Unfortunately no data was collected for the mean proportion of CFU-Fs Pre and 
Post enrichment in BM aspirates, this was due to the low overall numbers of cells 
isolated from this source, but in FH and RIA these rose from 0.56% and 0.0049% to 
5.57% and 0.85% respectively (Figure 13C).  
In summary CliniMACS technology was successful in enriching MSCs from all 3 
tissues tested, proving the concept of clinical grade CD271 based MSC enrichment.  
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Figure 12:  An example of MSC gating strategy Pre and Post CliniMACS enrichment 
Representative matched dot plots showing the CD45-/low CD73+ population in 
unprocessed BM (Pre) (A) and the positive (Post) fraction (B). Representative 
matched dot plots showing the CD45-/low CD73+ CD271+ population (double-positive, 
large square) and CD45+ CD271low CD73- population (single positive, small box) in 
unprocessed BM (C) and the processed positive fraction (D). 
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Figure 13: Enrichment of MSCs using the CliniMACS system 
The mean percentage of the CD45-/low CD73+ population (A) and the double-positive 
CD45-/low CD73+ CD271+ population (B)  measured by flow cytometry Pre (white bar) 
and Post (grey bar). The mean proportion of CFU-Fs Pre (white bar) and Post (grey 
bar) CliniMACS enrichment (C). Values above each box pair show mean fold 
increase. All data n=3 displayed as mean and standard deviation. 
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4.3.3.  Depletion of unwanted cells and assessment of total cell 
viability following CliniMACS enrichment 
The contamination of the Post enrichment, positive fraction with other cell types 
(non-MSCs) is a critical factor when considering this technology for clinical therapy 
development. This is of particular importance when considering allogeneic use. 
Although MSCs do not illicit an immune response (Ren et al. 2009; Francois et al. 
2012; Krampera et al. 2013) other cell types would, potentially with serious 
consequences if administered systemically.  
CD45+ cells, leukocytes (Mason et al. 1987) represent the majority of non-MSC cells 
in a BM aspirate. Before enrichment, the mean proportion of cells expressing a 
CD45+ CD271- CD73- phenotype in BM, FH and RIA samples were 80.3%, 67.8% and 
86.1%, respectively. These cells were depleted in each case to 18.7%, 20.3% and 
35%, respectively, in the Post enriched fraction (Figure 14A). Although CD45+ cells 
were depleted substantially there was still a considerable proportion remaining in 
the Post enrichment fraction.  
There was also a significant population of CD45- cells in BM aspirates, cells 
expressing a CD45- CD271- CD73- phenotype are possibly erythroid progenitor cells 
and RBCs (Della Porta et al. 2006), They initially represented a mean proportion of 
18.2%, 23.5 and 13.4%  of the cellular content of the Pre fraction of BM, FH and RIA, 
respectively;  this was substantially increased following enrichment to 59.2% in BM, 
but was reduced in FH and RIA to 14.2% and 5.1%, respectively (Figure 14B).  
Additionally as detailed in Chapter 3, BM contains a significant portion of cells that 
express CD271 at a low level as well as the CD45 antigen (CD45+ CD271low CD73-) 
shown in Figure 12C. Since the microbeads used in this CliniMACS-based procedure 
are specific to CD271 only, contamination of the Post enrichment positive fraction 
with this ‘passenger’ cell type was anticipated. There was however, a relatively 
modest increase in this population in BM and FH from a mean of 0.48% and 1.42% 
to 7.10% and 5.46%. When RIA samples were analysed, a more substantial increase 
in the proportion of these cells was detected, from 0.24% to 18.2% (Figure 14C).  
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Lastly, it is important to note that total cell viability was not substantially 
compromised by the enrichment process. Mean cell viability, measured by 
exclusion of DAPI, dropped slightly after enrichment in BM and RIA from 92.6% and 
97.7% to 89.2% and 91.4%. There was a more substantial drop in viability in FH 
samples, from 89.4% to 74.6% (Figure 14D), possibly due to increased sample 
storage, and enzyme treatment. 
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Figure 14: Unwanted cell content and total cell viability Pre and Post CliniMACS 
enrichment 
The proportion of cells expressing a CD45+CD271-CD73- (A), CD45-CD271-CD73- (B) 
and CD45+ CD271lowCD73- (C) phenotype Pre (white bar) and Post (grey bar) 
CliniMACS enrichment procedure. Values above each box pair show mean fold 
change. The proportion of viable cells Pre (white bar) and Post (grey bar) CliniMACS 
enrichment (D). All data n=3 displayed as mean and standard deviation.  
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4.3.4.  Examining the MSC enrichment efficiency of the 
CliniMACS system 
Volumetric flow cytometry and CFU-F assays were used to assess the absolute 
number of MSCs present in the Pre enriched samples and in the Post enriched 
positive fractions. The total number of CD45-CD73+ cells in BM, FH and RIA dropped 
from 6.4x105, 5.0x107 and 1.1x107 to 2.9x104, 1.88x106 and 3.08x105, respectively 
(Figure 15A). A similar drop was observed in the number of double-positive (CD45-
CD73+CD271+) cells in BM, FH and RIA, from 5.1x105, 2.6x107 and 5.8x106, to  
2.9x104, 1.6x106 and 2.7x105, respectively (Figure 15B).  
Further confirmation of substantial losses in MSC numbers was given by analysis of 
the total number of CFU-Fs in the Pre and Post enrichment fractions. No data was 
collected for BM aspirates, but the mean total number of colonies in FH dropped 
from 7.5x106 to 2.4x105 and from 1.8x105 to 1.2x104 in the RIA (Figure 15C).  
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Figure 15:  Analysis of the MSc isolation Efficiency of the CliniMACS system 
The total number of cells expressing a CD45-/low CD73+ (A) and CD45-/low CD73+ 
CD271+ (B) phenotype and the total number of CFU-Fs (C) present in sample Pre 
(white bar) and Post (grey bar) CliniMACS enrichment. Values above each box pair 
show the proporation of cells recovered in the Post fraction, as percentage of Pre 
fraction. All data n=3 displayed as mean and standard deviation. 
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4.3.5. Where are MSCs lost during the CliniMACS enrichment 
procedure 
During the enrichment process there are several possible stages where MSCs could 
be lost. To assess the possible cause of MSC loss I analysed all cell fractions 
generated throughout the enrichment process from BM aspirate (n=1) by flow 
cytometry, in this case by examining the CD45-/low CD271+ population. These were: 
the Pre fraction (the BM immediately following collection), the cell suspension 
immediately prior to cell separation (before separation, BS) fraction, the 1st and 2nd 
wash fractions, the cells discarded in the supernatant following washing, the cells 
discarded in the negative fraction and the cells collected in the Post fraction. This 
experiment is shown in Figure 16.  Of the initial 4.9x105  CD45-/low CD271+ cells 
present in the unprocessed BM (Figure 16A) roughly half were lost prior to initiation 
of the automated portion of the separation procedure (Figure 16B). These losses 
could not be accounted for by loss from the discarded supernatant (Figure 16C-D). 
Of the remaining MSCs, 12% were discarded in the negative fraction (Figure 16E) 
and only 3.1x104 MSCs representing 12% of the 2.6x105 loaded into the CliniMACS 
device,  were recovered in the positive fraction, although at relatively high purity 
(Figure 16F). 
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Figure 16: MSC content in process fractions generated by CliniMACS enrichment. 
Representative dot plots showing total MSC number and percentage purity in 6 
fractions generated as a result of the CliniMACS purification procedure. 
Unprocessed (Pre) BM (A), BM immediately prior to bead selection (B), 1st wash 
fraction (C), 2nd wash fraction (D), negative fraction (E), positive fraction (Post) (F). 
Values in top left corners show total number and proportion of MSCs in each 
fraction.  
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4.4. Discussion 
This work demonstrates that BM MSCs can be effectively concentrated using both 
the MarrowStim and SmartPrep 2 concentrator devices. Whereas both significantly 
increased the total cellularity of BM aspirates, the MarrowStim device was more 
effective at increasing MSC concentration relative to its initial value. Despite good 
performance at concentrating the total cellular content of BM aspirates, the 
SmartPrep 2 device was not as effective at concentrating MSCs specifically. The 
discrepancy indicates that efficient concentration of total cellular content does not 
guarantee efficient MSC concentration. The fact that the MarrowStim device 
suffered less from this issue suggests that careful optimisation of the centrifugation 
technique to accommodate the specific characteristics of MSCs could improve the 
efficiency of these devices.  
The number of MSCs in the Pre concentrated BM was far greater in samples 
concentrated with the SmartPrep 2 device, this could be due to the normally high 
variability of MSCs observed in aspirates (D'Ippolito et al. 1999; Pittenger et al. 
1999; Hernigou et al. 2005a). However, since both devices are supplied with the 
reagents and equipment used to obtain aspirates including trocar, subtle 
differences between the equipment used for BM aspiration could also influence 
aspirate quality.  
The failure of either of these devices to increase the purity of MSCs in BM 
reinforces the notion that this type of device is not suitable for allogeneic therapy. 
This is likely the case for other types of concentrator devices based on filtration 
since cell size is the only selection criteria (Dawson et al. 2013; Otsuru et al. 2013). 
Additionally the inclusion of other cell types, particularly large numbers of 
erythrocytes, may be a problem in autologous therapy. Although largely marketed 
as being capable of removing erythrocytes significant numbers can persist, neither 
are erythrocytes  removed in the case of filtration devices (Dawson et al. 2013; 
Otsuru et al. 2013). This is important, since in vitro evidence suggests that colony 
formation is more efficient in the absence of erythrocytes (Horn et al. 2008; Horn et 
al. 2011). Conversely it is likely that platelets are also carried over into the Post 
fraction, this may represent an added benefit since MSCs proliferation is known to 
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be stimulated by platelet derived growth factor (PDGF) (Doucet et al. 2005; Zaky et 
al. 2008; Dhillon et al. 2012). Indeed, platelet rich plasma alone and in combination 
with concentrated BM has been investigated for its potential to promote bone and 
cartilage regeneration, with some success (Betsch et al. 2013; Lee et al. 2014). 
However, it has been suggested that metabolising, contaminating cells may limit 
MSC survival by competing for oxygen and nutrients (Hernigou et al. 2005a). 
Therefore with the exception of platelets, it is desirable to remove as many 
contaminating cells as possible from MSC preparations.  
A high level of enrichment can only be achieved clinically by immunemagnetic cell 
selection. CD271 is an ideal candidate for immunomagnetic cell selection due to its 
ubiquitous expression on BM MSCs and low cross-reactivity with other cell types 
(Jones et al. 2002; Jones et al. 2006; Tormin et al. 2011; Boxall et al. 2012; Bianco et 
al. 2013b). In every case CD271 selection resulted in a substantial increase in the 
proportion of MSCs. Aspirated BM aspirates had the lowest starting proportion of 
MSCs out of all the tissues tested but  enrichment resulted in the highest fold 
increase in purity (186 or 204 fold depending on analysis method used). However, 
MSCs enriched from this source had the lowest final purity. Indeed, the initial purity 
of samples processed with this system seems to largely determine the final purity of 
the product, BM has the lowest initial (0.066%, determined with the CD45-
/lowCD73+CD271+ phenotype) and final purity (13.5%), RIA was intermediate initial 
(0.12%) and final purity (34.9%)  and FH had the highest initial (3.72%) and final 
purity (52.4%).  
Importantly, leukocytes were not fully depleted remaining at around 20% of the 
enriched product in FH , 30% in RIA and 19% in BM aspirate. CD271 enrichment did 
not cause substantial loss of cell viability in the majority of cases, although some 
loss of cell viability was observed after MSC enrichment from FH. However, this 
tissue was stored for a prolonged period and exposed to aggressive enzyme 
treatment, factors that are likely to negatively impact cell survival. Although some 
enrichment of the CD45+CD271low CD73- non-MSC population was observed, in all 
cases these cells were enriched to a lesser degree than that seen with MSCs, 
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suggesting that CD271 microbeads preferentially select MSCs possibly because they 
express high levels of the CD271 antigen (Jones et al. 2002; Tormin et al. 2011).  
The substantial losses of MSCs observed during enrichment demonstrate that this 
magnetic enrichment procedure remains sub-optimal. In one experiment, in which 
this was investigated in detail, approximately 50% of MSCs were lost prior to the 
selection process, most likely as a result of clotting. This may be prevented in the 
future by the inclusion of a more stringent anticoagulation regime such as inclusion 
of ACDA. A substantial proportion of MSCs were not eluted in either the positive or 
negative fractions indicating that these may have been retained within the tubing; 
this could be tested in the future by removing the tubing and flushing with trypsin 
solution followed by flow cytometry. Furthermore, although the proportion of 
MSCs in the negative fraction was substantially lower, they accounted for 
approximately 50% of the eluted MSCs, this may be due to an insufficient number 
of beads present at the labelling stage leading to incomplete or sub-optimal bead 
loading. Although the concentration of beads may be increased, this may also 
increase the level of contamination with CD45+ CD271low CD73- ‘passenger’ cells. 
Although cell recovery may be improved, some cell loss is inevitable and has been 
reported with other rare cell selections using the CliniMACS system. Di Ianni et al 
reported an average recovery of 33.6% for regulatory T-cell selection (Di Ianni et al. 
2011), and Stamm et al reported an average recovery of 19.6% for CD133+ HSCs 
(Stamm et al. 2007).  
There were over 71000 total hip replacements in England and Wales in 2011 
(National Joint Registry for et al. 2011), the ready availability of raw material makes 
isolation from FHs without culture expansion an attractive prospect especially for 
allogeneic transplantation. Furthermore, there are three important issues that must 
be addressed before this approach can be adopted. Firstly, the purity of the end 
product and related to this the composition of the non-MSC contingent of the end 
product. Although allograft containing a limited proportion of leukocytes (~6%) 
(Baboolal et al. 2014)  has already been shown to be safe and effective (Hollawell 
2012; Tohmeh et al. 2012; Ammerman et al. 2013; Neman et al. 2013), cells 
enriched from FH, despite being the purest with respect to MSC content, still 
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contained roughly 20% leukocytes and this raises serious doubts regarding its 
suitability for allogeneic therapy. Further optimisation of CD271 enrichment or a 
second purification step to deplete leukocytes could address this issue. Secondly, 
although poorly understood, aberrant MSC activity has been implicated in the 
progression of OA (Murphy et al. 2002; Zhen et al. 2013). The abnormalities 
described included inappropriate subchondral bone formation driven by TGF-β in 
MSCs (Zhen et al. 2013).  For these reasons further research is required to ascertain 
that MSCs isolated from the osteoarthritic tissue do not possess undesirable 
phenotypic characteristics. Lastly, although allogeneic culture expanded MSCs have 
been shown not to illicit an immune response and are considered safe for 
transplantation (Ringden et al. 2006; Le Blanc et al. 2008; Galipeau 2013), this has 
not been unequivocally demonstrated for uncultured MSCs.  
Intramedullary reaming is also a common procedure often performed prior to 
insertion of intramedullary nails (Porter et al. 2009), and could also provide a 
plentiful source of MSCs for allogeneic therapy. However, collection of MSCs using 
the RIA system has a number of advantages over FHs. Since the tissue that is 
collected is not associated with any underlying disease there is less risk of 
transferring MSCs with undesirable characteristics. Crucially, since no enzymatic 
digestion is required as is the case with FHs (Jones et al. 2010b) therefore, 
processing time is reduced. This makes enrichment from RIA a credible option for 
intraoperative autologous MSC therapy. However, the minimum processing time 
for enrichment from RIA (>4 hours) still remains far greater than the typical 
processing time associated with the BM concentrator devices tested (~15 minutes). 
The absolute number of MSCs required for any given therapy is difficult to 
determine. Hernigou et al showed that successful treatment of fracture non-union, 
by percutaneous injection of concentrated BM, was associated with an average 
total dose of 30,000 MSCs, measured by CFU-F assay (Hernigou et al. 2005a). For 
successful treatment of avascular necrosis of the femoral head, by the same 
method an average of 147,000 MSCs are required (Hernigou et al. 2005b). 
However, Hernigou could not determine if the total dose or the concentration of 
MSCs was the critical factor in determining outcome. Nakamura et al  showed in a 
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pig cartilage defect model that implantation of between 2.2x107 and 3.8x107 MSCs 
could effect some degree of cartilage regeneration (Nakamura et al. 2012). 
However, this study used culture expanded MSCs and is therefore not directly 
applicable to minimally manipulated MSC therapy. One human study, again using 
culture expanded cells for full thickness cartilage repair used 1.3x107 autologous 
cells on average, but did not report any significant clinical improvement (Wakitani 
et al. 2002).  
In the case of non-union and avascular necrosis the numbers of MSCs required are 
attainable from iliac crest aspirates. However, this requires a lengthy and 
technically demanding harvesting technique (Hernigou et al. 2005a; Hernigou et al. 
2013). Additionally, cell losses experienced with CliniMACS enrichment (Stamm et 
al. 2007; Di Ianni et al. 2011) further add to the limitations of using iliac crest 
aspirates in conjunction with this technology. Bone digests have a limited appeal for 
autologous therapy, due to donor site morbidity. RIA aspirates in conjunction with 
CD271-based cell selection have genuine promise as a source of MSCs that may be 
used for autologous therapy in bone and may be a credible alternative to 
concentrated BM. Intramedullary reaming is a relatively simple technique 
(Giannoudis et al. 2009; Cox et al. 2011a; Cox et al. 2011b) and although the 
protocol described in this chapter was sub-optimal, it recovered an average of 
14,000 MSCs, measured by CFU-F assay. Even so, this compared favourably to the 
most successful concentrated BM tested which had a total of 6450 MSCs, measured 
by CFU-F assay. If efficiency could be improved to a level comparable with other 
rare cell enrichments using the CliniMACS (Stamm et al. 2007; Di Ianni et al. 2011), 
the number of MSCs recovered may be substantially improved. 
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5. Characterisation of the membrane generated as a 
result of the Masquelet technique 
5.1. Introduction 
5.1.1.  Critical size defects 
Large bone defects represent a particular challenge in the field of clinical 
orthopaedics. A critical size defect is defined as a bone defect that cannot be 
spontaneously bridged and is therefore, beyond the capacity of the bone to self-
heal leading to non-union (Gugala 2007; Dimitriou et al. 2011b; Dimitriou et al. 
2012). It is generally accepted that a defect ≥ 1.5 to 2 times the diameter of the 
long bone diaphysis is of a critical size (Gugala 2007; Dimitriou et al. 2012). Several 
factors influence the likelihood that a defect will progress to non-union including 
the mechanical environment, the location of the defect, the condition of the 
surrounding soft tissue and patient related factors such as age and related co-
morbidities (Dimitriou et al. 2005; Talbot et al. 2008; Reichert et al. 2009). They 
may result from trauma, tumour resection, infection, deformity correction or 
aseptic loosening around implants (Gugala 2007; Dimitriou et al. 2011b; Dimitriou 
et al. 2012).  
Several methods for bone reconstruction exist but all have specific limitations. 
Autologous cancellous bone grafting is the most common approach but this has 
major shortcomings. These include poor structural integrity, limited availability of 
graft material and donor site morbidity also, this approach is not suitable for 
defects larger than 6cm due to rapid graft resorption (Gugala 2007). Distraction 
osteogenesis and bone transport is capable of regenerating larger bone defects. 
Here following mechanical stabilisation, closure of the defect is achieved by bone 
transport, simplistically this means pushing the remaining bone together to close 
the defect (Tsuchiya et al. 1997). A fracture is then made in an area of healthy bone 
whilst keeping the periosteum intact. Bone is then regenerated by gradual 
mechanical stretching of the newly formed callus allowing constant vascularisation 
and remodelling (Tsuchiya et al. 1997), a process that mimics longitudinal bone 
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growth in adolescence. However, this process is technically demanding and has 
several disadvantages, the most important of which is the lengthy treatment period 
required, both in the distraction phase (1mm per day) and the consolidation period, 
which is usually twice that of the distraction phase (Gugala 2007; Dimitriou et al. 
2011b). Quarto et al suggested an alternative which relies on in vitro expansion of 
autologous MSCs followed by seeding onto a porous ceramic scaffold (Quarto et al. 
2001). This scaffold was then implanted into >4cm defects and integration into the 
host bone was observed after two months (Quarto et al. 2001). The speed of 
healing demonstrated was impressive however, this technique has not been 
adopted widely, perhaps due to technical, regulatory and logistical difficulties 
associated with the use of in vitro expanded MSCs in this setting. 
 
5.1.2.  Guided bone regeneration and the use of barrier 
membranes 
The concept of guided bone regeneration, to treat bone defects, was initially 
developed based on the hypothesis that a non-cell permeable membrane can 
exclude the invasion of inhibiting cells to the defect site; whilst simultaniously 
allowing angiogenic and osteogenic cell ingress from the BM (Greenstein et al. 
2009; Dimitriou et al. 2012; Dahlin et al. 2014). Initial experiments using a Teflon 
membrane for repair of a mandibular defect in rats demonstrated the efficacy of 
non-absorbable membranes for this approach (Dahlin et al. 1988). Non bio-
absorbable membranes are available as Polytetrafluoroethylene (PTFE, Teflon), 
titanium reinforced PTFE and titanium mesh (McAllister et al. 2007; Francois et al. 
2012). Bone regeneration involves angiogenesis and ingress of osteogenic cells from 
the periphery towards the centre of the defect followed by woven bone deposition 
and finally remodelling and lamellar bone formation (McAllister et al. 2007; 
Dimitriou et al. 2012).  
Despite the success demonstrated with PTFE, the outcome of therapy using this 
type of membrane was limited due to complications of soft tissue dehiscence 
leading to membrane exposure and infection (McAllister et al. 2007). This led to the 
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development of bio-absorbable scaffolds and these are now available as synthetic 
or natural polymers. Aliphatic poly-esters such as polyglycolic acid are the most 
widely used synthetic polymers (Cheung et al. 2007; Gloria et al. 2010); whereas, 
cross-linked bovine collagen is the most commonly used natural bio-absorbable 
polymer (Behring et al. 2008; Dimitriou et al. 2012).   
 
5.1.3.  The induced membrane technique 
The Masquelet or induced membrane (IM) technique is a two stage procedure 
which involves the implantation of a cement spacer into the defect site in the first 
stage, resulting in the induction of a biological membrane around the implant 
(Giannoudis et al. 2011; Dimitriou et al. 2012; Gruber et al. 2012). At the second 
stage (6-8 weeks later) the cement is removed and the IM serves as a conduit to 
contain autologous cancellous bone graft which may be augmented by BMPs and 
BM aspirate (Giannoudis et al. 2011; Dimitriou et al. 2012; Cuthbert et al. 2013). 
Using this procedure Karger et al treated patients with defects larger than 10cm, 
using the IM technique and union was achieved in an average of 9 months with a 
success rate of 94% (Karger et al. 2012). Moreover, time to union was not 
dependent on defect size (Karger et al. 2012); this is important given that defects of 
up to 25cm have been repaired using the IM technique (Masquelet et al. 2000). 
These impressive results have generated interest in the properties of the IM itself. 
Animal studies have shown the IM to have osteogenic, osteoinductive and 
angiogenic properties, (Pelissier et al. 2004; Masquelet et al. 2010), but to date 
there have been no studies addressing the functional properties and characteristics 
of the IM in man. The anatomical location of IM in relation to the cement spacer 
implant closely resembles that of the diaphyseal periosteum in relation to 
underlying bone, suggesting that these tissues may be analogous.  
The periosteum is widely recognized to be of critical importance in bone formation 
and regeneration (Young 1962; Arnsdorf et al. 2009; Chan et al. 2012). Structurally 
it is divided into two distinct layers: an inner cambium layer and outer fibrous layer 
(Squier et al. 1990; Fan et al. 2008). The cambium layer has been shown to be a 
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reservoir of progenitor cells with an osteogenic potential comparable to BM derived 
MSCs and superior to synovial MSCs (Ng et al. 2005; De Bari et al. 2006; De Bari et 
al. 2008; Arnsdorf et al. 2009). The presence of intact periosteum has been shown 
to be an important factor in successful fracture healing (Knothe et al. 2005; Yu et al. 
2010), it is also highly vascularized and provides the cortical blood supply (Squier et 
al. 1990; De Bari et al. 2006; Fan et al. 2008). Following injury, an acute 
inflammatory reaction can be seen at the periosteum, this leads to periosteal cell 
proliferation and thickening of the periosteum itself, a process known as periosteal 
activation (Lin et al. 2014). Periosteal cells are critical for callus formation and 
induce robust chondrogenesis and osteogenesis accompanied by marked 
vascularization (Colnot et al. 2012). 
Given the excellent bone repair achievable by the IM technique and given the 
ability of MSCs to heal bone, a simple yet attractive hypothesis is that the IM 
technique leads to large scale recruitment of native MSCs to effect bone repair.   
This concept has been demonstrated for cartilage repair using a hydroxyapatite 
scaffold coated with TGF-β3 infused collagen type 1 (Lee et al. 2010). For bone 
regeneration an electrospun barrier membrane composed of poly-caprolactone and 
β-gelatin loaded with SDF-1, a potent MSC chemokine (Kitaori et al. 2009), was six 
times more effective than membrane alone in a rat model (Ji et al. 2013). These 
studies demonstrate the utility of recruiting endogenous MSCs to sites of tissue 
injury and thereby maximising the body’s own regenerative capacity. 
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5.1.4.  Chapter aim and objectives 
The aim of this chapter was to investigate the regenerativeproperties of the IM 
harvested from a series of patients undergoing treatment for large diaphyseal 
defects, in order to identify characteristics that may facilitate bone repair. 
Objectives: 
1. To use histology and immunohistochemistry techniques to build 
understanding of the morphology and localization of cells, growth factors 
and chemokines involved in bone regeneration. 
2. Use flow cytometry to investigate the cellular composition of IM and 
periosteum, in order to identify potentially regenerative cells present in IM. 
3. To confirm the presence of MSCs by examining the differentiation capacity 
of enzymatically released cells, in order to gain an understanding of the 
regenerative potential of IM.   
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5.2. Materials and methods 
5.2.1.  Surgical procedures and patient selection 
All procedures in sections 5.2.2 to 5.2.4 were carried out by clinical staff at the 
Academic unit of Trauma and Orthopaedics, Clarendon Wing, Leeds Teaching 
Hospitals NHS Trust. 
 
5.2.2.  Patient inclusion criteria  
Patients were selected from those admitted for treatment of either upper or lower 
extremity bone loss using the IM technique and invited to participate in this study. 
Patients that underwent treatment of bone defects by other methods of bone 
regeneration (i.e. distraction osteogenesis, allograft implantation following tumour 
excision) were excluded.  
 
5.2.3.  Patient characteristics 
Eight patients (7 male, 1 female) with a mean age 60 years (18-80) gave their 
consent to participate in this study. All defects were of post-traumatic nature. The 
distribution of the anatomical site of the defect is shown in Appendix 5. The mean 
size of the defect was 36.25mm (range 25-50mm). Six cases (numbers 1,2,3,4,6,7) 
were infected non-unions, most commonly with staphylococcus aureus, whereas 2 
cases (numbers 5,8), were aseptic bone defects.  
 
5.2.4.  Induced membrane technique and tissue harvesting  
An incision was made adjacent to the defect area of the affected limb. Once skin 
and muscle tissue had been withdrawn dead damaged or infected tissue was 
removed (debridement) from the defect area and a polymethyl methacrylate 
(PMMA) cement spacer (Heraeus Medical GmbH) was implanted. The affected limb 
was then stabilised with external fixation, by six to eight week following the initial 
stage an IM had formed around the cement spacer. The spacer was then removed, 
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during the second stage of the procedure by re-opening the defect site as before 
and incising the IM then removing the cement spacer. An area of at least of 1cm2 of 
IM tissue was harvested at the centre of the bone loss area (Figure 17). 
Subsequently, a 1cm2 sample of periosteum was harvested from the normal 
diaphyseal bone, this served as a control tissue for IM due to its similar localisation 
and the recognised importance of periosteum to bone regeneration (Young 1962; 
Arnsdorf et al. 2009; Chan et al. 2012). 
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Figure 17: Intra operative photograph showing the induced membrane 
Induced membrane (1) separated and elevated off the cement spacer (2) (tibial 
defect). Photograph kindly provided by P. Giannoudis. 
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5.2.5.  Digestion of IM and periosteum to release resident cells 
Tissue samples were bisected; 50% of each sample was retained for histological 
processing. Under sterile conditions the remaining tissue was first shredded using a 
scalpel, once transferred to a 50ml centrifuge tube, its total wet weight was 
recorded. The tissue was then enzymatically digested with collagenase as previously 
described (2.4). The resulting single cell suspension was then washed by dilution 
with 10ml of PBS, centrifugation at 400xg and re-suspension. Subsequently cells 
were manually counted and aliquots of 1x105 cells were taken for volumetric flow 
cytometry, as previously described (2.5) or frozen using standard freezing media 
(Appendix 2) at 5x105cells/vial. Freezing was used to ensure functional assay 
reproducibility owing to the rarity of these samples and the long intervals between 
collections. 
 
5.2.6.  Processing of IM and periosteum and preparation of 
histological slides 
To preserve tissue architecture and prevent mortification prior to the preparation 
of histological tissue sections, the collected tissue was embedded into paraffin wax 
blocks. The tissue was first incubated overnight at RT in fixing buffer (Appendix 2), 
once fixed samples were stored in 70% ethanol. Subsequently, tissue was loaded 
into an ASP300 (Leica Biosystems) tissue processor for graded alcohol dehydration 
followed by xylene and wax impregnation. Once processing was complete, the 
tissue was mounted into wax blocks and 4µm sections were prepared using a 
RM225 rotary microtome (Leica Biosystems). 
 
5.2.7.  Recovery of frozen cells from digested tissue 
Cryopreserved samples were defrosted and transferred to 10ml fluorescence 
activated cell sorting (FACS) buffer (Appendix 2) containing 20 U/ml DNAse I (Sigma 
Aldrich). Cells were centrifuged at 400xg and re-suspended in 150l of the same 
solution and counted manually. Two 45l aliquots were put aside for flow 
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cytometry, 2.4x105 cells were put aside for CFU-F assay and the remaining cells 
were expanded to generate MSC cultures as previously described (2.9). 
 
5.2.8.  CFU-F assay 
CFU-F assay was performed to enumerate the MSCs recovered from the digested 
tissue. Recovered cell were seeded into duplicate 35mm diameter tissue culture 
dishes (Corning) at a density of 1.2x105 cells/dish, the assay then proceeded as 
previously described (2.7). 
 
5.2.9.  Flow cytometry  
Flow cytometry was performed to examine the cellular composition of IM and 
periosteum. Two aliquots of cells were incubated in FACS buffer with 10% v/v FcR 
blocking reagent (Miltenyi) for 20 minutes at RT. Each aliquot was then incubated 
for 20 minutes at RT with one of 2 preparations of monoclonal antibody cocktails: 
Mix 1: CD271-APC, CD45-PECy-7, CD146-PE, CD34-PcP, CD90-FITC. Mix 2: CD271-
APC, CD45-PECy-7, CD146-PE, CD73-PcPCy-5.5, CD31-FITC (Appendix 4).  Cells were 
subsequently centrifuged at 400xg for 5 minutes and re-suspended in 500l FACS 
buffer (Appendix 2) the cell suspension was analysed using a LSR II flow cytometer 
(BD). Single antibody stained and unstained controls were used before each 
experiment to ensure accurate spectral compensation. 
 
5.2.10.  Differentiation assays 
Enzymatically recovered MSCs were expanded as previously described (2.9) to 
provide a minimum of 5x105 total cells; this required up to 2 passages. Cells were 
then seeded for osteogenic differentiation, as previously described (2.10). For 
chondrogenic differentiation, cells were seeded into ChondroPrime SF media (PAA 
laboratories), otherwise differentiation proceeded as previously described (2.14). 
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For adipogenic induction cells were seeded into NH adipoDiff medium (Miltenyi), 
otherwise differentiation proceeded as previously described (2.13).   
 
5.2.11.  Haematoxylin and eosin staining of sectioned IM and 
periosteum tissue  
Paraffin-embedded tissue sections (4μm thick) were de-waxed by 3 serial 
incubations in xylene for 5 minutes at RT and rehydrated through a graded ethanol 
series to water 100% ethanol 3x1 minute, 90% ethanol 1x1 minute, 70% ethanol 
1x1 minute, dH2O 1x3 minutes. Sections were then incubated in Mayer’s 
haematoxylin solution (Sigma Aldrich) for 5 minutes, washed under running water 
briefly and transferred to Scott’s Tap-water substitute (Appendix 2). After a second 
brief wash in running water, sections were transferred to eosin Y solution (Sigma 
Aldrich) and incubated at RT for 1 minute. Sections were then washed in running 
water again before being de-hydrated by reversing the re-hydration schedule above 
and returned to xylene. Finally sections were mounted using DPX mountant (Sigma 
Aldrich). Photomicrographs were taken using a C7070 digital camera (Olympus, 
Tokyo, Japan) attached to an Eclipse E1000 microscope (Nikon). These images were 
then analysed using NIS elements BR 2.20 imaging software (Nikon, Tokyo, Japan), 
for measurements of IM and periosteum thickness. 
 
5.2.12.  Immunohistochemistry  
Immunohistochemistry was used to determine the tissue localisation of specific cell 
types and proteins and was carried out on formalin-fixed paraffin embedded 
histological tissue sections. Immunohistochemistry staining was performed using a 
REAL peroxidise/DAB+ detection system (Dako) and specific mouse and rabbit 
primary antibodies to detect CD271, CD31, CD146, BMP-2, SDF-1 and VEGF 
(Appendix 4). Paraffin-embedded tissue sections (4μm thick) were de-waxed in 
xylene and rehydrated through a graded ethanol series to water (5.2.11). 
Endogenous peroxidase activity was quenched by incubation with peroxidase block 
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kit component; antigen retrieval was performed in a 900W microwave oven for 
10min with 10mM citrate buffer (pH 6.0). Non-specific binding sites were blocked 
by 30 minute RT incubation with antibody diluent solution (Life Technologies). 
 All primary antibodies were diluted with antibody diluent (Dako, refer to Appendix 
4 for working concentrations).  Secondary antibody labelling and colour 
development were carried out according to Dako REAL peroxidise kit instructions.  
Sections were counterstained by a 5 minute RT incubation with Mayer’s 
haematoxylin solution (Sigma Aldrich), followed by a 1 minute RT incubation in 
Scott’s tap-water substitute (Appendix 2). The slides were dehydrated by incubation 
in a graded ethanol series (5.2.11) and ‘cleared’ with xylene before being mounted 
with coverslips with DPX mountant (Sigma Aldrich). Positive control tissue 
(umbilical cord liver and kidney) was used to assess antibody specificity, negative 
controls (omission of primary antibody) were included in each assay. 
Photomicrographs were taken using a C7070 digital camera (Olympus). 
 
  
133 
 
5.3. Results 
5.3.1.  Histological comparison  
In order to understand the morphology of IM and how this may be related to its 
functional characteristics, a histological and immunohistochemical examination of 
IM was carried out using periosteum as a comparator. The gross morphology as 
well as the localisation of cells and extracellular factors known to be associated with 
bone and blood vessel formation was examined. The cell markers CD31 (endothelial 
cells) (Garlanda et al. 1997), CD271 (MSCs) (Jones et al. 2002; Tormin et al. 2011) 
and CD146 (Pericytes) (Chen et al. 2009) were chosen as well as the extracellular 
factors VEGF (blood vessel formation) (Gerber et al. 1999), BMP-2 (osteogenesis 
induction) (Noel et al. 2004) and SDF-1 (MSC migration) (Ponte et al. 2007).  All 
antibodies performed well with strong positive staining in control tissues, no 
staining was observed in negative controls (Figure 18). 
The IM shared a number of morphological features with periosteum including the 
presence of layers analogous to the inner cellular cambrial layer and outer 
fibroblastic/collagenous layer observed in periosteum (Squier et al. 1990; Chan et 
al. 2012). However, in IM the total median thickness was significantly greater: 
1422m (range:  981-2126) compared to 860m (range: 468-1019) in periosteum 
(p=0.032) (Figure 19A). The presence of blood vessels was confirmed by CD31 
expression at the luminal border of vessels (Figure 19B). Perivascular CD146 
positive staining was indicative of the presence of pericytes (Chen et al. 2009) in 
both periosteum and IM (Figure 19C). The presence of CD271, a marker of BM 
MSCs (Jones et al. 2002; Quirici et al. 2002) was observed in high abundance in both 
tissues; staining was always closely associated, but not limited, to blood vessels 
(Figure 19D).   
Tissues were also stained for molecules known to be important in osteogenesis and 
vessel formation (Pelissier et al. 2004). BMP-2 was predominantly observed on the 
luminal edges and the outer border of blood vessels in both tissues (Figure 19E). 
VEGF and SDF-1 expression was found throughout the structure of blood vessels in 
both tissues (Figure 19F-G). Semi-quantitative scoring of the intensity of staining 
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(Smith et al. 2006) for these molecules did not reveal any significant differences 
(Figure 20).  
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Figure 18: Immunohistochemistry controls. 
Figure shows example positive control staining for CD271 in umbilical cord (x200 
magnification) (A), CD146 in umbilical cord (x100 magnification) (B), CD31 in 
umbilical cord (x200 magnification) (C), BMP-2 in kidney (x100 magnification) (D), 
VEGF in liver (x200 magnification) (E), and SDF-1 in kidney (x200 magnification) (F). 
G, H and I show negative controls (omission of primary antibody) in umbilical cord 
(x100 magnification), kidney (x100 magnification) and liver (x100 magnification) 
respectively. Umbilical cord, kidney and liver sections were kindly donated by D. 
Kouroupis and M Shires. 
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Figure 19: Tissue architecture cell and growth factor localisation in IM and control 
periosteum 
Histological sections stained with haematoxylin and eosin, i: inner cellular layer, ii: 
outer fibrous layer (x40 magnification) (A). Sections labelled with specific antibodies 
to CD31 (B), CD146 (C), CD271 (D) BMP-2 (E), VEGF (F) and SDF-1 (G) (all x200 
magnification), white arrows indicate regions of positive staining. 
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Figure 20: Semi-quantitative scoring of extracellular protein expression 
Manual histological scoring of VEGF (A), SDF-1 (B) and BMP-2 (C) expression in 
periosteum (PO) n=5 and induced membrane (IM) n=7. Total labelled protein 
expression ranked 0-3 where 0=no staining, 1=weak staining, 2=moderate staining 
and 3=strong staining. Slides were kindly scored blind by Thomas Baboolal. 
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5.3.2.  Quantitative comparison of cellular composition 
following enzymatic release 
The total number of viable cells per gram of tissue measured by flow cytometry 
immediately following enzymatic digestion was 11-fold higher in IM (p=0.043), 
compared to matched periosteum (Figure 21A). In IM the number of infiltrating 
lymphocytes identified as CD45+ with a low side scatter profile (Jones et al. 2010a) 
per gram of tissue was greatly increased, with IM having 31-fold more lymphocytes 
(median 9.9x105) than periosteum (median 3.2x104,Figure 21B); this possibly 
reflects a more active process of immune cell recruitment. Similarly, the number of 
CD45-/lowCD271+ cells/gram was greater by a factor of 15.5 in IM (median 1.4x106) 
compared to matched periosteum (median 8.7x104, p=0.043, Figure 21C). Leading 
on from this, a more detailed phenotypic analysis was performed on cryogenically 
preserved cells (5.2.7). The relative proportion of endothelial cells, identified as 
CD45-CD31+(Jones et al. 2010a) was comparable in IM and periosteum (Figure 22A). 
However, the proportion of cells expressing markers of pericytes (CD45-CD34-
CD146+) (Chen et al. 2009) was 3 fold greater in IM (p=0.043, Figure 22B).  
 
  
138 
 
 
 
Figure 21: Cell composition measured by volumetric flow cytometry immediately 
following enzymatic digestion of matched periosteum (PO) and induced 
membrane (IM). 
Total viable cells (A), infiltrating lymphocytes (B), and CD45-CD271+ cells (C), 
expressed as cells per gram of digested tissue. For (B) and (C) events were gated on 
DAPI- (live cells) prior to gating shown.  Absolute cell numbers were calculated by 
inclusion of a volumetric counting bead. Cell populations of interest are highlighted 
in coloured boxes green: Periosteum (left), red: Induced membrane (right). All data 
n=5, * denotes p<0.05. 
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Figure 22: Cell composition measured by flow cytometry following recovery of 
frozen enzymatically released cells from matched periosteum (PO) and induced 
membrane (IM). 
Proportion of CD45-CD31+ endothelial cells (A), events were gated on DAPI- (live 
cells) prior to gating shown. CD45-CD34-CD146bright pericytes (B), events were gated 
on DAPI- and CD34- prior to gating shown to exclude endothelial cells. Cell 
populations of interest are highlighted in coloured boxes-green: Periosteum (left), 
red: Induced membrane (right). All data n=5, * denotes p<0.05. 
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5.3.3.  Colony forming potential 
To investigate the proportion of MSCs present in IM and periosteum able to initiate 
MSC colonies, the colony forming potential of enzymatically released cells was 
determined. Following enzymatic digestion, adherent colonies grow readily from 
both tissues; colonies were composed of fibroblastoid cells which were highly 
proliferative and formed discrete radial colonies (Figure 23A). There was no 
significant difference between the proportion of MSCs between matched 
periosteum and IM (n=6, Figure 23B). This was surprising given the highly elevated 
number of CD45-/lowCD271+ cells detected in IM by flow cytometry. 
 
5.3.4.  Differentiation potential 
Adherent, culture expanded cells (passage 2) derived from enzymatically digested 
matched tissues (n=5) were subjected to conditions promoting adipogenesis, 
chondrogenesis and osteogenesis. In adipogenic conditions, accumulation of lipid 
vacuoles was observed and highlighted by uptake of Oil Red (Figure 24A). Cell 
pellets obtained from cultures derived from both tissues exposed to chondrogenic 
conditions displayed cartilage specific metachromasia when stained with toluidine 
blue (Figure 24B).  Osteogenic culture conditions led to induction of alkaline 
phosphatase after 14 days to similar degrees in both tissues. The degree of calcium 
deposition at 21 days post induction was also similar in both periosteum and IM 
(Figure 24C). Altogether, these data demonstrated that enzymatically released, 
plastic adherent cells from both tissues possessed tri-lineage differentiation 
potential upon expansion, thus confirming that they were true MSCs with the 
capacity to participate in tissue regeneration. 
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Figure 23: Colony forming potential following recovery of frozen enzymatically 
released cells for matched periosteum (PO) and induced membrane (IM). 
Representative duplicate donor-matched CFU-F plates generated by cells released 
from digested periosteum and induced membrane, stained with methylene blue (1 
colony >50 tightly clustered cells) (A).  The Proportion of the 1.2x105 cells seeded 
into each dish that resulted in the formation of a colony n=6 (B). Box plot shows 
interquartile range median and extreme values. 
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Figure 24: Differentiation potential following recovery of frozen enzymatic 
digested tissue: matched periosteum (PO) and induced membrane (IM). 
Representative donor matched wells following adipogenic induction, adipocytes 
shown by uptake of oil red (x400 magnification) (A). Chondrogenic pellets showing 
purple metachromasia (cartilage) after toluidine blue staining of cell pellets (x200 
magnification) (B). Calcium generated per well from osteogenic cultures with 
matched alkaline phosphatase (upper, blue) and alizarin red (lower, red) stain n=5 
(C). Box plot shows interquartile range median and extreme values. 
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5.3.5.  Examination of MSC transcriptional profile 
Matched IM and periosteum samples (n=5) were cultured up to passage 2 RNA was 
isolated and cDNA was produced for analysis on a Taqman low density array (Life 
Technologies) [34]. Five donor matched IMs and periosteum were analysed, 
together with control unmatched, passage 2 iliac crest BM-MSCs (n=4) and skin 
fibroblast cell lines (n=3, Lonza and ATCC). All gene expression was normalised to 
HPRT. Open-source clustering software utilising clustering methods described by 
Eisen et al was used to perform cluster analysis.  
The expression level of genes known to influence MSC proliferation, osteogenesis, 
chondrogenesis, migration and stimulation of angiogenesis were measured. These 
included receptors for fibroblast growth factor (FGF) and PDGF (proliferation) 
(Gronthos et al. 1995; Zaragosi et al. 2006), proteins associated with TGF-β/BMP 
and WNT signalling (osteogenesis) (Bennett et al. 2007; Chen et al. 2012), aggrecan 
and sex determining region Y box 9, (chondrogenesis) (Yano et al. 2005), SDF-1 
(migration) (Miller et al. 2008) and VEGF (angiogenesis) (Sato et al. 2011). Analysis 
revealed close clustering between periosteum and IM MSCs. MSCs from both these 
tissues clustered more closely to iliac crest MSCs than negative control fibroblasts 
(Figure 25A). When the molecular profile of IM MSCs was compared to those 
originating from the periosteum the gene encoding SDF-1 was significantly up-
regulated (p=0.043, Figure 25B). All other transcripts showed no significant change. 
This data further confirms that MSCs are present in the IM, the increase in SDF-1 
transcript may suggest a potential mechanism for regenerative cell recruitment to 
IM. 
Analysis of the transcriptional profile of expanded MSCs from periosteum and IM 
was undertaken by Sarah Churchman. 
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Figure 25: Molecular profile of induced membrane and periosteum derived MSCs 
Cluster analysis of log 2 transformed relative expression data: 2-ΔΔCt normalised to HPRT 
(A). IM - induced membrane, PO - matched periosteum, BM - control bone marrow (a-d) 
and FIB – fibroblasts (C: CRL-2063, H: HFF1 and N-NHDF). Green < HPRT, red > HPRT, 
black = HPRT, grey is missing data n=17. (B), mean fold change of relative expression 
data; comparative 2-ΔΔCt method normalising to HPRT and periosteum n=5. Yellow 
indicates p<0.05, inlayed: difference in expression (2-ΔΔCt) of CXCL12 (SDF-1) between 
matched periosteum and induced membrane. Data provided by Sarah Churchman 
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5.4. Discussion 
The purpose of this chapter was to investigate the cellular and molecular basis for 
the excellent fracture healing noted in man following the use of the Masquelet or 
IM technique (Masquelet 2003; Retzepi et al. 2010).   Experiments in a rabbit model 
have shown some important characteristics of IM, such as vascularisation and 
production of VEGF, TGFβ1 and BMP-2, (Pelissier et al. 2004). Additionally the 
presence of MSCscapable of differentiation into bone and cartilage has been 
demonstrated in a rat model (Gruber et al. 2012). However no human studies 
detailing the characteristics of IM had been reported. The IM and periosteum 
shared strong architectural similarities including, vascular features and growth 
factor expression. This suggests that IM is actively participating in new bone 
formation and these tissues share common functional roles. 
The colony forming potential and tri-lineage differentiation capacity of 
enzymatically released cells confirmed that IM is a rich source of MSCs. 
Furthermore, the number of CFU-Fs generated from IM and periosteum was similar 
and both far greater than the observed frequency in BM aspirates. Chapter 3 of this 
thesis demonstrated that the absolute number of CD45-/lowCD271+ cells to closely 
correlate with the number of CFU-F colonies generated from BM aspirates. This was 
not replicated in periosteum or IM digests, suggesting that CD271 expression is not 
limited to MSCs in this tissue. This is interesting due to the significantly increased 
number of cells expressing CD271 in the IM and warrants further investigation. The 
histological composition of the IM showed that it was well vascularised and 
comparable to periosteum, but the membrane was much thicker.  In keeping with 
this, flow cytometry revealed an increased number of cells with a pericyte 
phenotype suggesting more active vessel formation and/or maturation (Chen et al. 
2009; Stratman et al. 2012).  
The molecular analysis of expanded cells from IM and periosteum revealed a 
broadly similar RNA profile to BM-MSCs, but significantly different from skin 
fibroblasts with respect to osteoprogenitor and chondroprogenitor transcripts. 
However, the relative abundance of SDF-1 transcript (CXCL12) was greater in 
expanded cells from IM compared to periosteum. SDF-1 is a chemokine released by 
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MSCs which acts on a number of cell types including MSCs themselves (Ponte et al. 
2007), endothelial progenitor cells, haematopoietic lineage cells and 
haematopoietic stem cells (Ponte et al. 2007; Miller et al. 2008; Maksym et al. 
2009). The expression of this molecule has been validated by staining for SDF-1 
protein on tissue biopsies, and was shown to be present in the areas surrounding 
vessels. It is possible that SDF-1 is involved in autocrine and paracrine regulation of 
MSC trafficking into the newly-formed tissue. This property of IM derived MSCs 
suggests an enhanced ability to recruit cells into the defect area capable of directly 
or indirectly participating in tissue repair. The increased numbers of lymphocytes 
found in IM also supports this hypothesis.  
Additionally, expanded MSCs from both tissues showed similar osteogenic 
potential. Therefore, the regenerative capacity of these tissues in vivo is likely to be 
comparable, an important finding given the recognised importance of periosteum 
in both endochondral and intramembranous ossification during fracture healing 
(Chan et al. 2012). In order to achieve the number of cells required to demonstrate 
tri-lineage differentiation some culture expansion was carried out. The effect of 
culture expansion on MSC tri-lineage potential has been well documented, as the 
number of population doublings increases differentiation capacity declines (Banfi et 
al. 2002; Wagner et al. 2008; Wagner et al. 2009) this particularly affects adipogenic 
differentiation, which has been shown to decline more rapidly with culture 
expansion than osteogenic and chondrogenic differentiation potentials (Wagner et 
al. 2008) and may explain the low level of adipogenesis observed. Similarly it has 
been shown that phenotypic properties of MSCs such as their immunosuppresive 
capacity can be transiently suppressed following freezing (Francois et al. 2012). For 
these reasons it is possible that in vivo MSCs in both periosteum and IM have 
greater differentiation capacity than observed in vitro. 
The implantation of a scaffold that replicates the ability of a cement spacer to 
induce membrane formation, without the need for removal at a later stage could 
result in improved clinical outcomes. Therapy could be carried out as a one-step 
procedure, minimising economic impact and patient recovery time. This would 
represent a radically simple and inexpensive approach compared to alternative 
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strategies that have been suggested such as composite scaffolds (Wang et al. 2007), 
decellularised bone scaffolds (Grayson et al. 2010) and bioactive scaffolds 
incorporating growth factors such as BMP-2 and VEGF (Huang et al. 2005; Niu et al. 
2009). Such approaches normally incorporate extensive MSC culture expansion and 
are therefore subject to regulation under GMP guidelines further increasing their 
cost (Couto et al. 2012).  
Although the work presented here gives insight into the mechanism by which the 
IM promotes bone regeneration, it does not address the underlying mechanisms 
that are responsible for the generation of the IM itself. Nor does it address the role 
played by the nature and application of the cement spacer. Future work should be 
directed at understanding the mechanisms by which the IM is generated. The 
process of IM formation may be similar to that which occurs as part of the foreign 
body response; here acute inflammation is followed by local vascularisation and 
fibrous capsule formation (Luttikhuizen et al. 2006; Anderson et al. 2008). Certainly, 
there is clearly an increased number of CD45+ leukocytes present in IM, compared 
to periosteum and the presence of fibrous tissue. However, the similarity of IM to 
periosteum may indicate a unique reaction, driven in part by the proximity of intact 
periosteum. 
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6. The effect of tofacitinib on MSC proliferation and 
differentiation 
6.1. Introduction 
In the last chapter it was seen that native MSCs were very abundant in the IM, a 
surgically induced periosteum like tissue. Some human arthropathies such as 
ankylosing spondylitis (AS) and psoriatic arthritis (PsA) are characterised by 
spontaneous new bone formation at the entheses (tendon and ligament insertions). 
In AS this particularly effects the spine and culminates in joint fusion (Ball 1983; 
Braem et al. 2012).   
Whilst new bone formation is highly desirable in major bone defects, in the context 
of AS and PsA it may be desirable to inhibit bone formation, thus avoiding the 
associated, progressive disability (Braem et al. 2012). Unfortunately, the most 
effective drugs currently available to treat AS and PsA, the anti-TNF agents, 
although very effective at resolving inflammation, do not stop ongoing new bone 
formation (van der Heijde et al. 2008a; van der Heijde et al. 2008b).  Whilst tumour 
necrosis factor α blockade often halts joint erosion in RA (Lipsky et al. 2000; 
Feldmann 2002), radiographic progression, in this case bone formation, to a 
variable degree continues in AS (van der Heijde et al. 2008a; van der Heijde et al. 
2008b).  The failure of TNF blockade to address radiographic progression, has 
served as an impetus for continued research and has stimulated the search for 
alternative therapies to treat AS and PsA. 
Developed under drug development code CP-690,550 and first noted for its ability 
to prevent allograft rejection (Changelian et al. 2003), tofacitinib is one of several 
JAK inhibitors in clinical use for the treatment of RA (Kyttaris 2012). It is a small 
molecule inhibitor which competitively binds the ATP binding site of janus kinase 1 
(JAK1), JAK2, JAK3 and to a lesser extent tyrosine kinase 2 (TYK2) (Karaman et al. 
2008; Meyer et al. 2010). Administered orally, tofacitinib has shown promising 
results in phase III trials with patients showing rapid and clinically meaningful 
improvements in signs and symptoms of RA over six months, with an acceptable 
safety profile (Burmester et al. 2013). It is now licenced in many countries, but not 
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the UK. The interest in using tofacitinib to treat PsA and AS is building especially 
with data showing efficacy for psoriasis (Papp et al. 2012), an important clinical 
manifestation of PsA (Busquets-Perez et al. 2012). Given the important role of MSC 
biology in bone homeostasis, this offers a novel opportunity to investigate the 
effect of tofocitinib on MSC biology using a drug that is destined for the clinic. 
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6.1.1. Chapter aim and objectives 
The aim of this chapter was to examine the effect of tofacitinib on MSC growth and 
differentiation, as a pre-clinical in vitro model, to look for effects on new bone 
formation. 
1. Objectives:To confirm the ability of tofacitinib to inhibit STAT 
phosphorylation following JAK activation. 
2. To characterise the effect of pharmacological doses of tofacitinib on MSC 
proliferation and differentiation. 
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6.2. Materials and methods 
6.2.1. JAK activation in peripheral blood mononuclear cells 
In order to confirm the ability of tofacitinib to inhibit JAK activity, STAT-3 
phosphorylation following cytokine stimulation was assessed in peripheral blood 
mononuclear cells (PBMCs). Blood was taken from a single donor (Female, age 22) 
and PBMCs were isolated by density gradient centrifugation; 20ml of whole blood 
was mixed in a 1:1 ratio with PBS, this was then divided into two equal volumes and 
carefully layered onto 15ml lymphoprep solution (Axis Shield) in two 50ml 
centrifuge tubes. These tubes were then centrifuged at 1150xg for 20 minutes with 
moderate acceleration and no brake. Following centrifugation the PBMCs had 
formed a distinct turbid band, which was harvested using a Pasteur pipette. 
Following addition of 30ml of PBS a further centrifugation at 650xg was used to 
remove the lymphoprep solution and the PBMCs were re-suspended in 10ml of 
DMEM (Invitrogen).  
PBMC were counted using a haemocytometer (2.3) and divided into 8 separate 
aliquots each containing 3x106 cells suspended in 3ml DMEM. The cells were 
subsequently exposed to tofacitinib and/or cytokines as seen in Table 3. IL-6 
(10ng/ml) and IL-21 (50ng/ml) (Cocco et al. 2012) were chosen to stimulate STAT-3 
phosphorylation since signalling by these cytokines is known to be mediated by 
STAT-3 (Rodig et al. 1998; Habib et al. 2002). Cells were incubated in DMEM or 
DMEM plus drug for 30 minutes at 37°C prior to any cytokine stimulation. Cytokines 
were added directly to the cell suspensions which were then incubated at 37°C for 
30 minutes, cells were subsequently pelleted by centrifugation and the supernatant 
was removed. Cells were then lysed by addition of sample buffer (Appendix 2), and 
heated to 90°C for 10 minutes to prevent further enzyme activity and denature 
cellular proteins. Cell lysates were then frozen and stored at -20°C. 
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6.2.2. Detection of phosphorylated STAT-3 by western blotting 
Frozen PBMC lysates generated in section 6.2.1 were probed for the presence of 
phosphorylated STAT-3 (pSTAT-3) using western blotting with anti-human pSTAT-3 
(Millipore). The BioRad Protein 3 mini electrophoresis system was used for casting 
gels and all electrophoresis steps. A 10% acrylamide gel was prepared as described 
in Appendix 2, with a thickness of 1mm using a western blot gel mould (Bio-Rad) 
and allowed to fully set, a stacking layer was added to improve band resolution 
(Appendix 2). The gel was subsequently loaded into an electrophoresis chamber 
with running buffer (Appendix 2). Following a 5 minute incubation at 90°C, 20µl of 
each protein lysate generated in section 6.2.1  were loaded into separate wells; 
10µl of a visible protein ladder Precision Plus Protein™ Dual Color Standards 
(BioRad) was also loaded into one well in order to determine the molecular weight 
of labelled proteins. A constant 125V was applied to the gel for 1 hour, after which 
it was removed and from the gel tank and taken out of its mould.  
Next, the gel was loaded into a transfer cassette in contact with a nitrocellulose 
membrane (Amersham). The transfer cassette was loaded into a second 
electrophoresis tank containing transfer buffer (Appendix 2). A constant 100V was 
applied for 1 hour at 4°C. Once transfer was complete, the nitrocellulose membrane 
was taken out of the cassette and incubated in 15ml of blocking buffer containing 
5% w/v marvel milk powder (Appendix 2) for 3 hours at RT to block non-specific 
protein binding. Using the visible protein ladder as a guide the membrane was then 
cut into a high molecular weight (>50kDa) and a low molecular weight (<50kDa) 
portion.   
The high molecular weight portion was incubated overnight at 4°C in 15ml of 
blocking buffer containing a monoclonal rabbit anti human pSTAT-3 (Tyr705) 
antibody (Appendix 4). The membrane was then washed 4 x 20 minutes in 15ml of 
washing buffer and incubated in 15ml of blocking buffer containing goat anti-rabbit 
IgGs conjugated to horseradish peroxidase (HRP) enzyme (Appendix 4) for 1 hour at 
RT. Finally, the membrane was washed again, as previously described and 
incubated with SuperSignal West Pico Chemiluminescent Substrate (Thermo) for 5 
minutes, enzymatic conversion of the substrate by HRP results in the generation of 
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a chemiluminescent product. The excess reagent was discarded and the membrane 
was wrapped in Saran wrap (Dow). In the dark, Amersham hyperfilm ECL film (GE 
healthcare) was exposed to the now chemiluminescent membrane for 1 minute and 
then developed using a SRX-101A developer (Photon). pSTAT-3 was expected to 
appear at 84Kda (pSTAT-3α) or 76DKa (pSTAT-3β) (Chakraborty et al. 1996).  
The low molecular weight portion was incubated overnight at 4°C in 15ml of 
blocking buffer containing mouse anti human β-Actin monoclonal antibody 
(Appendix 4), this was done to demonstrate equal total protein loading into each 
well. The membrane was then washed 4 x 20 minutes in washing buffer and 
incubated in 15ml of blocking buffer containing HRP conjugated goat anti mouse 
IgGs (Appendix 4) for 1 hour at RT. The membrane was washed as previously 
described and subsequently incubated with Pierce ECL Western Blotting Substrate 
(Thermo) for 1 minute. The excess reagent was discarded and the membrane was 
wrapped in Saran wrap. In the dark, Amersham hyperfilm ECL film was exposed to 
the membrane for 5 seconds and then developed as previously described. Β-actin 
was detected as a 42kDa band (Hu et al. 1993). 
Table 3: Activation conditions used to stimulate STAT-3 phosphorylation in PBMCs 
Aliquot / well number Cytokine Tofacitinib 
1 IL-6 10ng/ml  - 
2 IL-21 50ng/ml  - 
3 IL-6 10ng/ml 500nM  
4 IL-21 50ng/ml 500nM 
5 IL-6 10ng/ml 100nM 
6 IL-21 50ng/ml 100nM 
7 - - 
8 - 500nM 
 
6.2.3. CFU-F assay 
The effect of tofacitinib on MSC colony initiation and growth was determined. Iliac 
crest BM aspirates were taken from 8 donors (mean age 46, 5 male 3 female). The 
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assay was performed using whole BM aspirates and proceeded as described (2.7) 
with some modifications. 100l of BM aspirate was seeded in duplicate 10cm 
culture dishes containing 15ml of NH media. Tofacitinib was added to the culture 
media at a range of concentrations, 100nM, 500nM, 1000nM and 10000nM. These 
concentrations were decided in consultation with Pfizer, with 1000nM the expected 
pharmacological concentration. A carrier control was also included containing 
dimethyl sulfoxide (DMSO) at a concentration equivalent to that required to 
constitute the 10M dose, this was achieved by adding 1.5µl DMSO per dish. A no 
drug/no DMSO control was also included. The number of colonies was scored as 
previously described (2.7) and the total colony area was measured as previously 
described (2.8). 
 
6.2.4. Tri-lineage differentiation assays 
To assess the effect of tofacitinib on MSC differentiation, osteogenic, adipogenic 
and chondrogenic differentiation assays were performed as described (2.14). For 
these assays passage 3 MSC cultures from 6 BM donors were used (mean age 47, 3 
male, 3 female). Osteogenic cultures were terminated after 14 days for assessment 
of ALP activity (2.11), and after 21 days for analysis of calcium production (2.12). 
Chondrogenic cultures were terminated after 21 days and gycosaminoglycan (GAG) 
accumulation was assessed by toluidine blue staining (2.14) and alcian blue assay 
(6.2.6). Adipogenic induction was terminated at 14 or 21 days and assessed by oil 
red (2.13) and Nile red (6.2.5) staining. 
Tofacitinib was added to each differentiation media (Appendix 2) at a concentration 
of 500nM, 1000nM and 10000nM and as mentioned above, a DMSO control was 
included. Media changes proceeded as described previously for all assays with 
tofacitinib addition as above at each media change. This assay assumed no stability 
associated decrease in drug concentration in culture.  
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6.2.5. Quantitative assessment of adipogenesis 
Quantitative measurement of adipogenic induction was assessed by spectral 
analysis of photomicrographs taken following oil red staining as described (2.13), 
and by the measurement of fluorescence following Nile red staining.  
For Nile red staining, culture expanded MSCs were seeded in 0.5ml/well of 
adipogenic media (Appendix 2) in triplicate at a density of 4x104 cells/well into 48 
well tissue culture grade plates (Corning), differentiation then proceeded as for oil 
red assay previously described (2.13). At the end of the culture period, following 
formalin fixation in fixing buffer (Appendix 2, 0.5ml/well), cells were washed with 
0.5ml PBS; which was aspirated fully and further 200l of PBS was added to each 
well. A Mithras LB 940 plate reader (Berthold) was then used to measure emission 
at 460nm and 535nm following excitation at 355nm and 485nm respectively, this 
was taken as a background reading. The PBS was then replaced with PBS 
supplemented with 0.2% saponin (Sigma Aldrich), 1µg/ml DAPI (Sigma Aldrich) and 
1g/ml Nile red (Sigma Aldrich), saponin forms pores in lipid bilayers enabling the 
entry of Nile red which is strongly fluorescent in the presence of lipid. Cells are then 
incubated for 15 minutes at RT before washing with 1ml PBS. As before, wells were 
filled with exactly 200l of PBS and read at 460nm and 535nm following excitation 
at 355nm and 460nm respectively. To calculate fold induction of adipogenesis, the 
background reading for each individual well was subtracted from the second 
reading; the mean emission at 535nm for each triplicate well was divided by the 
mean reading of the control (DMSO only) triplicate to give fold change in 
adipogenic induction. This was repeated to calculate the relative difference in DAPI 
fluorescence at 460nm. Fluorescent images were capture using an Eclipse Ti 
microscope (Nikon).  
Following initial experiments using tofacitinib at concentrations between 500nM 
and 10000nM the assay was repeated at concentrations of tofacitinib of 10, 50, 100 
and 500nM. The induction time was lengthened to 21 days and the assay was 
performed on passage 3 expanded BM MSCs from 7 donors (mean age 51, 5 male 2 
female). This was to further explore the effect of tofacitinib on adipogenic induction 
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at lower concentrations of drug, a longer induction time was used in order to 
increase assay sensitivity. 
 
6.2.6. Detection of glycosaminoglycans 
Gycosaminoglycan production was measured in order to quantitatively measure 
chondrogenic induction. Day-21 chondrogenic pellets generated in section (2.14) 
were washed with 1ml of PBS and digested by incubation overnight at 65°C 
overnight in 1ml of papain buffer (Appendix 2). The resulting solution was mixed by 
vortexing and then centrifuged at 5000xg for 5 minutes to remove the residual 
debris. Subsequently a, sGAG quantitative kit (Wieslab) was used to measure the 
produced sGAG according to manufacturer’s instructions. This assay utilises alcian 
blue binding to GAGs, which were then detected by measuring absorbance at 
600nM using an Opsys MR plate reader (Dynex Technologies).  
 
6.2.7. Statistics 
Friedman’s two-way analysis of variance by ranks was used to detect statistical 
difference in all data sets, with pairwise post-hoc comparison used to analyse 
significance between variables. The significance level was set at 95%. *denotes 
statistical significance *p<0.05, **p>0.01, ***p>0.001. 
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6.3. Results 
6.3.1. Effect of tofacitinib on cytokine induced STAT-3 
phosphorylation in PBMCs 
In order to confirm the ability of tofacitinib to inhibit JAK mediated STAT 
phosphorylation, PBMS were exposed to cytokine stimulus known to be mediated 
by STAT-3 phosphorylation (Kiu et al. 2012). PBMCs were chosen due to the 
presence of cells known to be responsive to IL-6 and IL21 (Cocco et al. 2012).   Pre-
incubation with 500nM tofacitinib has a clear inhibitory effect on IL-6 and IL-21 
mediated STAT-3 phosphorylation in PBMCs (Figure 26). Lysates from cytokine-
stimulated PBMCs showed a high level of pSTAT-3 which was clearly reduced with 
pre-incubation of 500nM tofacitinib to a level equal to or below the unstimulated 
control. Phosphorylation of the heavier α-isoform in particular was inhibited leading 
to loss of detection at the 500nM concentration of tofacitinib. Tofacitinib pre-
incubation at a concentration of 100nM also had a reduced but clear inhibitory 
effect on STAT-3 phosphorylation, especially with IL-21 stimulation. Tofacitinib was 
not able to inhibit baseline STAT-3 phosphorylation. In summary this data shows 
that tofacitinib is able to inhibit IL-6/IL-21 induced JAK mediated STAT-3 
phosphorylation, this experiment provides a positive control for subsequent CFU-F 
and differentiation assays. 
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Figure 26: Western blot of pSTAT-3 / β-Actin in IL-6 and IL-21 stimulated PBMCs 
Scanned image of combined western blot films showing pSTAT-3α (84kDa), pSTAT-
3β (76kDa) and β-Actin (loading control, 42kDa) from lyzates of activated PBMCs 
(stimulated with IL-6 and IL-21, pre incubated with 500nM or 100nM tofacitinib). 
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6.3.2. Effect of tofacitinib on BM CFU-F potential 
Once the inhibitory effect of tofacitinib on JAK activity had been confirmed, its 
influence on MSC colony formation and differentiation was investigated. The 
addition of tofacitinib did not have any detectable effect on BM MSC colony 
forming potential at any of the concentrations tested (Figure 27A). Tofacitinib did 
not have any discernible effect on overall colony area (Figure 27B) or the average 
size of individual colonies (Figure 27C). Overall there was no evidence to suggest 
that tofacitinib has any effect on MSC attachment or expansion in vitro (all data n=8 
donors).  
A well-known mediator of MSC self-renewal is FGF (Tsutsumi et al. 2001; Bianchi et 
al. 2003; Zaragosi et al. 2006), this elicits its response independently to the 
JAK/STAT pathway. Other mediators of MSC proliferation include PDGF and 
epidermal growth factor (EGF) (Gronthos et al. 1995). Although both these factors 
are known to activate the STAT pathway, their effect on MSC proliferation is 
thought to be mediated by activation of the MAPK and PI3K pathways 
(Kratchmarova et al. 2005; Rodrigues et al. 2010). This negative result supports the 
notion that JAK/STAT signalling is not important for in vitro MSC expansion. 
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Figure 27: The effect of tofacitinib on MSC colony forming potential. 
The effect of Tofacitinib on the ability of BM MSCs to initiate adherent colonies and 
expand in vitro (A). The effect of Tofacitinib on the rate of MSC expansion measured 
as the total area occupied by colonies (B), or as the mean area occupied by a single 
colony (C). All data n=8. 
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6.3.3. The Effect of tofacitinib on in vitro MSC osteogenesis 
The inclusion of tofacitinib in culture medium during osteogenic induction of MSCs 
did not have a noticeable effect on alkaline phosphatase activity following 14 days 
of induction (Figure 28A). The accumulation of calcium was similarly unaffected by 
tofacitinib at any of the concentrations tested (Figure 28B). Overall there is no 
evidence to suggest that tofacitinib had any effect on in vitro osteogenesis of MSCs 
at the concentrations of tofacitinib tested (all data n=6 donors). This result indicates 
that JAK/STAT signalling is not required for in vitro osteogenesis in this particular 
model system despite the documented stimulatory effect of GH on osteogenesis 
mediated by JAK2 (Wang et al. 2004; Hadjidakis et al. 2006; DiGirolamo et al. 2007; 
Giustina et al. 2008).   
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Figure 28: Effect of tofacitinib on MSC osteogenesis. 
Fast blue staining for ALP activity following osteogenic induction of MSC 
differentiation in the presence or absence of tofacitinib. Figure shows a single 
representative donor sample 14 days post induction, shown in triplicate wells (A). 
The Effect of tofacitinib on osteogenic differentiation assessed by accumulation of 
calcium day-21 post osteogenic induction n=6 (B). 
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6.3.4. Effect of tofacitinib on in vitro MSC chondrogenesis. 
The inclusion of tofacitinib in culture medium during chondrogenic induction of 
MSCs did not affect the accumulation of GAGs in chondrogenic pellets (all data n=6 
donors, Figure 29).  Tofacitinib had no effect on pellet formation or GAG content as 
shown in Figure 29A. Quantitative measurement of GAG production following 
chondrogenic induction confirmed this observation (Figure 29B). This result is 
encouraging for the use of tofacitinib in RA especially, where cartilage preservation 
is a critical concern. It also further weakens the hypothesis that tofacitinib can 
inhibit in vivo osteogenesis since endochondrial ossification is proceeded by 
chondrocyte proliferation (Maes et al. 2010; Mackie et al. 2011; Dirckx et al. 2013). 
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Figure 29: Effect of tofacitinib on MSC chondrogenic differentiation. 
The effect of tofacitinib on MSC chondrogenic differentiation, assessed by 
accumulation of GAGs following 21-day chondrogenic induction. Toluidine blue 
staining of chondrogenic pellets (A). Assessment of total GAG content in digested 
chondrogenic pellets n=6 (B). 
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6.3.5. The effect of tofacitinib on in vitro MSC adipogenesis. 
When MSCs were cultured in adipogenic conditions the presence of tofacitinib had 
a clear effect. The rate of adipogenesis was noticeably increased in cultures 
exposed to high concentrations of tofacitinib (Figure 30A). The median proportion 
of area occupied by lipid vacuoles stained with oil red, was increased by incubation 
with 1000nM tofacitinib to 8.21% (range 4.14-15.69) compared to 5.35% (range 
2.08-11.20) in the DMSO control; although this change was short of statistical 
significance. Statistical significance was achieved at a tofacitinib concentration of 
10000nM (10.67%, range 4.15-22.06, p=0.022, Figure 30B).  
Further confirmation of the stimulatory effect of tofacitinib on in vitro MSC 
adipogenesis was observed following the analysis of fluorescence after Nile red 
staining (Figure 31A). As with oil red measurement, there was a significant increase 
in the extent of adipogenesis measured by median fluorescence emission of Nile 
red, detected between the DMSO control and 10000nM tofacitinib concentration 
(2.02 fold, range 1.34-4.44, p=0.022). (1.99 fold, n=6 donors, range 0.91-3.16, 
p=0.075).   
Further investigation of this phenomenon using lower concentrations of tofacitinib 
and a longer adipogenic induction (21 days), revealed a clear dose-dependent 
increase in adipogenesis. There were significant increases in the median 
fluorescence emission after Nile red staining with a 100nM dose (1.38 fold, range 
1.01-1.54, p=0.041) and a 500nM dose (2.14 fold, range 1.26-2.57, p<0.001) relative 
to the carrier control (Figure 31C). A significant difference was also observed 
between the 10nM dose compared to 100nM and 500nM doses (p=0.041 and 
p<0.001 respectively). These data provided compelling evidence that JAK inhibition 
in adipogenically differentiating MSCs by tofacitinib leads to an increase in 
adipogenesis. In order to determine if this effect was a result of proliferation of 
increased adipogenic induction the ratio of Nile red to DAPI fluorescence was 
compared at each concentration of tofacitinib. When standardised to DAPI signal 
tofacitinib induction of adipogenesis was only significant compared to the carrier 
control at the 500nM dose (p=0.001, Figure 31D), although a significant change was 
also observed between the 10nM and 50nM doses compared to the 500nM dose 
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(p=0.004 and 0.041 respectively). The drop in sensitivity observed suggests that 
proliferation as well as enhanced adipogenic induction   
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Figure 30: Oil red staining on day 14 of MSC adipogenic differentiation in the 
presence of tofacitinib. 
Representative photomicrographs showing the effect of different concentrations of 
Tofacitinib or DMSO carrier control on MSC adipogenesis, shown by uptake of oil 
red into lipid vacuoles (red) counterstained with haematoxylin (A). Measurement of 
oil red stained area in photomicrographs of adipogenic cultures supplemented with 
tofacitinib n=6 (B). Box plot shows interquartile, range median and extreme values, 
*denotes p<0.05. 
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Figure 31: Adipogenic differentiation of MSCs in the presence of tofacitinib 
measured by Nile red fluorescence. 
Representative photomicrograph showing Nile red uptake into lipid vacuoles (red), 
counterstained with a nuclear DAPI stain (blue) (A). MSC adipogenesis in the 
presence of tofacitinib or carrier control shown by Nile red fluorescence following 
14 day induction n=6 (B) and 21 day induction n=7 (C) Adipogenesis shown as a Nile 
red fluorescence normalised to DAPI fluorescence following a 21 day adipogenic 
induction in the presence of tofacitinib. Box plots show interquartile range, median 
and extreme values, * denotes p<0.05, **p<0.01, ***p<0.001. 
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6.3.6. The effect of tofacitinib on in vitro adipocyte proliferation 
The measurement of DAPI fluorescence has previously been proposed as a means 
of standardising Nile red signal in quantitative adipogenic assays (Aldridge et al. 
2013). However, this assumes that the proportion of MSCs that successfully 
differentiate into adipocytes is the only factor governing the number of adipocytes 
present. Increased proliferation of MSCs or pre-adipocytes could increase the DAPI 
signal. Therefore, it is not appropriate to use DAPI fluorescence as a means of 
standardising this assay. Nevertheless DAPI fluorescence is a useful indicator of the 
relative number of cells in adipogenic cultures since DAPI forms highly fluorescent 
complexes with DNA (Wang et al. 2000).  
Induction of adipogenesis for 14 days resulted in a significant increase in DAPI 
fluorescence over the DMSO control at 500nM (1.44-fold, range: 1.33-2.11), and 
10000nM (1.69-fold, range: 1.30-2.25) concentrations of tofacitinib (n=6, p=0.044 
and 0.005 respectively, Figure 32A). A 21 day adipogenic induction resulted in a 
significant increase in DAPI signal at the 500nM (1.10-fold, range: 1.03-1.21) 
concentration of tofacitinib (n=7, all p=0.001, Figure 32B). All together this data 
shows that the total number of cells following in vitro MSC adipogenesis is 
increased by the presence of tofacitinib. Tofacitinib has been shown not to affect 
MSC proliferation in vitro (Figure 27), therefore this increase is likely partly a result 
of increased pre-adipocyte or adipocyte proliferation.  
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Figure 32: Adipocyte hyperplasia during adipogenic differentiation of MSCs in the 
presence of tofacitinib.  
Relative cell number measured by DAPI fluorescence after 14 day n=6 (A) and 21 
day n=7 (B) induction of MSC adipogenesis in the presence of tofacitinib. Box plots 
show interquartile range median and extreme values, * denotes p<0.05, **p<0.01. 
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6.4. Discussion 
Aberrant entheseal new bone formation in AS and PsA has been tentatively 
associated with dysregulated osteoprogenitor activity (Lories et al. 2005). Existing 
therapies fail to control this abnormal post inflammatory reaction (van der Heijde 
et al. 2008a; van der Heijde et al. 2008b). This chapter examined the effect of 
tofacitinib, a novel JAK inhibitor in pre-clinical development for AS and PsA, on MSC 
proliferation, osteogenic, chondrogenic and adipogenic differentiation. Tofacitinib 
clearly inhibited JAK mediated STAT3 phosphorylation following the stimulation of 
PBMCs with both IL-6 and IL-21. However, JAK inhibition did not have a detectable 
effect on MSC colony forming potential or proliferation assessed by measurement 
of colony area. Neither did JAK inhibition effect osteogenic or chondrogenic 
differentiation.  
Tofacitinib had a clear effect during adipogenic differentiation. Concentrations as 
low as 50nM were able to significantly increase the lipid content measured by Nile 
red assay in comparison to control cultures. DAPI fluorescence indicates that total 
cellularity is also significantly increased with tofacitinib stimulation. This is 
surprising given that studies examining adipogenesis in 3T3-L1 cells, a cell line 
widely used as an in vitro adipogenic differentiation model (Deng et al. 2000; Floyd 
et al. 2003; Zhang et al. 2011) suggested that STAT5A and STAT5B promoted 
adipogenesis particularly in the early stages of differentiation, and one might 
expect that a JAK inhibitor would antagonise this process (Nanbu-Wakao et al. 
2002; Floyd et al. 2003). Moreover, Deng et al showed that STAT3 was activated 
and bound to DNA during proliferative phases of adipogenesis and suggested that 
STAT-3 regulates preadipocyte proliferation (Deng et al. 2000). This was later 
confirmed and JAK2 was found to act upstream of STAT-3 as demonstrated by small 
interfering RNA silencing (Wang et al. 2010; Zhang et al. 2011). However, pre-
adipoyctes are responsive to several cytokines that have been shown to inhibit 
adipogenesis including IFN- (Gregoire et al. 1992), oncostatin M (OSM) (Song et al. 
2007) and neuropoietin (White et al. 2008), all of which are potent activators of JAK 
kinases.  
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Adipose-specific disruption of JAK2 or STAT3 signalling in vivo results in increased 
adipose mass associated with hypertrophy in mice, adipocytes became enlarged 
with increased lipid content (Cernkovich et al. 2008; Shi et al. 2014). Shi et al found 
that adipocyte-specific JAK2 deficiency led to increased weight gain, impaired 
lipolysis and insulin resistance with aging. This led to the proposition that JAK2 
inhibition causes excessive lipid accumulation in mature adipocytes (Shi et al. 2014). 
This is interesting given that hyperlipidaemia has been reported as a side effect of 
tofacitinib treatment of rheumatoid arthritis (Kremer et al. 2012; van Vollenhoven 
et al. 2012; O'Shea et al. 2013).  
Measurement of DAPI fluorescence following adipogenic induction in the presence 
of tofacitinib indicated increased cellularity and likely reflects enhanced pre-
adipocyte proliferation. Careful measurement of adipocyte size during adipogenesis 
is required to determine if adipocyte hypertrophy also occurs in this context, or if 
the enhanced lipid content observed was solely driven by pre-adipocyte 
differentiation.  Further investigation is required to elucidate the mechanism by 
which tofacitinib stimulates adipogenesis.  
The ability of tofacitinib to induce adipogenesis in vitro may also have implications 
for in vivo osteogenesis and chondrogenesis. There is a significant body of evidence 
that suggests that osteogenesis and adipogenesis are antagonistic in the context of 
WNT signalling (Kennell et al. 2005; Kawai et al. 2007; Laudes 2011). A growing 
body of evidence suggests that this dichotomy is also relevant to the JAK/STAT 
pathway. Indeed, OSM a member of the IL-6 family of cytokines, has been shown to 
promote osteogenesis and suppress adipogenesis in MSCs, an effect for which JAK2 
is a crucial mediator (Song et al. 2007; Nawa et al. 2013). Leptin, secreted by 
adipocytes, is another cytokine known to signal via the gp130 family of cytokine 
receptors (Vaisse et al. 1996). Obese mice deficient in leptin or the signalling form 
of its receptor have increased vertebral trabecular bone volume due to increased 
bone formation (Ducy et al. 2000). Leptin has been shown to have a direct 
inhibitory effect on MSC adipogenesis, which is lost in MSCs derived from 
osteoporotic donors (Astudillo et al. 2008). The data presented in this thesis 
demonstrates that inhibition of JAK/STAT signalling has a direct stimulatory effect 
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on MSC adipogenesis. Although no decrease in osteogenesis was observed, this 
may be because artificial, chemical induction of osteogenesis is not sensitive to the 
more subtle cues that govern in vivo cell fate. 
In summary, the data presented in this chapter clearly shows that JAK/STAT signal 
inhibition has a direct effect on MSC adipogenesis in vitro. The effect of tofacitinib 
on lipid metabolism warrants further investigation and has potential important 
implications to insulin sensitivity and type II diabetes. Finally, the possibility that 
stimulating adipogenesis may lead to inhibitions of osteogenesis in vivo has 
important implications to bone metabolic disorders including OP, OA and AS. 
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7. General discussion 
This thesis has sought to demonstrate that insights into the nature of human MSCs 
in vivo can be used to develop novel therapeutic approaches for the treatment of 
bone disease. The development of MSC based therapies in general has been 
hampered by a number of factors; these include the limited utility of animal 
models, due to interspecies differences (Peister et al. 2004; Pittenger 2013), the 
difficulty of obtaining large numbers of MSCs from human subjects (Hernigou et al. 
2005b; Jones et al. 2010b; Hernigou et al. 2013), the historical lack of unique and 
consistent phenotypic markers (Buhring et al. 2009; Nombela-Arrieta et al. 2011; 
Boxall et al. 2012) and culture expansion induced changes to MSCs (Wagner et al. 
2008; Wagner et al. 2009; Boxall et al. 2012). The concept articulated by Caplan in 
1991 of isolation, expansion and re-introduction of MSCs leading to differentiation 
in order to replace damaged tissue (Caplan 1991), has not been translated into 
widespread clinical applications. Early hopes that haploidentical MSCs may be 
transplanted, leading to engraftment and differentiation also were frustrated 
(Horwitz et al. 2001; Otsuru et al. 2012).  
The notion of using autologous MSCs that have not been subject to culture 
expansion has produced some encouraging successes in the field of bone 
regeneration (Hernigou et al. 2002; Hernigou et al. 2005a; Hernigou et al. 2005b). 
The use of autologous MSCs in the form of BM aspirates has become fairly common 
practice in orthopaedic medicine (Dimitriou et al. 2011b; Giannoudis et al. 2011; 
Giannoudis et al. 2013; Kassem 2013), despite the relatively low and highly variable 
MSC content in BM aspirates (Hernigou et al. 2005b; Jones et al. 2010b; Hernigou et 
al. 2013). This is important, because MSC content has been shown to dictate 
treatment outcome (Hernigou et al. 2005a) and cannot be assessed easily at the 
point of use. This issue was addressed in chapter 3, which detailed a rapid MSC 
enumeration technique that can be performed in <40 minutes. Although this 
technique as it stands could be used as an intraoperative quality control, its reliance 
on specialist expertise limits its value. However, as a proof of concept it does have 
significance, as it demonstrates that enumeration of the CD45-/low CD271+ 
population can be used to accurately predict the MSC content of aspirates. Further 
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refinement of this assay, using more advanced equipment, such as acoustic 
focussing flow cytometers and the development of simplified protocols could cut 
assay time significantly. This would be achieved by faster sample preparation time 
and more rapid data acquisition. A total assay time of <20 minutes, with a protocol 
simplified such that it may be performed by non-specialist theatre staff is a realistic 
goal for the development of this technique, and would greatly enhance its utility for 
MSC therapy in the orthopaedic setting.  Careful control of the number of MSCs 
administered could have an immediate impact in therapeutic approaches that seek 
to stimulate bone regeneration by the application of concentrated BM. 
The dogma that MSCs are rare in the bone has been challenged both by this thesis 
and by others, who have shown that trabecular bone contains large numbers of 
MSCs (Noth et al. 2002; Sakaguchi et al. 2004; Jones et al. 2010b). FHs removed as 
part of total hip replacements offer a potential abundant source of MSCs that may 
be used for therapy (Noth et al. 2002; Sakaguchi et al. 2004; Jones et al. 2010b). Yet 
the safety and efficacy of cell therapy utilising MSCs recovered from osteoarthritic 
hips remains unproven, an issue highlighted by the discovery of a MSC driven 
component to OA (Zhen et al. 2013).  
The liquid waste product of intramedullary reaming is also a potential source of 
large numbers of MSCs (Porter et al. 2009; Cox et al. 2012; Churchman et al. 2013). 
Unlike FHs they are not associated with diseased tissue and do not require 
enzymatic recovery, their primary disadvantage to BM MSCs for therapy lies with 
the large volume of liquid that they are collected in. The enrichment of these cells 
using the CliniMACS device together with an anti-CD271 microbead, as 
demonstrated in chapter 4 goes some way to solving this problem. However the 
long processing time required (>4 hours) will inevitably limit clinical uptake of the 
CliniMACS system for immediate use. The Prodigy cell sorter (Miltenyi Biotec) 
represents the next generation of magnetic bead cell sorters, is a completely 
automated enclosed system. This has the potential to reduce the time required for 
sample processing by eliminating the need for manual handling during enrichment. 
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The utility of MSC therapy is dependent on several factors the most salient of these 
are safety, purity, time required for processing, preservation of desirable 
phenotypic properties and cost. The usefulness of CD271 microbead enrichment of 
MSCs will ultimately be determined by the application. For autologous therapy, 
MSCs enrichment from RIA waste fluid offers an attractive alternative to 
concentrated BM, giving far higher numbers of MSCs at superior purity. However, 
further optimisation of the technique used in these experiments is required to 
maximise MSC yield. The addition of an anticoagulant at the point of harvesting 
should greatly improve MSC yield by reducing the number of cells lost prior to 
selection. Optimisation of the harvesting technique itself may also improve yields, 
currently harvesting is optimised only for collection of the solid retentate with no 
consideration to the liquid filtrate. A standardised procedure for collection of this 
fraction could increase the initial number of MSCs harvested prior to processing. 
In chapter 4 the proportion of MSC as well as the proportion of leukocytes prior to 
and following enrichment was measured. A detailed assessment of the cell types, 
other than MSCs, that are carried over into the enriched fraction was not 
performed. This is important because the identity of these cells, particularly those 
expressing the CD271low CD45+ CD73- phenotype may facilitate their removal; a 
necessary step if this technology were ever considered for allogeneic use. Nor was 
the differentiation capacity of cells isolated from these tissues confirmed. However, 
confirmation of the tri-lineage potential of CD271 selected cells from BM has 
already been reported by others using a research grade bead (Jarocha et al. 2008). 
Additionally, the presence of MSCs expressing CD271 has already been 
demonstrated in FH digests and the intramedullary cavity of long bones (Jones et al. 
2010b; Cox et al. 2012). Therefore, it is likely that CD271 selection from these 
tissues will yield MSCs capable of tri-lineage differentiation, although for 
completion this should be demonstrated. 
There is an increasing interest in the use of “smart” scaffolds that rather than 
relying on MSCs extracted from a remote location such as the iliac crest, seek to 
stimulate migration of endogenous MSCs into the scaffold matrix (Dashnyam et al. 
2014; Jin et al. 2014).  Chapter 5 dealt with the examination of an induced 
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membrane that is formed as a reaction to the implantation of a bone cement 
spacer, that could be considered as a natural analogue of synthetic smart scaffolds.  
The tissue formed was rich in MSCs, the fact that these cells expressed significantly 
more SDF-1 transcript than MSCs isolated from the periosteum even following 
culture expansion is significant. SDF-1 transcript expression in MSCs declines rapidly 
with culture expansion (Churchman et al. 2012), implying that the in vivo expression 
of IM MSC may be considerably greater than that observed in these experiments. In 
light of evidence suggesting perivascular localisation of MSCs in vivo (Sacchetti et al. 
2007; Tormin et al. 2011), the observed perivascular expression of SDF-1 protein 
strengthens this conclusion. Data also suggests that IM is an active site of 
vascularisation, with a higher proportion of pericytes than in normal periosteum. 
This is an important quality due to the well-recognised importance of 
neovascularisation in resolving fractures (Megas 2005; Frolke et al. 2007).  
Greater understanding of the mechanism that drives IM formation could potentially 
lead to a new generation of orthopaedic implants that actively participate in 
stimulating new bone formation by driving the recruitment of regenerative cells 
and vascularisation. In many respects, IM formation mirrors the foreign body 
reaction, where a fibrous capsule is formed around an implant following an initial 
inflammatory stage (Anderson et al. 2008). However, the high degree of 
vascularisation seen in IM is not a typically observed feature of the foreign body 
reaction (Zhang et al. 2013). This suggests that IM formation may be a unique 
event, driven in part by the proximity of the periosteum. The periosteum contains a 
developed vasculature and a reservoir of MSCs (Chan et al. 2012; Colnot et al. 
2012); its close proximity may influence MSC recruitment and vascularisation of the 
defect site.  
This begs the question, what role does the implant itself play in IM formation? Is it 
merely a flat surface that provides support for outgrowth of the periosteum or do 
certain chemical properties of PMMA bone cement itself induce membrane 
formation? The experiments presented in this thesis do not address these 
questions, but the mechanism of IM formation and the effect of the cement spacer 
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are important when considering therapy development. Currently, bone cement 
must be carefully removed at the second stage of the procedure, whilst ensuring 
the membrane is left intact (Giannoudis et al. 2011).  If a bio-absorbable alternative 
could be used, this would at least simplify the second stage of the IM procedure, 
and at best eliminate the need for a second surgical stage altogether. 
Although animal models are by no means an ideal tool in investigating human MSCs 
in vivo, investigations into the potential use of other materials in the IM technique 
necessitates in vivo testing. A rabbit model may be most suitable, since this has 
already been shown to be a useful tool for study of IM (Pelissier et al. 2004). 
Substituting the material and location of the implant, as well as investigating the 
timing of implant removal could answer many of the open questions relating to the 
influence of the periosteum and the composition of the implant on membrane 
formation. 
Understanding the factors that drive MSC migration and differentiation is also 
important when considering diseases that have a MSC driven component. AS and 
OA are two examples where inappropriate or abnormal bone formation negatively 
effects the progression of the disease (Braem et al. 2012; Zhen et al. 2013). In these 
cases, inhibition of bone formation may be desirable. Chapter 6 showed that 
tofacitinib does not have any effect on MSC proliferation or differentiation into 
bone or cartilage. Whilst this is an advantage when considering tofacitinib for the 
treatment of RA where preservation of bone and cartilage is paramount, it is less 
encouraging for the treatment of AS which shares the inflammatory aspect of RA 
but is associated with excessive bone formation at the enthesis rather than bone 
and cartilage erosion at the joints (Ball 1983; Braem et al. 2012).  
There is the possibility that although tofacitinib does not affect in vitro 
osteogenesis, promotion of adipogenesis seen with tofacitinib treatment may be 
sufficient to inhibit chondrogenesis and osteogenesis in vivo. Indeed, a large body 
of evidence suggests an inverse relationship between BM adiposity and bone 
formation in the progression of OP (Rosen et al. 2006a; Astudillo et al. 2008; Duque 
et al. 2008). The experiments presented in this thesis cannot fully address the effect 
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of tofacitinib on MSCs, since in vitro differentiation cannot replicate the subtle cues 
that influence in vivo cell fate. Further experiments in vivo must be used to address 
this issue. Currently, collaberative experiments are being carried out using a DBA/1 
mouse model of spontaneous arthritis; these DBA/1 mice develop ankylosis as a 
result of entheseal cell proliferation and chondrogenic differentiation (Braem et al. 
2012). If administration of tofacitinib to these animals does prevent the progression 
of ankylosis, the effect of tofacitinib on MSC adipogenesis is one possible 
mechanism for this affect.  
Tofacitinib was found to strongly enhance in vitro adipogenesis, a result that runs 
contrary to much of the published literature describing JAK/STAT signalling in 
adipogenesis (Deng et al. 2000; Nanbu-Wakao et al. 2002; Floyd et al. 2003). 
Interestingly, the adipocyte hyperplasia observed with tofacitinib stimulation is also 
seen in a mouse model of adipocyte specific knockout of retinoid related orphan 
receptor γ (RORγ) (Meissburger et al. 2011b). In this study RORγ disruption resulted 
in reduced adipocyte size, enhanced adipogenesis and protected against loss of 
insulin sensitivity in mice fed with a high fat diet. Meissburger et al suggested that 
this effect was mediated by loss of matrix metalloproteinase 3 (MMP-3) expression 
(Meissburger et al. 2011b). A separate study also showed that a related protein, 
tissue inhibitor of matrix metalloproteinase 1 (TIMP1) negatively regulates 
adipogenesis (Meissburger et al. 2011a). This is significant in the light of a study by 
Li et al who showed that JAK3 inhibition blocked OSM induced MMP and TIMP 
expression (Li et al. 2001). I believe this provides a testable hypothesis that would 
explain the pro-adipogenic action of tofacitinib, which could be tested by 
monitoring adipocyte size and the expression of MMP-3 and TIMP1 during 
tofacitinib stimulated adipogenesis. 
Further evidence of a link between drug induced adipogenesis and the reduction 
and bone mass is provided by the use of thiazolidinediones to treat of type II 
diabetes (Ahmadian et al. 2013). These drugs are powerful insulin sensitizers but 
have the serious side effects of increasing fracture rates caused by reduced bone 
mass, weight gain, edema and congestive heart failure in humans (Ahmadian et al. 
2013). Although this does support the idea that stimulating adipogenesis can lead 
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to reduced bone formation it also raises serious concerns, particularly for long term 
tofacitinib treatment. 
In summary, understanding the in vivo nature of MSCs is crucial for bone disease 
therapy approaches that seek to harvest and reapply MSCs to sites of bone damage 
or loss. Understanding the phenotypic characteristics of in vivo MSCs can lead to 
improved clinical practice by providing the basis of a quality control procedure and 
can also be utilised to enrich MSCs to high levels of purity. Appreciation of the 
factors that govern MSC recruitment towards implants such as bone cement may 
lead to the development of new orthopaedic implants that actively induce bone 
formation. Finally, evidence that tofacitinib induces adipogenesis in vitro coupled 
with understanding of the in vivo dichotomy between adipogenesis and 
osteogenesis may provide important insights into the potential use of tofacitinib to 
treat spondyloarthropathies. 
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8. Future work plan 
There are several ways that the work contained in this thesis could be expanded 
upon. The use of BM aspirates for MSC therapy is hampered by their extremely 
variable quality in relation to MSC content. For this reason I developed a rapid 
means to quantify the MSCs in BM aspirates based on CD271 expression that could 
be used as an intra-operative quality control. Further experiments should focus on  
optimising the technique to make it faster, this will largely be achieved by exploiting 
the latest flow cytometry technology which relies on acoustic rather than 
hydrodynamic focussing (Goddard et al. 2007). The purpose would be to streamline 
and simplify the protocol, to a point where it could be routinely used by non-
specialist theatre staff. A training program for the use of this technology by non-
research staff should also be developed. I believe this approach represents an 
important innovation that could revolutionise the practice of autologous BM 
grafting.  
Next I hope to develop protocols for the rapid seeding of MSCs onto biological 
scaffolds. I plan to select MSCs from BM aspirates using clinical-grade anti-CD271 
microbeads in order to produce a highly-enriched MSC fraction; this will be used to 
explore cellular interactions governing MSC attachment to biological scaffolds. By 
combining rapid MSC enumeration for quality control of aspirates, with a rapid and 
efficient seeding technique, I could develop intraoperative scaffold loading 
protocols applicable to a broad range of therapeutic applications. However, due to 
the recognised utility of MSCs in bone repair my chief focus will be scaffolds that 
are applicable to bone regeneration.  
Lastly, I plan to demonstrate the broad utility of this approach to the field of 
musculoskeletal tissue regeneration as a whole. This will be achieved by 
demonstrating that MSCs are retained and proliferate on scaffolds, and that they 
are able to act as initiators of endogenous repair by the release of tropic factors, in 
addition to their already well characterised differentiation potential. The focus of 
these experiments will be to detect the stimulation of angiogenesis and cell 
migration towards seeded scaffolds in vitro. If successful, this will demonstrate the 
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benefit of providing an autologous MSC-driven kick-start to enhance endogenous 
colonisation.  
Further investigation of the induced membrane formed as a result to the IM 
procedure also merits further investigation. Understanding of the mechanism 
driving IM formation is key to advancing clinical practice. Research should focus on 
determining if the chemical nature of the cement spacer itself is critical in inducing 
membrane formation, whether IM formation is possible in other locations other 
than long bone defect sites and how the properties of the IM are modulated over 
time. It is also important to determine the net contribution of each of the 
components used in the second stage of the procedure, what is the benefit of BMP 
use over autologous bone graft alone. Indeed, is it possible that membrane 
induction without autologous grafting is sufficient for defect repair? 
These questions are important because although this procedure has clear 
advantages over other techniques used to reconstruct large bone defects, it relies 
on a second surgical procedure after membrane induction (Giannoudis et al. 2011). 
If this could be avoided it would represent a substantial improvement in patent 
care as well as a significant reduction in the cost associated with this treatment. 
Experiments using an animal model are the most appropriate means of addressing 
these questions. The experiment carried out in this thesis may form the basis for 
assessing membrane induction. However, inter-species differences in terms of 
antibody specificity and tri-lineage differentiation induction must be considered. 
The ultimate goal of this investigation would be the development of a means of 
stimulating IM formation that facilities treatment as a one stage procedure.   
Finally, the effect of tofacitinib on attenuating aberrant bone formation is already 
under investigation by a collaborative effort, using a mouse model of AS. Aside 
from this, I propose a more detailed investigation of the effects of tofacitinib on 
adipogenic differentiation. My hypothesis is that tofacitinib drives enhanced 
adipogenesis by inhibition of MMP-3 and TIMP1 expression; this may be tested by 
western blotting for expression of these proteins during adipogenic induction in the 
presence and absence of tofacitinib. An accurate means of determining adipocyte 
size following adipogenic induction should also be developed. If MMP-3 and TIMP1 
expression are found to be reduced and this is accompanied by a reduction in 
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adipocyte size this would indicate that tofacitinib treatment may mimic the 
phenotype observed in mice following homozygous deletion of Ror (Meissburger 
et al. 2011b). If this proves to be the case, the next step should be to examine the 
effect of tofacitinib administration to obese mice, since Ror deletion was shown to 
recover insulin sensitivity in obese mice (Meissburger et al. 2011b). It should also be 
determined if other JAK/STAT inhibitors have similar effects. In summary it is 
possible that JAK/STAT inhibition may provide a novel means of controlling obesity-
associated insulin resistance. 
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Appendix 2: Standard Solutions 
Acrylamide gel 10% (Western blotting) 
dH2O – 2.95ml, 30% (w/v) acrylamide/methylene bisacrylamide solution (37.5:1 
ratio) (National Diagnostics) – 2.5ml, 1.5M Tris base (Fisher) solution (pH8.8) – 
1.88ml, 10% Sodium dodecyl sulfate (SDS, Sigma Aldrich) - 75µl, 10% ammonium 
persulfate (Sigma Aldrich) - 100µl, N,N,N′,N′-Tetramethylethylenediamine (Sigma 
Aldrich) - 5µl. 
Acrylamide gel stacking (Western blotting) 
dH2O – 3.56ml, 30% (w/v) acrylamide/methylene bisacrylamide solution (37.5:1 
ratio) (National Diagnostics)– 0.75ml, 0.5M Tris base (Fisher) solution (pH6.8) – 
625µl, 10% SDS (Sigma Aldrich) - 50µl, 10% ammonium persulfate (Sigma Aldrich)  - 
25µl, N,N,N′,N′-Tetramethylethylenediamine (Sigma Aldrich) -7µl. 
Adipogenic media 
DMEM (Gibco/Life Tech) – 22320-022) contains 1g/l D-Glucose, L Glutamine, HEPES, 
Pyruvate. with additional supplements: 10% foetal calf serum (PAA), 10% horse 
serum (Stem Cell Technologies), 0.5 mM isobutylmethylxantine (Sigma Aldrich), 60 
M indomethacine (Sigma Aldrich), 0.5mM hydrocortisone (Sigma Aldrich), 
Penicillin/streptomycin (Sigma Aldrich). 
Blocking buffer (western blotting) 
PBS with 5% marvel w/v milk powder (Premier International Foods), 0.1% v/v 
Tween 20 (Sigma Aldrich). 
Cell freezing media 
90% FCS (PAA), 10% DMSO (Sigma Aldrich). 
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Chondrogenic Media 
DMEM (2.5g/L glucose) with additional supplements: Ascorbic acid 2 phosphate 
200mM (Sigma Aldrich), Sodium Pyruvate (Sigma Aldrich), Proline (Sigma Aldrich), 
BSA (PAA laboratories) and Penicillin/streptomycin.  
With additional supplements added prior to use: Insulin transferrin sodium selenite 
(ITS+3) cell culture supplement 1:100, (Sigma Aldrich), TGFβ3 10µg/ml (R&D 
Systems) and Dexamethasone 100nM.  
Citrate fixative (ALP assay) 
Two volumes of citrate working solution: 1:100 dilution of citrate concentrate 
(Sigma Aldrich) with 3 volumes of acetone (Sigma Aldrich). 
FACS Buffer  
PBS with 1% w/v bovine serum albumin (BSA) (Sigma Aldrich).  
Fast blue solution (ALP assay) 
One capsule of fast blue RR salt (Sigma Aldrich) dissolved in 48ml of distilled water, 
with the addition of 2ml Naphthol AS-MX phosphate alkaline solution (Sigma 
Aldrich). 
Fixing buffer (histology) 
4% formalin solution (v/v) (Sigma Aldrich) in PBS. 
Methylene blue solution (CFU-F assay) 
1% w/v methylene blue, dissolved in 10mM disodium tetraborate (pH 8.0). 
Oil red solution (adipogenesis assay) 
0.5% w/v oil red in isopropanol solution is diluted 3:2 in dH2O. The solution is then 
passed through 0.8µm and 0.22µm filters respectively to remove precipitate. 
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Osteogenic Media 
DMEM (Gibco/Life Tech) containing 1g/l D-Glucose, L Glutamine, HEPES, Pyruvate 
with additional supplements: Foetal calf serum 10% (PAA), Ascorbic-2-phosphate 
(As2P) 100M (Sigma Aldrich),  glycerophosphate 10mM (Sigma Aldrich), 
Dexamethasone 100nM (Sigma Aldrich), Penicillin/streptomycin (Sigma Aldrich). 
Papain buffer (GAG assay) 
50mM sodium phosphate buffer pH 6.5 (15mM Na2HPO4, 35mM NaH2PO4), 
containing 2mM Acetyl cysteine (Sigma Aldrich), 2mM EDTA Sigma Aldrich), and 
1mg/ml Papain (Sigma Aldrich). 
Red blood cell lysis solution  
168mM NH2Cl, 10mM KHCO3, 1mM EDTA (pH8.0). 
Running buffer (western blotting) 
dH2O – 10L, Tris base (Fisher) – 30.3g, glycine 144.2g, SDS (Sigma Aldrich) – 10g. 
Sample buffer (western blotting) 
50mM Tris pH 6.8 (Fisher), 5% β-mercaptoethanol (Sigma Aldrich), 2% w/v SDS 
(Sigma Aldrich), 0.1% w/v bromophenyle blue (Sigma Aldrich), 10% glycerol (Sigma 
Aldrich). 
Scott’s tap-water substitute (histology) 
Sodium bicarbonate 42mM (Sigma Aldrich), magnesium sulphate (heptahydrate) 
8mM (Sigma Aldrich) dissolved in dH2O. 
Toludine blue solution (chondrogenesis assay) 
1% Toludine Blue (Sigma Aldrich) in 50% v/v isopropanol (Sigma Aldrich) 50% v/v 
dH2O. 
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Transfer buffer (western blotting) 
H2O – 3.5L, Glycine (Sigma Aldrich) – 50g, Tris base (Fisher) - 10.6g, methanol 
(Sigma Aldrich) - 700ml. 
Washing buffer (western blotting) 
PBS with 0.1% v/v Tween 20 (Sigma Aldrich). 
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Appendix 3: Tissue culture plastic use 
Throughout this report, unless otherwise stated, the volume of media added to 
each type of culture vessel was as follows. All tissue culture plastic was supplied by 
Corning unless otherwise stated. 
Type of vessel Volume of media applied 
T150 30ml 
T75 20ml 
T25 8ml 
10cm dish 15ml 
6 well plate 4ml/well 
12 well plate 2ml/well 
24 well plate 1ml/well 
48 well plate 0.5ml/well 
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Appendix 4: Antibodies used 
Specificity Application Conjugate Clone Host Dilution Manufacturer 
CD31 IHC None JC70A Mouse 1:50 Dako 
CD31 FC FITC WM59 Mouse 1:10 AbD Serotech 
CD34 FC PcP 8G12 Mouse 1:5 BD Pharmingen 
CD34 FC PE 563 Mouse 1:5 BD Pharmingen 
CD45 FC PECy-7 HI30 Mouse 1:20 BD Pharmingen 
CD73 FC PE AD2 Mouse 1:5 BD Pharmingen 
CD73 FC PECy-5.5 AD2 Mouse 1:20 BD Pharmingen 
CD90 FC FITC 5E10 Mouse  1:5 BD Pharmingen 
CD146 IHC None P1H12 Mouse 1:50 Chemicon Int. 
CD146 FC PE 3A6 Mouse 1:5 BD Pharmingen 
CD271 IHC None NGFRS Mouse 1:50 Abcam 
CD271 FC APC ME20.4-1H4 Mouse 1:11 Miltenyi Biotec 
CD271 FC PE ME20.4-1H4 Mouse 1:11 Miltenyi Biotec 
CD271 FC PE C40-1457 Mouse 1:5 BD Pharmingen 
BMP-2 IHC None Polyclonal  Rabbit 1:100 AbD Serotech 
SDF-1 IHC None 79018 Mouse 1:20 R&D Systems 
VEGF IHC None Polyclonal Rabbit 1:20 Santa Cruz 
Isotype  FC FITC MOPC-31C Mouse 1:5  BD Pharmingen 
Isotype FC PE MOPC-21 Mouse 1:5  BD Pharmingen 
Isotype FC APC IS5-21F5 Mouse 1:11 Miltenyi Biotec 
pSTAT-3 WB None EP2147Y Rabbit 1:20000 Millipore 
β-Actin WB None AC-15 Mouse 1:20000 Sigma Aldrich 
Rabbit IgGs WB HRP Polyclonal Goat 1:20000 Jackson Labs 
Mouse IgGs WB HRP Polyclonal Goat 1:10000 Dako  
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Appendix 5: Patient Demographics 
 
Patient Sex Age Size of defect Location of 
defect 
1 M 46 45mm Femur 
2 M 72 40mm Femur 
3 M 64 40mm Tibia 
4 M 66 25mm Radius 
5 M 27 25mm Radius 
6 M 18 25mm Ulna  
7 F 80 40mm Femur 
8 M 72 50mm Radius 
 
Table shows patient sex, age at time of procedure (second stage), the size of the 
defect and its anatomical location. 
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Appendix 6: Concentrator product inserts 
SmartPrep2 concentrator product insert (re-produced from literature supplied with 
the SmartPrep2 device).  
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MarrowStim product insert (reproduced from literature supplied with MarrowStim 
device). 
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